Enhancing vascular endothelial repair in the setting of insulin resistance: effects of insulin-like growth factor binding protein-1 by Aziz, Amir
1 
 
Enhancing vascular endothelial repair 
in the setting of insulin resistance: 
effects of insulin-like growth factor 
binding protein-1 
 
 
 
 
 
PhD Thesis 
 
 
 
 
 
Dr. Amir Aziz 
 
Submitted in accordance with the 
requirements for the degree of Doctor of 
Philosophy 
 
The University of Leeds 
School of Medicine 
July 2014
2 
 
The candidate confirms that the work submitted is his own, except where work which has 
formed part of jointly-authored publications has been included.  The contribution of the 
candidate and the other authors to this work has been explicitly indicated below. The 
candidate confirms that appropriate credit has been given within the thesis where reference 
has been made to the work of others. 
 
Aziz A, Wheatcroft S.  Insulin resistance in Type 2 diabetes and obesity: implications for 
endothelial function.  Expert Rev Cardiovasc Ther. 2011 Apr;9(4):403-7. doi: 
10.1586/erc.11.20. 
 
Review article which forms part of Chapter 1 of my thesis.  I drafted the manuscript which 
was then edited by my co-author. 
 
Kahn MB, Yuldasheva NY, Cubbon RM, Smith J, Rashid ST, Viswambharan H, Imrie H, 
Abbas A, Rajwani A, Aziz A, Baliga V, Sukumar P, Gage M, Kearney MT, Wheatcroft SB.  
Insulin resistance impairs circulating angiogenic progenitor cell function and delays 
endothelial regeneration.  Diabetes. 2011 Apr;60(4):1295-303. doi: 10.2337/db10-1080. 
Epub 2011 Feb 11. 
 
Rajwani A, Ezzat V, Smith J, Yuldasheva NY, Duncan ER, Gage M, Cubbon RM, Kahn MB, 
Imrie H, Abbas A, Viswambharan H, Aziz A, Sukumar P, Vidal-Puig A, Sethi JK, Xuan S, 
Shah AM, Grant PJ, Porter KE, Kearney MT, Wheatcroft SB.  Increasing circulating IGFBP1 
levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, 
and protects against atherosclerosis.  Diabetes. 2012 Apr;61(4):915-24. doi: 10.2337/db11-
0963. Epub 2012 Feb 22. 
 
Original research publications resulting from the primary author’s studies.  I assisted in 
some experimental work.  The results from these two papers have been included and form 
part of Chapter 1 of my thesis, with acknowledgement given to the primary authors. 
 
This copy has been supplied on the understanding that it is copyright material and that no 
quotation from the thesis may be published without proper acknowledgement. 
 
 
 
 
 
 
 
© 2014. The University of Leeds. Dr Amir Aziz. 
3 
 
Acknowledgments 
 
I am indebted to my supervisors for their help, guidance and support 
throughout my research. The attention, tireless enthusiasm, wisdom and 
encouragement offered by Dr Stephen Wheatcroft, Dr Karen Porter and 
Professor Mark Kearney at every stage of this project has been invaluable 
and I am truly grateful.  I would also like to thank Dr Nadira Yuldasheva for 
her excellent supervision and guidance. 
 
In addition, I would like to thank the British Heart Foundation for generously 
funding this clinical PhD studentship. 
 
The research undertaken in this thesis is my own, but where the assistance 
of other individuals has contributed to my project, this is indicated explicitly 
within the relevant section. I am particularly grateful for the significant 
contributions of Dr Nadira Yuldasheva for her help with the vascular injury 
experiments and Mrs Jessica Smith for her expertise and help in western 
blot analyses and tutoring of cell culture techniques. 
 
This project includes other notable contributions. These include in particular 
Dr Kirsten Riches, Dr Matthew Gage, Dr Romana Mughal, Dr Helen Imrie, Dr 
Matt Kahn, Dr Ric Cubbon, Mr David O’Regan, Dr Gareth Howell, Dr Kate 
Gatenby, Dr. Ben Mercer, Dr. Anshuman Sengupta and Dr. Noman Ali 
 
Finally, I am forever grateful to my family and friends for their help and 
support during my research. Most important of all, I am indebted to my 
parents for their unfaltering support, commitment and kindness throughout 
my life and career.  I will forever be in their debt.  I would also like to thank 
my sisters, Maria and Shabeena who make life all the more enjoyable. 
 
 
 
 
 4 
 
Abstract 
 
Insulin resistance (IR) leads to the development of type 2 diabetes mellitus 
and predisposes to cardiovascular disease (CVD) through its link with 
endothelial dysfunction.  Cardiovascular risk factors and iatrogenic damage 
lead to biochemical and structural injury to the endothelium.  Endogenous 
repair mechanisms are in place to regenerate injured endothelium.  Insulin 
resistance has recently been shown to impair endothelial repair.  The 
endogenously produced circulating insulin-like growth factor binding protein-
1 (IGFBP-1) is potentially protective in the vasculature by stimulating nitric 
oxide production and enhancing insulin signalling in the endothelium.  Cross-
sectional studies have shown an association between low IGFBP-1 levels 
and CVD.  This raises the possibility of exploiting IGFBP-1 therapeutically to 
prevent CVD in patients with diabetes.  This project investigated whether 
IGFBP-1 enhances vascular endothelial repair in insulin resistant mice in 
vivo and probed potential molecular mechanisms by examining the effects of 
IGFBP-1 on human endothelial cells (EC) and angiogenic progenitor cells 
(APCs) in vitro.  Endothelial regeneration was enhanced following arterial 
endothelium-denuding injury in IRKO mice by over-expressing human 
IGFBP-1.  This was not explained by altered abundance or function of APCs.  
Incubation with IGFBP-1 significantly enhanced the ability of human EC to 
adhere to and regenerate denuded human vein ex vivo.  In EC, IR was 
mimicked by the pro-inflammatory cytokine tumour necrosis factor-alpha 
(TNF-α) which significantly inhibited EC migration and proliferation in vitro.  
Co-incubation with IGFBP-1 restored the migratory and proliferative capacity 
of EC.  IGFBP-1 significantly increased FAK phosphorylation, induced rapid 
activation of RhoA, and increased expression of α5β1 and αVβ3 integrins in 
EC.  These multifactorial effects of IGFBP-1 on EC responses and 
acceleration of endothelial regeneration in mice raise the possibility that 
manipulating IGFBP-1 could be a strategy to enhance endothelial repair in 
humans with IR. 
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1.1 Type 2 Diabetes Mellitus and insulin resistance 
Diabetes mellitus is a chronic multifactorial disease characterised by 
hyperglycaemia resulting from defects in insulin secretion, insulin action or 
both.  Chronic hyperglycaemia is associated with long-term damage to vital 
organs such as the heart, blood vessels and kidneys, leading to 
cardiovascular disease (CVD) and chronic kidney disease.  Two main types 
of diabetes mellitus are described, reflecting two distinct patho-physiological 
processes involved in diabetes development.  Type 1 diabetes mellitus 
(T1DM) is characterised by autoimmune destruction of the β-cells of the 
pancreas leading to insulin deficiency; whereas type 2 diabetes mellitus 
(T2DM) is caused by abnormalities leading to resistance in the actions of 
insulin1–3.  Other types of diabetes4, for example gestational diabetes 
(occurring during pregnancy), neonatal diabetes and maturity onset of 
diabetes in the young5 (MODY) – a hereditary form of diabetes, are much 
lower in prevalence. 
    
The prevalence of T2DM, representing 90-95% of all cases of diabetes6 is 
rising globally. It is estimated that 382 million people (4% of the world’s 
population) are affected by diabetes currently and it is predicted that this will 
increase to 592 million people by 20356.  The management of patients with 
diabetes incurs a significant burden on healthcare resources around the 
world.  In 2010-2011, the cost of T2DM in the UK was estimated to be 
approximately £21.8bn7, which equated to 21.2% of the total NHS budget. 
 
Insulin resistance (IR) is an imbalance of insulin-glucose homeostasis in 
which insulin’s ability to stimulate glucose uptake in peripheral tissues (e.g. 
skeletal muscle and adipose tissue) or to inhibit hepatic gluconeogenesis is 
reduced8.  IR is an important metabolic abnormality in obesity, metabolic 
syndrome and T2DM, where CVD is the most significant cause of morbidity 
and mortality. IR develops as a result of combined genetic, lifestyle and 
environmental factors.  The most likely reason for the recent increase in the 
global prevalence of IR is the ‘Westernisation’ of the world, i.e. increased 
calorie intake with decreased physical exercise9.  Diabetes develops 
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gradually over a number of years, in which the evolution of hyperglycaemia 
is preceded by a slowly progressive decline in insulin-sensitivity.  The 
decline in insulin-sensitivity is associated with compensatory 
hyperinsulinaemia – a state which is often termed ‘pre-diabetes’10 (Figure 
1.1) in which fasting blood glucose levels are maintained at near-normal 
concentrations for many years, with mild elevation of post-feed levels. 
Diabetes is diagnosed when relative deficiency in pancreatic insulin 
secretion allows  hyperglycaemia to develop11.   
 
 
 
Figure 1-1 Representative diagram of the evolution of diabetes.   
The pre-diabetes phase increases cardiovascular risk before diabetes is 
present clinically.  Reproduced with permission from Wheatcroft et al, 
Diabetic Medicine, 20, 255-268. 
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1.1.1 Insulin resistance (metabolic) syndrome, T2DM and 
cardiovascular disease  
Diabetes can affect multiple organs, however vascular complications 
predominate and can be broadly categorised as microvascular (e.g. 
retinopathy, neuropathy and nephropathy) or macrovascular (e.g. stroke, 
peripheral arterial disease and coronary heart disease).  Macrovascular 
complications represent the most common cause of death in individuals with 
diabetes. 
 
Insulin resistance (metabolic) syndrome was first described in 1988 by 
Reaven as “a cluster of risk factors for diabetes and cardiovascular 
disease”10 comprising obesity (especially abdominal), hypertension, glucose 
intolerance, dyslipidaemia, hyperinsulinaemia, endothelial dysfunction with 
insulin resistance being at the core of the syndrome12.  IR and the multiple 
components of the metabolic syndrome contribute to CVD development10,13–
15.   
 
CVD represents the most common cause of morbidity and mortality in 
individuals with T2DM.  The Framingham study was one of the earliest 
studies to demonstrate an increased risk of cardiovascular mortality in 
people with diabetes (mainly T2DM)16.  Another observational study based in 
Finland showed that patients with T2DM, without a previous history of CVD 
have as high a risk of having a myocardial infarction as patients who had a 
previous myocardial infarction but had no history of T2DM17.  
 
T2DM is often preceded by a long period of IR, during which normal blood 
glucose levels are maintained by compensatory hyperinsulinaemia.  During 
this period, subtle abnormalities of glucose regulation can arise - which are 
observed clinically as impaired glucose tolerance or impaired fasting 
glycaemia6,12.  This asymptomatic pre-diabetic period of IR is linked with 
increased cardiovascular risk18 and the population affected by pre-diabetes 
is increasing.  In a recent population based cross-sectional study, the 
prevalence of pre-diabetes in adults in the UK increased dramatically from 
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11.6% in 2003 to 35.3% in 201119.  The San Antonio Heart Study observed 
2569 individuals who were non-diabetic at baseline. Over 5 years of follow-
up, 187 subjects experienced a cardiovascular event, with individuals in the 
highest quintile of IR having an approximately 2.5-fold increased incidence 
of CVD20.  In the Botnia study, 3606 non-diabetic individuals were observed 
over a 7 year period. Metabolic syndrome increased the risk of CVD by 
threefold and metabolic syndrome was seen in 78% of women and 84% of 
men with T2DM21.  A recent meta-analysis of 65 cohort/nested case-control 
studies showed that IR, measured by Homeostasis Model Assessment 
(HOMA), was a better predictor of cardiovascular events than fasting levels 
of glucose or insulin in adults without DM22.  These studies suggest that 
diabetes leads to a CV mortality risk similar to that attributable to a prior 
diagnosis of coronary artery disease. 
  
1.2 Endothelium 
1.2.1 Endothelium in health 
The vascular system is lined by a continuous monolayer of cells termed the 
endothelium (Figure 1.2) which provide a physical barrier between the 
vessel wall and lumen, but importantly play a major role in regulating 
vascular homeostasis.  Endothelial cells (EC) secrete vasoactive substances 
which modulate vascular tone, vascular smooth muscle function 
(proliferation and migration), inflammatory cell adhesion, platelet 
aggregation, thrombosis and fibrinolysis23,24.  The endothelium functions in 
paracrine, autocrine and endocrine manners.  Vascular homeostasis is 
maintained through the secretion of vasodilators such as Nitric Oxide (NO)  
(a key anti-atherogenic molecule which will be discussed in more detail) and 
bradykinin and vasoconstrictors (endothelin-1, thromboxane A2, angiotensin 
II and certain reactive oxygen species)23.   
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Figure 1-2 The endothelium in health.   
Endothelial cells form a monolayer and secrete vasoactive molecules such 
as Nitric Oxide (NO) to maintain vascular homeostasis. 
 
1.2.2 Endothelial dysfunction 
Vascular homeostasis is maintained through secretion of vasoactive 
molecules such as NO and endothelin-1.  Endothelial dysfunction occurs 
when there is an imbalance in the bioavailability of these vasoactive 
molecules.  Reduced bioavailability of NO, in particular, promotes 
thrombosis, occlusion, vasospasm and increases adhesion molecule 
expression (e.g. E-selectin, P-selectin, vascular-cell adhesion molecule 1 
and intercellular adhesion molecule 1)25.  Endothelial dysfunction promotes 
uptake of inflammatory cells into the arterial wall and also leads to vascular 
smooth muscle cell proliferation and migration26.  Not only does damaged 
endothelium disturb the balance of vasodilatory and vasoconstrictory 
substances, there is also an increase in inflammatory cytokine expression 
such as tumour necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6)27.   
 
Endothelial dysfunction commonly arises as a consequence of biochemical 
damage attributable to exposure to cardiovascular risk factors such as IR, 
smoking, hyperlipidaemia and hypertension.  More importantly longitudinal 
studies have shown that endothelial dysfunction leads to impaired 
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endothelial repair, predisposes to atherosclerosis and is predictive of future 
cardiovascular disease28–30.  
 
Endothelial dysfunction can also occur through mechanical damage to EC. 
Physical trauma to the endothelium resulting in loss of endothelial integrity is 
an inevitable consequence of clinical revascularisation procedures (e.g. 
angioplasty, stent insertion and coronary artery bypass surgery).  Loss of EC 
integrity is a potent driver for adverse vascular remodelling and leads to 
atherosclerosis, bypass graft failure, restenosis and stent thrombosis.   
 
 
 
1.2.3 Nitric oxide and eNOS  
Endothelium-Derived Relaxing Factor (EDRF) was discovered in the 1980s 
by the pioneering experiments of Furchgott and Zawadzki31 and was later 
identified as nitric oxide (NO)32,33.  Since the 1980s numerous studies 
exhibited the important roles NO plays in the human body34,35.  NO is the 
major compound secreted by EC and is also the most widely studied.  This 
anti-atherogenic signalling molecule possesses vasodilator, anti-platelet, 
anti-inflammatory and antioxidant properties36 (Figure 1.3), these will be 
discussed in greater detail later. 
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Figure 1-3 The vasculoprotective effects of Nitric Oxide.   
NO inhibits platelet aggregation; prevents EC apoptosis whilst promoting EC 
migration and proliferation; inhibits leukocyte and platelet adhesion to the 
endothelium and finally inhibits vascular smooth muscle cell proliferation and 
migration. 
 
ECs produce NO from L-arginine in a reaction catalysed by eNOS 
(endothelial isoform of nitric oxide synthase).  NO diffuses locally within the 
vascular wall  to regulate vascular tone, inflammatory cell adhesion, platelet 
aggregation and vascular smooth muscle cell proliferation23.  Bioavailability 
of NO is dependent upon its rate of production and inactivation by binding to 
reactive oxygen species (ROS) such as superoxide37.  
 
The effects of NO on its target tissues are mediated through guanylate-
cyclase-mediated increases in cyclic guanosine monophosphate.  In 
vascular smooth muscle cells27,38, this results in vascular smooth muscle 
relaxation and vasodilatation, which are often used as functional markers of 
the health of the endothelium. 
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NO is generated by three isoforms of its synthetic enzyme, NOS, namely 
neuronal (nNOS), inducible (iNOS) and endothelial (eNOS), all of which are 
expressed in the CV system and eNOS is the major isoform in ECs.  eNOS 
expression was originally thought to be constitutive, however studies show 
that it’s expression levels is regulated in response to mechanical stimulation, 
cytokines and growth39. 
 
eNOS is a bi-domain enzyme comprising a C-terminal reductase domain 
which binds nicotinamide adenine dinucleotide phosphate (NADPH), the 
flavins adenine dinucleotide (FAD) and mononucleotide (FMN); an N-
terminal oxidase domain which binds heme, zinc, calmodulin and 
tetrahydrobiopterin (BH4)
39.  BH4, FAD and FMN are essential cofactors and 
calcium-loaded calmodulin stimulates enzyme activity and phosphorylation40.  
Also, where there is either L-arginine or BH4 deficiency e.g. in diabetes, 
eNOS may produce superoxide, hence reduced NO bioavailability may 
partly be due to eNOS-mediated superoxide production41,42.   
 
 
1.2.4 Reactive oxygen species  
Reactive oxygen species (ROS) are a natural by-product of oxygen 
metabolism. Examples of ROS include oxygen ions, peroxide, hydrogen 
peroxide and superoxide.  ROS are classically generated at sites of 
inflammation and are a cause of oxidative stress.  At high concentrations, 
ROS can cause cell injury and death.  Generation of ROS, such as 
superoxide, plays a major role in endothelial dysfunction and is a risk factor 
in IR associated vasculopathy43,44.  Superoxide reduces NO bioavailability by 
reacting quickly with NO to produce peroxynitrite, which itself may exert 
toxicity by nitrosylating cellular proteins45,46.  Superoxide is also involved in 
the regulation of platelet aggregation47, smooth muscle proliferation48 and 
endothelial activation leading, for example, to monocyte attachment to the 
endothelium8,49.  Potential sources of superoxide within the vascular system 
include lipoxygenases, xanthine oxidase, mitochondrial oxidases, 
cytochrome P450 and eNOS in the presence of low tetrahydrobiopterin 
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levels43.  More recently, a major source of superoxide in blood vessels has 
been found to be a phagocyte-type NADPH oxidase50,51, this plays an 
important part in endothelial dysfunction in the insulin resistant setting52.  
 
The effects of ROS on the endothelium are the result of its overproduction 
and/or a deficiency of antioxidant mechanisms, put simply “oxidative stress 
results from the metabolic reactions that use oxygen and represents a 
disturbance in the equilibrium status of pro-oxidant versus anti-oxidant 
reactions”53.  
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1.3 Insulin and the endothelium 
1.3.1 Insulin signalling and the endothelium 
 Insulin’s actions are not limited to canonical insulin responsive tissues (liver, 
skeletal muscle and adipocytes).  Indeed, the presence of Insulin receptors 
on ECs implies insulin may play an important role in endothelial cell 
function12.  It has been elucidated there is a complete biochemical signalling 
pathway which links the insulin receptor to eNOS activation in the vascular 
endothelium.  Insulin stimulates EC NO production through a similar 
signalling pathway to which it promotes glucose uptake in skeletal muscle54–
57.  The pathway (Figure 1.4) involves insulin receptor phosphorylation of 
Insulin Receptor Substrate-1 (IRS-1), which binds and activates 
Phosphatidyl Inositol-3 kinase (PI3-K), this leads on to phosphorylation of 
PDK-1/2 and then protein kinase B which finally leads to endothelial Nitric 
Oxide Synthase (eNOS) phosphorylation and NO production.  Insulin also 
activates a separate pathway, the ras-mitogen activated protein kinase 
(MAPK) signalling cascade pathway which is pro-mitogenic.  In this pathway, 
binding to the insulin receptor initiates a signalling pathway involving 
intermediaries (Shc, SOS, Ras and GRB2), which results in activation of 
MAPKs58.  This is important for the mitogenic effects of insulin which include 
smooth muscle cell proliferation and migration, endothelial cell activation, 
stress responses and expression of endothelin, a potent vasoconstrictor.  
  
IR results in reduced NO bioavailability due to selective inhibition of the PI3-
kinase(PI3-k)/Akt signalling59,60.  In contrast to this, the Mitogen-activated 
Protein Kinase (MAPK) pathway remains largely unaffected by IR, causing 
an imbalance in the activation states of both signalling pathways.  
Furthermore, because IR is accompanied by hyperinsulinaemia, insulin 
signalling leads to an increase in MAPK activity whilst the PI3-k/Akt pathway 
remains unresponsive.  As a result enhancement of the mitogenic pathway 
promotes a pro-inflammatory and pro-atherogenic environment61. 
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The multi-faceted insulin signalling pathway has multiple components at 
different levels which may be direct targets of IR.  Experimental models have 
shown that defects in several components of the insulin signalling pathway 
can induce IR.  However, the relative contribution of these models to cases 
of human IR are not fully clarified.  Proposed theories include down-
regulation of tyrosine phosphorylation of the insulin receptor, PI3-kinase, IRS 
proteins and reduced amount of these proteins45,62,63. 
 
Figure 1-4 Schematic drawing of insulin signalling pathways in EC and 
VSMC.  
Activation of either PI3-kinase or MAP kinase (MAPK) can mediate insulin's 
actions, with the former stimulating anti-atherogenic effects and the latter 
stimulating atherogenic actions.  IR is associated with selective down 
regulation of the PI3-k pathway whereas MAP-kinase pathway is enhanced 
and therefore promotes atherosclerosis.  
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1.3.2 Insulin resistance and endothelial dysfunction 
There is an important pathophysiological reciprocal relationship between IR 
and endothelial dysfunction which has been demonstrated in numerous 
studies61,64,65, including those in subjects with T2DM66 or obesity64.  
Mechanisms that contribute to IR and endothelial dysfunction include 
inflammation, lipotoxicity and glucotoxicity.   
 
In healthy young men of South Asian origin, IR is associated with reduced 
NO bioavailability and decreased shear stress-induced NO production 
elicited by flow-mediated brachial artery dilatation67.  The relationship of IR 
with endothelial dysfunction and other cardiovascular risk factors has led to 
the ‘common soil’ hypothesis, in which genetic factors may predispose 
individuals to the development of IR and CVD68.  In addition to these genetic 
influences, a range of biochemical and signalling alterations have been 
discovered that are mechanistically implicated in the association between 
obesity, IR and endothelial dysfunction, which have been addressed by 
comprehensive research in models of IR (human and animal) and cell 
culture studies69. 
 
In animal models, it has been shown that disrupting insulin signalling leads 
to decreased PI3-k/Akt and phospho-eNOS activation which results in 
endothelial dysfunction, adverse vascular remodelling and atherosclerosis70.  
Mice with hemizygous deletion of insulin receptors and exhibit normal 
glucose levels but are hyperinsulinaemic have a significant reduction in NO 
bioavailability, hypertension and increased ROS production71.  These 
findings are consistent with the concept of endothelial dysfunction being 
induced by IR.  However the proposed mechanism that this is dependent 
upon down regulation of PI3K/Akt signalling has come under debate.  One 
study used mice with genetic ablation of insulin receptors and Akt1 to 
investigate the mechanism of obesity-related endothelial dysfunction72.  This 
study confirmed that obesity leads to endothelial dysfunction characterised 
by impaired insulin-induced eNOS phosphorylation, but this may be 
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attributable to free fatty acid inhibition on eNOS phosphorylation rather than 
defective upstream signalling via Akt69. 
 
A murine model with endothelial-specific expression of a dominant negative 
human insulin receptor (ESMIRO), in which glucoregulation is intact, 
demonstrated that endothelium-selective IR results in impaired NO release 
and increased ROS production70,73.  Another study looking at a mouse 
model where insulin receptors were selectively deleted in ECs (VENIRKO) 
showed reduced eNOS expression and susceptibility to hypertension and 
atherosclerosis74.  In summary, these studies provide evidence that even 
without any systemic effects of IR, IR in ECs is sufficient to promote 
endothelial dysfunction and damage with reduced NO bioavailability and 
increased ROS production. 
 
Oxidative stress as a result of increased ROS generation is believed to play 
a role in linking IR, endothelial dysfunction and impaired endothelial 
regeneration.  The enzymes most strongly linked with endothelial 
dysfunction associated with T2DM and obesity are NADPH oxidase and 
uncoupled eNOS.  Normally eNOS produces NO, however if there is 
deficiency in the essential cofactor tetrahydrobiopterin, eNOS uncoupling 
results in superoxide generation75. 
 
T2DM is associated with reduced bioavailability of tetrahydrobiopterin, the 
diabetic vasculature is therefore exposed to the proatherosclerotic 
combination of reduced NO production and increased superoxide production 
by eNOS in EC76.  Overall, there is convincing evidence that insulin 
resistance in endothelial cells contributes to endothelial dysfunction. 
 
1.3.3 Unifying mechanisms underlying IR and endothelial 
dysfunction 
As mentioned there is a reciprocal relationship between IR and endothelial 
dysfunction, however the question of whether they are directly linked with 
each other or represent manifestations of a common underlying pathology 
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remains uncertain27.  This section will discuss potential mechanisms that link 
IR and endothelial dysfunction. 
  
1.3.3.1 Intracellular signalling pathways 
In IR, individuals exhibit resistance to the metabolic and to some of the 
vascular actions of insulin.  As mentioned, the signalling pathways involved 
are similar for NO production and glucose uptake stimulated by insulin.  
Insulin binds to cell membrane insulin receptors which promotes GLUT4 
translocation in skeletal muscle and increases eNOS activity in the 
endothelium through the PI-3-kinase/Akt signalling cascade77.  In the insulin 
resistant setting and diabetes, insulin-mediated eNOS activation via PI-3-
kinase/Akt is down-regulated, whilst MAPK pathway remains intact60 which 
promotes endothelin production (a potent vasoconstrictor and mitogen)78, 
vascular smooth muscle production79 and to the expression of pro-
inflammatory adhesion molecules e.g. ICAM-127, which may promote 
vascular disease27,80.   
 
Human studies support these mechanisms. In healthy humans, insulin 
stimulates vasodilatation and increases blood flow in peripheral tissues 
which is endothelial mediated, but this effect is reduced in patients with DM 
and IR65,81.  Hyperinsulinaemia accompanies IR and is also an independent 
risk factor for CVD82.  In the early phase of IR, there is a hyperinsulinaemic 
phase to maintain normal glucose levels.  Montagnani et al designed a 
number of investigations mimicking metabolic IR by blocking the PI3-kinase 
pathway and exposing ECs to increasing levels of insulin.  They found that 
PI3-kinase inhibition blocked insulin stimulated eNOS expression with no 
alteration to the MAP-kinase pathway and enhanced mitogenic activity of 
ECs80. 
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1.3.3.2 Cytokines and inflammation 
EC can be activated by pro-inflammatory molecules such as tumour necrosis 
factor-alpha (TNF-α) and C-reactive protein which promotes endothelial 
dysfunction and an atherogenic phenotype83,84, this then promotes 
expression of adhesion molecules which accelerates atherosclerosis, and in 
turn leads to decreased eNOS expression and reduced NO bioactivity85–87. 
Adipose tissue is a major source of circulating pro-inflammatory cytokines 
such as interleukin-688 and TNF-α89.  TNF-α expression is increased in 
muscle and adipose tissue89 samples in insulin resistant humans.  Cross-talk 
between adipose depots and blood vessels is mediated, at least in part, by 
TNF-α which reduces the bioavailability of NO in ECs and impairs 
endothelium-dependent dilatation in human and animal studies76,90.  Other 
proposed molecular mechanisms for the detrimental effects of TNF-α on 
blood vessels include increased superoxide production by vascular NADPH 
oxidase and TNF-α-mediated decrease in the half-life of eNOS mRNA91. 
 
1.3.3.3 Oxidative stress 
As mentioned earlier, oxidative stress plays a major role in the pathogenesis 
of endothelial dysfunction and has been shown to be associated with insulin 
resistant states in human and animal models92,93.  Arterial tissue exposure to 
hyperglycaemia or increased free fatty acid concentrations induces 
superoxide production and impairs NO bioavailability in the endothelium94,95.  
In murine models with whole body or endothelium specific IR, Kearney et al 
demonstrated the presence of significant oxidative stress and reduced NO 
bioavailability73,96.  NADPH oxidase and dysfunctional eNOS are seen as the 
major ROS sources in the vascular wall42. 
 
1.4 Endothelial damage and repair 
Since ECs play an essential role in maintaining vascular health, when the 
endothelium is damaged, repair mechanisms are essential to institute timely 
and effective regeneration of functional endothelium.  Endothelial damage 
occurs due to a number of reasons: exposure to risk factors leading to 
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endothelial dysfunction and endothelial cell apoptosis, mechanical loss of 
endothelial cells following injury such as coronary interventional procedures 
or coronary artery bypass grafting and following acute inflammation 
associated with sepsis97. 
 
Long-term exposure to vascular risk factors, e.g. IR, causes exhaustion of 
the endogenous anti-inflammatory systems within EC.  Endothelial 
dysfunction ensues, along with loss of structural integrity, senescence, 
apoptosis and ultimately detachment of EC from the extracellular matrix into 
the circulation (Figure 1.5).  Endothelial microparticles are derived from such 
cells and are used as a marker of EC apoptosis.  Exposure to risk factors 
such as atherosclerotic disease, chronic inflammatory diseases such as 
systemic lupus erythematosus and rheumatoid arthritis leads to an increase 
in endothelial microparticle release, which in turn is evidence of continuing 
EC loss29,98.   
 
Figure 1-5 Endothelial damage mechanisms.   
EC express adhesion molecules such as VCAM-1 or ICAM-1, this allows 
leukocytes to adhere, migrate through the EC and initiate an inflammatory 
cascade reaction and release of endothelial microparticles.  ECs become 
senescent and detach from the basement membrane matrix. 
 
Arterial wall injury following angioplasty, stent insertion and coronary artery 
bypass surgery leads to loss of ECs either through direct trauma, apoptosis 
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or necrosis.  The endothelial cell loss triggers a number of local responses 
including vascular smooth muscle proliferation and migration, resulting in 
neointimal hyperplasia99.  The exposed basement membrane matrix attracts 
leukocytes and platelets100–102, predisposing to thrombosis.  Accordingly, 
loss of EC integrity acts as a potent driver for a range of vascular 
pathologies including atherosclerosis103, bypass graft failure104, post-
angioplasty restenosis105, in-stent restenosis and stent thrombosis106.   
 
Release of chemotactic factors and mitogens from platelets occurs which 
affects VSMC.  In addition, angioplasty causes stretching of the vessel and 
cell lysis of EC and VSMC, this then causes proliferation and migration of 
VSMC plus synthesis of the ECM and hence neo-intimal hyperplasia leading 
to restenosis especially post-stent insertion100,107,108. 
 
It has long been recognised that damaged endothelium is ‘repaired’ by the 
regeneration of the endothelial monolayer109–111.  Endothelial repair (Figure 
1.6) is believed to occur through a series of interactions between native ECs 
(migration and proliferation of EC to sites of damage)110–112 and circulating 
bone-marrow derived angiogenic progenitor cells (APCs)113,114 which are 
recruited to the diseased vessel.  Studies conducted in the 1970s and early 
1980s suggested a dominant role for EC mitosis and migration in mediating 
endothelial regeneration after vascular damage110–112,115,116. Following 
arterial injury110,116–118 local endothelial cell migration and proliferation from 
adjacent non-injured endothelium has been highlighted as the central 
mechanism in endothelial regeneration.     
 
Endothelial regrowth following arterial injury or angioplasty occurs through 
EC replicating to restore endothelial continuity.  Migration and proliferation of 
ECs is initiated by loss of contact inhibition and growth factor secretion by 
vascular smooth muscle cells, ECs and APCs.  Regeneration of the injured 
endothelium commonly starts from the leading edge of the denuded area119 
begins within 24 hours and ceases within 6-10 weeks.  One study observed 
that the quicker the endothelium recovered following balloon injury, the less 
neo-intimal hyperplasia occurred120.  Therefore, facilitating rapid endothelial 
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regeneration after injury would be expected to be helpful in the clinical 
setting as this would reduce the incidence of restenosis.   
 
It has also been noted that following widespread denudation, EC are unable 
to re-endothelialise completely121,122 and the regenerated endothelium 
shows abnormal morphology such as close cell-to-cell contacts, ECs not 
aligned with the direction of blood flow and the presence of polygonal 
shapes and irregular size109,119,122–125. 
 
Figure 1-6 Endothelial repair.  
Damaged and denuded endothelium leads to EC migration and proliferation, 
leading to the restoration of the endothelium.  Angiogenic cytokines induce 
APC mobilisation from bone marrow and migrate to the damaged 
endothelium and integrate into the EC layer. 
 
The release of growth factors from the vessel wall plays an important role in 
endothelial regeneration.  One example is Fibroblast Growth Factor (FGF), 
which is formed and stored by ECs and VSMCs126–129.  Angioplasty leads to 
FGF release from injured cells130,131 and human studies have observed 
raised FGF levels in blood post-angioplasty.  VEGF is also observed to have 
increased levels following human angioplasty.  VEGF is synthesised by 
VSMC and binds exclusively to ECs108,132.  Over-expression of VEGF in 
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mice led to accelerated endothelial repair and reduced neo-intimal formation 
following arterial wire injury133.  In the following sections, aspects of 
molecular biology and cell biology pertinent to EC regeneration will be 
discussed in more detail before introducing the contribution of APCs to 
vascular repair. 
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1.4.1 Endothelial cell adhesion 
Endothelial cell adhesion to the extracellular matrix (ECM) plays a critical 
role in regulating EC migration, proliferation and survival.  Integrins and Rho 
GTPases are essential in mediating cellular responses downstream of ECM 
engagement134.  
 
Integrins are a family of cell adhesion molecules, which interact with the 
ECM or with adhesion molecules on other cells135.  In all, 24 integrins have 
been identified and each is a heterodimer of an α and a β subunit135.  
Integrins exhibit both inside-out/outside-in (bidirectional) signalling, i.e. 
signals within the cell cause integrins to change which leads to integrin 
activation and therefore an increased affinity for extracellular ligands.  In the 
opposite direction, integrins binding to their ligands can initiate change to 
their cytoplasmic domains and activate multiple signalling pathways136.  An 
ECM protein such as fibronectin can engage several integrins.  The most 
commonly expressed fibronectin-binding integrins are αVβ3 and α5β1 -  both 
bind to the Arg-Gly-Asp (RGD) tripeptide sequence within fibronectin134.  The 
RGD sequence is the major cell attachment site for a large number of 
proteins and the majority of integrins recognise the RGD sequence137. 
 
Rho GTPases are a family of small (21 kDa) signalling G proteins.  Rho 
GTPases play an essential role in transmitting integrin-mediated responses 
and by regulating the actin cytoskeleton dynamics, they provide a key-
signalling link through which migration and adhesion are controlled134.  The 
most studied Rho GTPases regulating cell adhesion are Rho, Rac and 
Cdc42138 which will be discussed later.  
 
1.4.2 Endothelial cell migration 
EC migration is essential in the re-endothelialisation in arteries after injury, 
angioplasty and coronary artery bypass grafting.  ECs migrate as a 
consequence of three principal mechanisms: chemotaxis, haptotaxis and 
mechanotaxis139.  Chemotaxis is the migrational direction of cells toward a 
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gradient of soluble chemoattractants; haptotaxis is the migrational direction 
of cells toward a gradient of immobilised ligands; and mechanotaxis is the 
migrational direction of cells generated by mechanical forces140.  Endothelial 
cell chemotaxis is typically driven by growth factors such as VEGF and basic 
fibroblast growth factor and haptotaxis is associated with increased EC 
migration activated in response to integrins binding to extra cellular matrix 
(ECM) component139.  Due to the location of EC at the inner face of the 
vessel wall, they are continuously in contact with shear stress.  This 
contributes to activate migratory pathways by initiating mechanotaxis and 
modulates migration steps which includes leading edge extension, adhesion 
to the matrix and adhesion release at the rear139,140.  EC migration is a 
mechanically integrated process which involves fluid changes in signal 
transduction, cell adhesion and cytoskeletal organisation. 
 
1.4.2.1 Role of focal adhesion kinases in endothelial cell 
migration and cell proliferation 
A coordinated process is required for cell migration to occur that involves 
rapid changes in actin filament dynamics, together with the formation and 
disassembly of cell adhesion sites141.  External stimuli that affects cell 
migration are transduced into intracellular biochemical signals through the 
interaction of transmembrane integrins that bind to the ECM.  Integrin 
activation allows there to be a functional connection between focal 
adhesions and actin cytoskeleton that is needed for cell migration139. 
 
Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, is a 
converging signalling point between Rho and integrins and it controls the 
assembly/disassembly of focal adhesions that is required with actin 
polymerisation regulation for EC migration142. 
 
FAK was identified in 1992 in normal cells as a highly tyrosine-
phosphorylated protein that localised to integrin-enriched cell adhesion sites 
known as focal adhesions141.  Focal adhesions are formed at ECM-integrin 
junctions and bring together cytoskeletal and signalling proteins during the 
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processes of cell migration and adhesion.  Early studies showed that FAK 
was activated by growth factors and phosphorylation of FAK is a rapid event 
associated with focal adhesion formation143. In keeping with a critical role for 
FAK in cell migration, it has been shown FAK-deficient cells spread more 
slowly on ECM, exhibited an increased number of prominent focal adhesions 
and migrated poorly in response to haptotactic and chemotactic signals144–
147.   
 
FAK regulates cell migration through a number of pathways but in particular 
through the Rho subfamily of small GTPases and the assembly/disassembly 
of actin cytoskeleton148.  FAK deletion in fibroblasts leads to increased RhoA 
activity, increased cell spreading and reduced cell migration – observations 
which can be rescued by FAK re-expression in these cells149–151. 
 
EC proliferation is one of the hallmarks of endothelial regeneration.  
However, these cells have a finite proliferative capacity.  In vitro studies have 
shown that focal adhesion kinase appears to regulate not only cell migration, 
focal adhesion disassembly, and cytoskeletal rearrangements, but also 
endothelial cell proliferation in vivo and endothelial cell permeability152–155. 
 
1.4.2.1 Rho Family GTPase and endothelial cell migration 
Over twenty Rho family proteins have been identified in humans156.  The 
Rho family GTPases RhoA, Rac and Cdc42 are most studied and modulate 
EC migration by regulating actin cytoskeleton rearrangement140,157 (Figure 
1.7).  These members act as ‘molecular switches,’ cycling between an 
inactive guanosine diphosphate (GDP)-bound and an active guanosine 
triphosphate (GTP)-bound state to activate the GTPase158.  RhoA induces 
the formation of actin stress fibres and focal adhesions and stimulates cell 
contraction through downstream effectors ROCK and mDia.  Rho-kinase 
(Rho-associated coiled-coil-containing protein kinase {ROCK}) is an effector 
of GTPase RhoA159 whilst Rac and Cdc42 regulate the polymerisation of 
actin to form peripheral lamellipodial and filopodial protrusions158. 
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Cdc42 and Rac operate at the leading edge of the migrating cell.  Cdc42 
generates filopodia through inducing actin polymerisation.  Rac generates a 
protrusive force through localised actin polymerisation160.  
 
RhoA activity is associated with focal adhesion assembly, cell contractility 
and rear end retraction.  The Rho target ROCK, which stimulates 
actin:myosin filament assembly, is essential for rear cell detachment158. 
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Figure 1-7 A migrating endothelial cell.   
Migrating endothelial cells perform coordinated steps in order to move.  
Cdc42 regulates cell direction.  Rac induces lamellipodial protrusion at the 
front of the cell, this is through actin polymerization stimulation and 
integrin/focal adhesion complexes.  Finally RhoA induces actin/myosin 
contraction at the rear of the cell. 
 
1.4.2.2 Actin Remodelling 
Actin, composed of 43-kDa monomeric subunits (G-actin) that polymerise 
into filaments (F-actin), is the major cytoskeletal component of ECs.   
Remodelling of the actin cytoskeleton into filopodia, lamellipodia and stress 
fibres is essential for cell migration.  Filopodia contain long parallel actin 
filaments that are arranged in tight bundles and are membrane projections 
which act as sensors of motile stimuli.  Lamellipodia are cytoplasmic 
protrusions which form at the leading edge of migrating cells161.  Stress 
fibres are actin filaments linked by α-actinin and myosin and distributed 
along contractile fibres162, they are also linked to the cell membrane at focal 
adhesions.  These three constructions are vital to drive the steps involved in 
actin-based endothelial cell motility.   
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The steps involved in endothelial cell migration (Figure 1.8) are 
1. Sensing of the motogenic signal by filopodia 
2. Formation and protrusion of lamellipodia and pseudopodia-like 
forward extension 
3. Attachment of the protrusions to the ECM 
4. Stress fibre-mediated contraction of the cell body to allow forward 
progress 
5. Rear release 
6. Recycling of adhesive and signalling molecules139. 
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Figure 1-8 Steps involved in endothelial cell migration.   
6 steps are involved (i) sensing of the motile stimuli by filopodia (ii) cellular 
extension of protruding lamellipodia (iii) lamellipodia attachment to the 
extracellular matrix at focal adhesions (iv) forward progression of the cell via 
stress fibre-mediated contraction (v) rear release of cell by stress fibre-
mediated traction forces (vi) recycling of the adhesive and signalling 
components.  Adapted with permission from Lamalice et al, Circulation 
Research, 2007; 100:782-794. 
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1.4.3 Angiogenic Progenitor Cells and endothelial repair 
Angiogenic progenitor cells (APCs) represent a sub-population of circulating 
blood mononuclear cells which have been suggested to play a part in re-
endothelialisation of injured arteries, ischaemia-induced neovascularisation 
and maintenance of endothelial function163,164.  APCs may therefore 
represent an endogenous repair mechanism through which the integrity of 
the endothelial monolayer is maintained165,166. 
 
APCs are thought to contribute to endothelial regeneration by two main 
methods, either through release of pro-angiogenic molecules which 
stimulate proliferation of EC or other APCs or secondly by differentiating into 
mature endothelial cells that integrate into the damaged vessels.  For this to 
occur, APCs “home” to angiogenic active sites and adhere to 
damaged/activated endothelial cells or to the extracellular matrix, therefore 
contributing to the endothelial repair process (Figure 1.6)167. 
 
APC mobilisation into the circulation occurs in response to chemokines, 
cytokines and angiogenic growth factors being released following particular 
stimuli, e.g. ischaemia or local trauma167.  In ischaemic tissues, granulocyte 
macrophage-colony stimulating factor (GM-CSF) amplifies APC mobilisation 
and recruits APCs into the site of new blood vessel formation168.  Hypoxia-
inducible factor-1 alpha (HIF-1α), a transcriptional regulator of hypoxia-
specific gene expression, induces the expression of stromal-derived factor-1-
alpha (SDF-1α) and vascular endothelial growth factor (VEGF) in APCs or 
ECs and facilitates APC adhesion to the diseased endothelium167.  SDF-1α 
(CXCL12) modulates haematopoiesis and angiogenesis169.  SDF-1α and 
VEGF up-regulate bone marrow matrix metalloproteinase-9 (MMP-9) activity, 
which cleaves the progenitor cell membrane-bound kit ligand and allows 
APC mobilisation into the bone marrow vascular zone.  VEGF-stimulated 
APC mobilisation occurs through S-nitrosylation of NO which activates MMP-
9170.  
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Several cardiovascular risk factors (e.g. T2DM, hypertension, 
hypercholesterolaemia, smoking) are associated with a reduction in APC 
numbers and function167.  A correlation between reduced APC levels and 
endothelial dysfunction, suggests that impaired APC-mediated vascular 
repair promotes the progression of vascular disease171.   
 
Animal studies have shown that APCs contribute to endothelial regeneration 
following endothelium-denuding injury172, bypass grafting173 and 
hyperlipidaemia174 and could also be exploited therapeutically as studies 
have shown that APCs enhance endothelial regeneration166,175–179 and 
prevents neo-intimal formation172.   APC infusion also reduces the 
development of endothelial dysfunction163 and neointima166.  Taken together, 
the evidence suggests a role for APCs in maintaining endothelial 
homeostasis and preventing atherosclerosis and restenosis. 
 
1.4.3.1 APC definitions and classification 
Two main methods are commonly cited in the literature for isolating and 
quantifying APCs; identification of cells expressing specific cell-surface 
markers by flow cytometry and enumeration of cells exhibiting typical 
functional properties in cell culture.  Asahara et al180 defined APCs as cells 
positive for the haematopoietic stem cell (HSC) marker CD34 and the 
vascular endothelial growth factor 2 (VEGFR2 or KDR in humans)181.  
However, at present there is no universal definition and no specific marker 
has been identified for murine or human APCs. 
 
1.4.3.1.1 Flow cytometry  
Flow cytometry is based on immunolabelling cells with antibodies targeted 
against specific cell surface antigens and is widely regarded to be the gold 
standard for obtaining quantitative data on circulating APCs as it is 
reproducible, sensitive and specific.  However this method has a number of 
important limitations.  Currently there is no fully specific marker available to 
characterise and quantify circulating APCs.  The markers currently used 
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overlap with those of other cell lineages which make it difficult to standardise 
and compare APC quantification between published studies.  In addition, 
defining circulating APCs by their expression of cell surface markers implies 
a presumed function is attributed to a simple antigenic phenotype182. 
 
In the absence of a specific marker, a combination of haematopoietic stem 
cell markers, e.g. CD34, CD117 (cKit) and CD133, and a marker for 
endothelial cells, e.g. KDR (vascular endothelial growth factor (VEGF) 
receptor 2) and Ve-cadherin is commonly used to identify APCs in 
humans183.  Because expression of cell surface markers differ between 
species, APCs in mice are commonly classified as co-expressing the stem 
cell marker Sca-1 and the endothelial marker KDR172. 
 
A preferred approach to identify circulating APCs in the peripheral blood may 
be to include as many markers as possible.  However this approach is 
limited by the low number of circulating APCs in the bloodstream, 
representing only 0.01 – 0.0001% of mononuclear cells (MNCs), and a 
number of other factors such as antibody affinity and the health of the 
subject183.   Although sub-optimal, APCs are commonly defined in practice 
based on their expression of 2 or 3 cell surface antigens182.  Even though 
there is no defining standard, interesting observations have emerged using 
flow cytometry to enumerate circulating APCs in healthy and diseased 
subjects. 
   
Functional characterisation of APCs requires the expansion of MNCs by cell 
culture, as only this approach will provide the sufficient cell numbers to study 
their biological properties.  Although APCs identified by flow cytometry are 
often considered similar to those enumerated in cell culture, it is important to 
recognise that these two assays are not necessarily measuring the same 
cells and the cells can demonstrate different phenotypes182. 
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1.4.3.1.2 Cell culture 
Functional characterisation of APCs derived from peripheral blood 
mononuclear cells or storage depots (e.g. bone marrow or spleen) requires 
an appropriate method of identification and expansion in cell culture.  
 
Three distinct APC phenotypes derived from human peripheral blood 
mononuclear cells have been described in culture181 (Figure 1.9).  As with 
flow cytometry, differences in culture techniques and markers used to culture 
and identify APCs, makes comparison between studies difficult. The 
derivation and role for APCs generated by each of the three recognised 
techniques are summarised as follows:  
 
After seeding mononuclear cells onto fibronectin coated cell culture plates 
and culturing in ‘endothelial’ medium, colonies of cells with an elongated and 
spindle shape are observed - similar to the APCs first reported by Asahara et 
al181.  Cells may be identified within this population which demonstrate 
typical endothelial properties, including dual-staining for expression of 
endothelial-specific lectin and uptake of DiI-labelled acetylated low density 
lipoproteins (DiL-AcLDL)184.  These cells are called ‘early’ APCs and typically 
die within 4 weeks. ‘Early’ APCs may display myeloid-like features and their 
ability to participate in vascular repair is thought to occur via secretion of pro-
angiogenic growth factors and cytokines (e.g. VEGF and IGF-1) as opposed 
to their direct integration into the endothelium185,186.  
 
Another method of culturing ‘early’ APCs involves a pre-plating step.  
Following 48 hours of incubation of whole blood mononuclear cells, non-
adherent cells are re-plated on fibronectin plates for a further 3 days187 
where APC colony-forming units emerge a few days later.  This method 
avoids contamination of early adherent cells e.g. differentiated monocytes.  
Following re-plating, the colonies are composed of spherical-shaped cells in 
the centre with surrounding spindle shaped cells.  These colony forming 
units also contain cells that stain for both DiI-AcLDL and lectin.  However, 
Yoder et al demonstrated that these colony-forming units ‘display 
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hematopoietic-restricted and macrophage-specific cellular proteins, possess 
limited hematopoietic colony-forming activity, and function as macrophages 
to ingest bacteria’188.  These cells, therefore, may be regarded  as different 
to traditional ‘early’ APCs which have a greater proliferative capacity and 
show greater endothelial morphology182.    
 
‘Late outgrowth’ APCs or endothelial colony forming cells (ECFCs) display a 
cobblestone morphology typical of endothelial cells after 3 weeks of culture 
and are capable of multiple passages181.  To generate late outgrowth APCs, 
peripheral blood MNCs are plated onto fibronectin-coated plates.  Non-
adherent cells are discarded at intervals allowing late-outgrowth APC 
colonies to develop from the adherent cells after 2-3 weeks.  Flow cytometry 
indicates that late outgrowth APCs are CD146+CD34+CD31+CD45-AC133- 
expressing cells - similar to mature circulating and resident ECs181,189. 
 
 46 
 
Figure 1-9 Differing methods of in vitro expansion of APCs.   
Image taken with permission from Hirschi et al ATVB 2008; 28: 1584-95. 
 
In vivo¸ all types of APCs show similar vasculogenic capacity185, however 
‘late’ APCs have a higher proliferative capacity, incorporate themselves into 
the endothelium and are considered by some to represent true endothelial 
progenitors184.  Studies using ‘Early’ APC colonies from peripheral blood 
culture of MNCs should be interpreted with caution as it has recently been 
demonstrated that platelet-derived microparticles can be taken up by MNCs, 
which can, as a consequence, artefactually acquire EC characteristics190.  In 
summary, there is no single, universally accepted definition for the 
identification of APCs, resulting in the use of different markers and culture 
assays used to isolate and measure APCs. Late-outgrowth APCs are very 
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difficult to culture from mice and only a few centres have succeeded in 
developing reproducible protocols191. 
 
1.4.3.2 APCs and Cardiovascular disease 
An imbalance between endothelial damage and repair has been proposed 
as an important step in the development of atherosclerosis.  In support of 
this suggestion, numerous reports indicate that reduced APC numbers and 
APC dysfunction are associated with an increased risk of CVD.  In particular, 
atherosclerotic risk factors are linked inversely with the number of APCs in 
the blood in vivo and with APC function in vitro169,183,187,192–196. 
 
1.4.4 Insulin resistance and defective endothelial repair 
Compelling evidence indicates a negative association between diabetes, IR 
and impairment in endothelial regeneration/repair.  Diabetes is associated 
with a pronounced increase in the risk of vascular pathologies in which 
effective endothelial regeneration is required. In-stent restenosis, stent 
thrombosis and bypass graft failure are all much commoner in individuals 
with diabetes than in those without197–199.  
 
At the mechanistic level, diabetes is associated with decreased expression 
of SDF1-α200 and CXCR4 in peripheral mononuclear cells201, which may 
inhibit APC recruitment from the circulation.  Diabetes not only impairs APC 
mobilisation, but is also associated with reduced numbers of APCs which are 
dysfunctional in vitro202-203, APCs from individuals with diabetes display 
multiple functional impairments such as reduced proliferation, adhesion, 
migration and incorporation into tubular structures204-205.  Li et al175 
conclusively demonstrated that T2DM is associated with impaired re-
endothelialisation following arterial endothelial denudation in mice. They 
found that diabetic APC recruitment to the injured vessel in vivo was 
reduced and in vitro, diabetic APCs exhibited decreased cell adhesion and 
migration.   
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Animal studies reveal that IR per se is sufficient to impede endothelial repair 
in the presence of normal blood glucose concentrations206.  In models of 
whole-body and endothelial-specific insulin resistance, PI-3 kinase/Akt 
signalling and NO bioavailability are downregulated70,71.  These pathways 
play essential roles in APC mobilisation and endothelial regeneration204,207. 
Endothelial regeneration following wire-injury of the femoral artery is delayed 
significantly in insulin receptor knockout (IRKO) mice compared with wildtype 
(WT) mice (Figure 1.10)206.  These findings were associated with reduced 
numbers of APCs and impaired APC mobilisation from the bone marrow in 
IRKO mice.  Interestingly this paper demonstrated that endothelial 
regeneration is restored to normal by transfusing insulin-sensitive APCs or 
bone-marrow cells from wild type mice206.  A recent study by Fu et al208 
investigated the effects of endothelial repair following femoral artery injury in 
non-obese diabetic and metabolic syndrome mice.  The authors found that 
diabetic and metabolic syndrome mice had a 5-6 times increase in 
neointimal hyperplasia and a prolonged period of EC apoptosis compared to 
WT mice208, hence confirming the theory that IR causes defective 
endothelial repair. 
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Figure 1-10.  Time dependent endothelial regeneration following 
vascular injury in WT and IRKO mice.   
IRKO mice show delayed and impaired endothelial regeneration compared 
to WT mice.  (*P<0.05; n=5 mice per group).  Reproduced with permission 
from Kahn et al206.  
* 
* 
* 
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1.5 Insulin-like growth factor binding protein-1 
In the preceding sections of this chapter, the role of insulin on the 
endothelium and the effects of IR on endothelial regeneration have been 
discussed.  However, there is recognised to be a close synergy between the 
actions of insulin and those of the related peptide Insulin-like Growth Factor-
1 (IGF-1) which has similarly been implicated in IR, T2DM and CVD209.  IGF-
1 shares similar signalling functions to insulin, possibly due to their receptors 
on ECs sharing structural qualities210 and more interestingly both insulin and 
IGF-1 play parallel roles in metabolic and vascular homeostasis211.   
 
Unlike insulin, in which bioactivity is modulated by rapid changes in plasma 
concentrations, the bio-availability of IGF-1 is dependent upon its interaction 
with a family of high affinity binding proteins (IGFBP). IGFBPs limit 
interaction of IGFs with their receptor and are generally considered to inhibit 
IGF bioavailability.  However, certain IGFBPs are now recognised to act as 
signalling molecules in their own right independently of IGFs.  IGFBP-1 is of 
particular interest as not only can it signal independently of IGF-1, but its 
plasma concentrations vary dynamically in response to nutritional cues 
allowing minute-by-minute regulation of IGF bioavailability.  
 
1.5.1 Insulin-like growth factor-1 
IGF-1 is produced mainly by the liver, with circulating IGF-1 levels largely 
regulated by growth hormone via a negative feedback mechanism212.  In 
addition to its action as a growth factor, IGF-1 acts as an important hormone 
in regulating glucose metabolism.  Like insulin, IGF-1 is capable of 
stimulating glucose uptake, glycogen synthesis, lipogenesis, increases 
insulin sensitivity and shares many components of the insulin signalling 
pathway213.  
 
IGF-1 circulates bound to IGF-binding proteins (IGFBPs).  IGFBPs extend 
the half-life of IGFs and modulate their interaction with receptors thereby 
influencing their biological activity214.  IGF-1 bioavailability is regulated tightly 
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by a family of 6 IGF-binding proteins (IGFBPs) which bind 99% of IGF-1 with 
high affinity215.  IGFBPs functions are regulated by phosphorylation, 
proteolysis, polymerisation and cell or matrix association of the IGFBP216.  
All IGFBPs have shown to inhibit IGF-1 action, but IGFBP-1, -3 and -5 have 
also been shown to stimulate IGF-1 activity under certain experimental 
conditions217. IGFBPs also have IGF-1 independent effects, not only acting 
as carrier proteins but also as signalling molecules218.  
 
Most IGFBPs form a binary complex with IGF-1 which crosses freely into the 
extravascular space. Over 90% of IGF-1 circulates in a large ternary 
complex with IGFBP-3219. This complex is restricted to the intravascular 
space, therefore it has been thought the role of IGFBPs is to restrict IGF-
bioavailability whilst prolonging its half-life.  
 
1.5.2 Insulin-like Growth Factor Binding Proteins 
IGFBPs are a family of homologous proteins, totalling 6 members all varying 
in molecular size, hormonal control and functional significance.  All members 
of the IGFBP family have a conserved N-terminal cysteine-rich domain, 
including the IGFBP motif GCGCCXXC, but vary in the intermediate region 
and C-terminal domain of the protein220.  The expression of IGFBPs is 
tissue- and developmental stage specific, and the concentrations in different 
compartments vary. IGFBPs functions are regulated by phosphorylation, 
proteolysis, polymerization and cell or matrix association of the IGFBP220. 
 
1.5.2.1 Structure 
IGFBP secretion is mainly hepatic, however they are also secreted in 
kidneys and reproductive organs and most cell types express at least one 
member of the IGFBP family.  The IGFBP family comprises 6 soluble 
proteins ranging in length from 216 to 280 amino acids221 and mass from 
approximately 24 to 50kDa222.  The IGFBPs share a similar overall 3-domain 
structure, with the structured N- and C-terminal domains connected by a less 
structured linker domain222.  The N-terminal domain of 80-93 amino acids 
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shares approximately 60% similarity across the IGFBP family, with cysteines 
that contribute to configuration by forming disulphide bonds223.  High-affinity 
binding to IGF is the only defined function shown for this domain220,224.  The 
C-terminal is also vital for IGF binding.  In addition this region contains 
individual motifs that can interact with biomolecules and therefore exert IGF-
independent actions.  For example, IGFBP-1 and IGFBP-2 contain an Arg-
Gly-Asp (RGD) motif which can interact with integrins225,226.  The least 
conserved region is the central linker domain.  The linker domain comprises 
sites affected by post-translational modifications including proteolysis and 
phosphorylation and contain specific binding motifs that facilitate ECM 
associations and interactions with cell-surface proteins227.  
 
1.5.2.2 Function 
The fundamental role of IGFBPs is to regulate IGF-1 bioavailability at the 
cellular level.  Interestingly, IGFBPs can also interact with a wide spectrum 
of molecules such as plasminogen, transferrin, integrins and fibronectin228 
and demonstrate novel actions independent of IGF-1.  Observational studies 
have shown altered levels of individual IGFBPs in certain diseases, alluding 
to a role for IGFBPs as potential biomarkers.  Low concentrations of IGFBP-
1, -3, -6 and increased concentration of IGFBP-2 predict increased 
neoplastic risk in breast and colorectal tissue; in addition IGFBP-3 is 
negatively associated with lung and prostate malignancy, and acute 
lymphocytic leukaemia220,229.  Low concentrations of IGFBP-1, -2 and -3 are 
associated with disorders of metabolic homeostasis and cardiovascular 
disease227. 
     
1.5.3 Insulin-like Growth Factor Binding Protein-1 
IGFBP-1 is a 25kDa protein produced mainly in the liver and kidney and with 
lesser expression in the reproductive system227.  The crystal structure of the 
C-terminal domain of IGFBP-1 has been determined.  The N- and C-terminal 
portions are highly conserved across the IGFBP family and are responsible 
for IGF binding (Figure 1.11).  Although less than 5% of total bound IGF is 
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bound to IGFBP-1227,230,231,  IGFBP-1 has a prominent role in regulation of 
IGF-1 bioactivity as its plasma concentration is acutely and dynamically 
regulated in response to nutritional cues (e.g. fasting or post-prandial 
states)227.  Inhibition of IGFBP-1 synthesis by changing hepatic portal insulin 
concentrations provides the connection between ambient insulin levels and 
the hypoglycaemic potential of IGF-112.  In addition to its regulatory role in 
IGF-1 bioactivity, IGFBP-1 can interact directly with cells through its Arg-Gly-
Asp (RGD) integrin binding motif, which has functional significance 
independent of IGF-1225.  
 
IGFBPs predominantly control the access of IGFs to tissues and cell-surface 
IGF receptors.  Of these, IGFBP-1 is the most likely candidate for acute 
regulation of IGF actions because of its acute down regulation by insulin and 
up regulation by other glucoregulatory hormones and cytokines and in 
catabolic states227.  Furthermore, trans-endothelial movement of IGFBP-1 
into the tissues is known to occur and to be enhanced by insulin.  IGFBP-1 
thus provides an important link between intermediary metabolism and 
regulation of IGF actions227.  Low IGFBP-1 concentrations result in greater 
IGF bioavailability and promote IGF-induced effects on major blood vessels, 
myocardial tissue and lipid metabolism227.  
 
IGFBP-1 has both inhibitory and stimulatory effects on IGF-1 bioavailability.  
With respect to glucose regulation, it has been suggested that an overall 
inhibitory effect predominates and therefore diminishes the hypoglycaemic 
response to exogenous IGF-1227.  
 
Serum levels of IGFBP-1 vary considerably depending on the metabolic 
conditions and correlate inversely with both body mass and serum levels of 
insulin.  Down-regulation of IGFBP-1 levels by insulin contributes to the 
metabolic response to food intake because a decrease in IGFBP-1 would 
increase the bioavailability of IGFs, which exert insulin-like metabolic 
functions.  Overexpression of IGFBP-1 in mice has provided additional 
insights into the physiological role of IGFBP-1 in glucose metabolism.  
Wheatcroft et al found reduced blood pressure after a glucose challenge and 
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increased vascular production of nitric oxide in mice expressing human 
IGFBP-1 under the control of the native promoter and regulatory 
sequences232.  Another study by the Wheatcroft group found that in IGFBP-
1-overexpressing mice subjected to diet-induced obesity, there was 
improved insulin sensitivity and increased insulin-stimulated NO 
generation233.  However some other data pertaining to the metabolic 
phenotype resulting from IGFBP-1 overexpression are conflicting. For 
example, transgenic mice overexpressing the IGFBP-1 gene under the 
control of different (constitutive) promoters showed impaired glucose 
tolerance and abnormalities of insulin action, suggesting that IGFBP-1 may 
participate in disruption of the physiological control of glucose 
homeostasis234.   
 
IGFBP-1 is post-translationally regulated by phosphorylation at multiple 
serine residues, which leads to an active form of the protein and this occurs 
in response to changes in the metabolic environment. The majority of 
circulating IGFBP-1 is in the phosphorylated form, which has a 10 fold higher 
binding affinity for IGF-1 than the dephosphorylated form.  Phosphorylation 
of IGFBP-1 therefore represents a potential mechanism by which IGF-1 
bioavailability is regulated235.   
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Figure 1-11 Generalised diagram of IGFBP structure showing proposed 
interaction with IGF-1 through both N and C domains.   
Reproduced with permission from Firth et al220. 
 
1.5.3.1 IGF-dependent actions of IGFBP-1 
Both inhibitory and stimulatory effects of IGF-1 activity by IGFBPs have been 
reported217,236–238.  An inhibitory effect of IGFBP-1 on glucose regulation is 
consistent with the observation that administration of IGFBP-1 reduces the 
hypoglycaemic response to exogenous IGF-1234,239.  IGFBP-1’s affinity for 
IGF-1 exceeds the affinity of IGF-1 for the type-1 IGF-receptor, therefore 
IGFBP-1 reduces free IGF-1 levels and inhibits signalling via the IGF 
receptor.  In the fasting state, IGFBP-1 levels are high due to the low 
inhibitory effect of insulin and the stimulatory effect of cortisol and glucagon 
on hepatic IGFBP-1 transcription.  The high IGFBP-1 state limits IGF 
bioavailability and therefore decreases the insulin-like activity of IGF-1 on 
peripheral metabolism.  In the post-fed state, the opposite occurs, 
carbohydrate loading causes insulin to rise and therefore IGFBP-1 levels fall 
rapidly, resulting in increased IGF-1 bioactivity which augments the insulin-
like actions of IGF-1227. 
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1.5.3.2 IGF-independent actions of IGFBP-1 on cells  
IGFBP-1 can independently enhance migration in certain (non-vascular) 
cells.  Jones et al225 found that IGFBP-1 increased Chinese hamster ovary 
cell migration independently of IGF-1 through α5β1 integrin activation.  
Integrin-mediated effects of IGFBP-1 have also been demonstrated in 
human trophoblast migration240 and in human breast cancer cells241.  
IGFBP-1 can directly interact with cells by the Arg-Gly-Asp (RGD) motif in 
the C-terminus of IGFBP-1 with cell surface α5β1 integrins, a mechanism 
which has been proposed to mediate IGF-independent effects225,242.  It is 
also interesting to note that integrin signalling influences metabolic 
pathways.  For example, FAK is activated after integrin engagement and 
interacts with multiple signalling pathways such as PI-3-kinase-Akt 
pathway243,244. 
 
1.5.3.3 Circulating Insulin-like Growth Factor Binding Protein-1 
and Insulin resistance 
There is overwhelming evidence supporting a strong association between 
IGFBP-1 and insulin-sensitivity. In particular, decreased IGFBP-1 levels are 
observed in individuals with insulin resistant states (metabolic syndrome, 
obesity, T2DM)245–247.   
 
In addition, low fasting circulating IGFBP-1 levels are found in obese 
children248, adolescents249 and adults250 and low IGFBP-1 is recognised as a 
marker for the metabolic syndrome in population studies245,251–253. 
 
One cross-sectional study254 looking at young healthy men in different ethnic 
groups found that fasting IGFBP-1 levels are a significant predictor of insulin 
sensitivity.  A combination of low fasting IGFBP-1 levels and relative insulin 
resistance was shown in healthy, glucose tolerant Asian patients, which may 
partially explain their higher risk of developing diabetes and cardiovascular 
disease. 
The IGF-1 system has been related to poor glucose control and low levels of 
IGF-1 are predictive of future T2DM255.  In addition, low IGFBP-1 and high 
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IGFBP-3 relate to increased cardiovascular risk214,256 and have all been 
independently associated with the presence of the metabolic syndrome and 
with insulin resistance257.  
 
Two prospective studies have identified low IGFBP-1 concentrations as a 
predictor of future development of diabetes.  One long-term follow-up study 
identified that low IGFBP-1 and low IGF-1 levels predicted an increased risk 
of T2DM255.  A Swedish longitudinal study found that low fasting IGFBP-1 
concentrations predicted the development of T2DM over ten years258.  
Interestingly, in individuals who developed diabetes, IGFBP-1 levels 
increased by almost a third in this study258.  Possible explanations were 
given for the rise in IGFBP-1 levels such as IGFBP-1 being a marker of 
decreasing β cell function and inflammatory cytokines playing an unspecified 
role. 
 
1.5.3.4 Insulin-like Growth Factor Binding Protein-1 and 
Cardiovascular Disease 
In addition to the links with metabolic regulation discussed above, circulating 
IGFBP-1 concentrations have also been associated with the risk of incident 
CVD and mortality.  The Rancho Bernardo Study259, a longitudinal study, 
demonstrated an association of low levels of IGFBP-1 with all-cause 
mortality.  Low circulating IGFBP-1 levels were associated with high 
triglyceride, low HDL cholesterol levels and higher concentrations of glucose 
and insulin259.  
 
Several cross-sectional studies have shown plasma IGFBP-1 concentrations 
are negatively correlated with markers of insulin resistance, cardiovascular 
risk factors and carotid intima thickness2,3,12,20,256,259–261.  These findings 
suggest that low levels of IGFBP-1 may be permissive for the development 
of CVD.  However some groups have found conflicting conclusions213,262.  
Hu and colleagues230 found a strong and significant association between 
higher IGFBP-1 and IGFBP-2 levels and mortality in the elderly.  
Paradoxically, despite the apparent association with increased mortality, 
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higher IGFBP-1 and IGFBP-2 levels were associated with favourable risk 
factors, including lower fasting glucose and lower fasting insulin levels.   
Mellbin et al investigated the prognostic importance of IGFBP-1 in patients 
with CVD and T2DM263.  In this study, copeptin (a peptide which is activated 
by stress and plays pivotal roles in vascular tone and osmoregulation) was 
associated with IGFBP-1 levels.  The investigators postulated the apparent 
association between IGFBP-1 and adverse outcomes observed in some 
studies may be explained by confounding through the association between 
IGFBP-1 and copeptin263. 
 
1.5.3.5 Insulin-like Growth Factor Binding Protein-1 and 
Endothelial function 
Interest in a potential role of IGFBP-1 in vascular physiology was prompted 
by previous work in our laboratory, with the generation of a transgenic 
mouse which over-expresses human IGFBP-1.  In this model, increased 
circulating IGFBP-1 concentrations were associated with increased basal 
vascular NO production and lower blood pressure232.  Recently our 
laboratory has shown that IGFBP-1 directly upregulates NO generation in 
ECs, independently of IGF-1, via PI-3 kinase activation and eNOS 
phosphorylation.  IGFBP-1 was also shown to favourably modulate vascular 
phenotype in vivo, specifically in the setting of insulin resistance. For 
example, in obese and non-obese mouse models of insulin resistance, 
IGFBP-1 over-expression protected against blood pressure elevation, 
rescued endothelial function and enhanced endothelial insulin-sensitivity 
(obese mouse model of insulin resistance only).  Finally in a murine model of 
pro-atherogenesis, IGFBP-1 over-expression protected against the 
development of atherosclerosis. 
 
In summary, this introduction has highlighted the increasing global 
prevalence of T2DM and IR.  Recognition that these states impair the 
capacity for endothelial regeneration emphasises the importance of 
discovering potential new treatments to improve endothelial regeneration 
and prevent cardiovascular disease.  IGFBP-1 is an endogenous protein 
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which is implicated inversely with IR and CVD.  In vivo and in vitro studies 
have shown a protective role for IGFBP-1 in endothelial function and 
atherosclerosis, however the effects of IGFBP-1 on endothelial regeneration 
have not been investigated and form the focus of this thesis.  Understanding 
the role of IGFBP-1 in endothelial regeneration is important in order to 
identify novel treatments to promote endothelial repair in insulin resistant 
patients. 
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2 Original hypothesis, 
objectives and experimental 
design 
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The fundamental hypothesis of this thesis is: 
 
IGFBP-1 augments vascular endothelial repair in the setting of insulin 
resistance by promoting endothelial cell/angiogenic progenitor cell reparative 
functions. 
 
2.1 Objectives 
1. To investigate the effect of IGFBP-1 over-expression on endothelial repair 
in vivo. 
2. To examine the effect of IGFBP-1 on the functional properties of human 
ECs implicated in endothelial repair in vitro. 
3. To examine the effect of IGFBP-1 on the functional properties of APCs 
implicated in endothelial repair in vitro. 
4. To identify the molecular mechanisms of functional effects determined in 
objectives 2 and 3. 
 
2.2 Experimental design 
The following complementary in vivo and in vitro approaches were employed 
to investigate endothelial-reparative effects of IGFBP-1: 
 
1. To assess the impact of IGFBP-1 on endothelial regeneration, murine 
models with over-expression of human IGFBP-1 either in an insulin 
sensitive or insulin resistant setting were subjected to arterial injury 
resulting in complete denudation of the endothelium.  The time-course 
and completeness of endothelial regeneration were then evaluated. 
2. To investigate the effect of IGFBP-1 on APC abundance, the number 
of APCs in the mononuclear fraction of peripheral blood was 
quantified by flow cytometry in murine models with over-expression of 
human IGFBP-1 with/without insulin resistance. 
3. To investigate the effect of IGFBP-1 on APC abundance and function, 
APCs were expanded from peripheral blood, bone marrow and spleen 
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from murine models with over-expression of human IGFBP-1 
with/without insulin resistance.. 
4. To assess the effect of IGFBP-1 on endothelial cell functional 
properties implicated in endothelial repair, the influence of direct 
IGFBP-1 exposure on cell migration and proliferation was investigated 
in human ECs. 
5. The effects of IGFBP-1 on ex-vivo angiogenesis and ex-vivo 
endothelial regeneration were also investigated using murine aorta 
and human saphenous vein samples respectively. 
6. Investigations were carried out to identify the molecular mechanisms 
by which IGFBP-1 modulates endothelial repair, focussing on Focal 
adhesion kinase, Rho-kinase and integrins. 
 
These 6 broad experimental approaches will be described in detail in 
chapters 4-7.  Chapter 3 will outline generic methods used in this research 
project in terms of their general application. 
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3 General Methods 
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3.1 Bioreactive agents 
Bioreactive agents that are used across a number of protocols are described 
here to detail their source and handling.  Purified native human IGFBP-1 
(Groprep, Adelaide, Australia) was reconstituted in 10mmol/L HCL and snap-
frozen in liquid nitrogen.  Qualitative analysis and mass spectrometry from 
the manufacturer confirmed the absence of other binding proteins and IGF-
1.  Recombinant cell-culture grade insulin (Sigma) was reconstituted in 
HEPES buffer when used with endothelial cells.  VEGF (R&D, Minneapolis) 
was reconstituted in filter-sterile water.  PBS and Trypsin/EDTA were 
obtained from Gibco, BRL.  BSA was purchased from Sigma.  FCS was from 
Biosera, East Sussex and was subject to in-house batch-testing. 
 
3.2 Endothelial cell culture 
Human umbilical vein endothelial cells (HUVEC) and human coronary artery 
endothelial cells (HCAEC) (Promocell, Heidelberg, Germany) were shipped 
at secondary passage in cryo-medium on dry ice and stored immediately in 
liquid nitrogen.  To recover the cells, the cryo-vial was submerged in a water 
bath at 37°C until fully thawed, and transferred to 5 mL of Endothelial cell 
growth medium (20% FCS).  Typical endothelial features such as 
cobblestone appearance and contact inhibition were confirmed on culture. 
 
Endothelial cells were seeded either in a 25cm3 or 75cm3 tissue culture flask 
and were maintained in a humidified incubator with 5% CO2 at 37°C.  Growth 
medium was half-exchanged every 2 days.  Once cells reached 90% 
confluence, cells were washed with warm PBS and then passaged at a ratio 
of 1:3 using Trypsin/EDTA at room temperature for 2 minutes.  Endothelial 
cells were reseeded in either a tissue culture flask or a cell culture plate.  In 
all cases, cells were used between passage number 4 - 7. 
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3.3 Animal husbandry 
3.3.1 Gene manipulation in mice 
Transgenesis of mice were not undertaken by the author, as breeding 
colonies were already established at the University of Leeds.  Generation of 
these models have been described by investigators in previously published 
literature, and is briefly summarised below. 
  
3.3.2 Insulin receptor knockout mice with over-expression of 
IGFBP-1 
Mice with transgenic over-expression of human IGFBP-1 were originally 
generated by Crossey et al234 at King’s College London.  A cosmid clone 
was purified which encompassed the human IGFBP-1 structural gene 
including all the cis sequences necessary for tissue specific regulation.  Mice 
with knockout of the insulin receptor were originally generated by Accili et 
al264 at the National Institute of Health, Bethesda, USA.  Mice for use in this 
project were supplied by the Medical Research Council Mammalian Genetics 
Unit, Harwell, Oxfordshire and backcrossed to C57BL6 for 12 generations.  
Mice with heterozygous knockout of the insulin receptor (IRKO) are viable, 
however mice homozygous for the null allele (IR-/-) die as neonates from 
ketoacidosis.  IGFBP-1 and IRKO mice were intercrossed to generate 
offspring of the following 4 genotypes: WT, IRKO, IGFBP-1  and 
IRKO*IGFBP-1.   
 
3.3.3 Housing and experimental conditions 
As mandated by the Experimental Animals (Scientific Procedures) Act 1988, 
experiments were conducted in full compliance with Home Office UK 
regulations.  Experiments were sanctioned under personal licence PIL 
40/9839 and project licence numbers 40/2988 up until 24/7/2011 and 
40/3523 from 25/7/2011 onwards.  Mice were housed in the University of 
Leeds animal facility, under standard laboratory conditions in humidity (55%) 
and temperature (21°C) controlled conditions with a 12-hour light-dark cycle, 
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and free access to food and water.  Offspring were weaned to standard 
chow diet (B&K Universal Ltd, Hull) at age 3-4 weeks, at this point littermates 
were separated by gender.  Ear-notching by punch-biopsy in conscious mice 
allowed numerical identification, the ear notches were subsequently used for 
DNA analysis. Littermates were housed together with same sex siblings in 
groups of up to four animals per cage. Housing of single animals was 
avoided wherever possible. 
 
Male mice aged 8-16 weeks were used for experimental procedures. 
Oestrogen is well known to significantly affect APC biology, therefore female 
mice were not studied due to their cyclical hormonal changes. 
 
For animal euthanasia, mice were left unconscious by 4 minutes of CO2 
exposure followed by blunt dislocation of the cervical spine, except in 
endothelial regeneration studies where terminal anaesthesia with perfusion 
fixation using paraformaldehyde was employed before femoral artery 
extraction. 
 
3.3.4 Breeding conditions 
Breeding pairs or trios (1 male with up to 2 females on an IRKO background) 
were established with only the male carrying the IGFBP-1 transgene.  This 
was to avoid the potentially confounding influence of maternal in utero 
IGFBP-1 over-expression.  Mating programmes required mice of at least 6 
weeks of age and ideally less than 6 months of age.  Mice were allowed free 
access to standard chow diet and water, and offspring were separated from 
parents after weaning. 
 
3.4 Blood sampling from mice 
3.4.1 Animal handling  
Prior to experiments mice were acclimatised for at least 10 minutes in an 
undisturbed quiet room at a controlled ambient temperature of 21°C. 
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Conscious mice were gently placed in a restraining device that allowed free 
air flow.  If mice became unduly agitated during a blood testing session the 
experiment was discontinued and repeated the next day. 
 
3.4.2 Blood sampling 
Blood was required from mice for flow cytometry and cell culture 
experiments.  For flow cytometry assessments, conscious mice were placed 
in a cylindrical restraining device head-first, whilst the right leg was gripped 
between the operator’s left thumb and index finger.  Typically, mice had 
already been acclimatised to restraining devices through prior training 
sessions.  The limb was removed of hair with hair removal cream, which 
exposed the lateral saphenous vein, this was them lightly punctured using a 
14G needle.  Up to 200μL of blood was collected into capillary blood 
collection tubes coated with powdered lithium heparin (Sarstedt, Numbrecht) 
and stored on ice before further processing.  Haemostasis at the puncture 
site was achieved with light pressure. When repeated sampling was 
required, light disturbance of thrombus at the puncture site was sufficient to 
provide fresh whole blood.  For cell culture experiments, up to 1mL was 
obtained from the vena cava under terminal anaesthesia.  Mice were 
anaesthetised with isofluorane (see below) before a vertical abdominal 
incision was made. The vena cava was exposed and up to 1mL of blood was 
aspirated using a 29G needle. 
 
3.5 General anaesthesia  
Invasive murine studies (arterial injury, vessel harvest, blood collection for 
APC culture) required a general anaesthetic (isoflurane).  The anaesthetic 
apparatus consists of tubes running from an isoflurane vaporiser to a carbon 
filter with valves that either open or close the tube’s circulation.  One tube 
controls the flow of isoflurane and oxygen to the induction chamber unit of 
the isoflurane set up (this is where the mouse is initially exposed to the 
anaesthesia and is sedated) and another tube controls the flow of isoflurane 
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and oxygen to the mask portion of the isoflurane set up, (this tubing has a 
nose cone attached and is eventually fitted to the mouse) (Figure 3.1). 
 
Figure 3-1 Apparatus for general anaesthesia.   
(With permission from Kahn MB PhD Thesis, University of Leeds). 
 
Once the system is checked to ensure there are adequate amounts of O2 
and isoflurane for the duration of the procedure, the system was set to flow 
towards the induction chamber and the O2 supply was turned on. The mouse 
was placed into the induction chamber (this housing unit is ventilated with 
oxygen and isoflurane) and the isoflurane vaporiser was turned on and 
adjusted to 2.5-3.5%.  The oxygen was then turned on and adjusted to at 
least 1 litre per minute (this level of oxygen was maintained throughout the 
entire procedure).  Once unconscious, the system was switched to flow to 
the nose cone, providing isoflurane to the mouse nose cone (at this point the 
gas to the induction chamber was turned off).  Tubing connected to the 
isoflurane vaporiser and oxygen was taped to the operating table and the 
mouse was then removed from the chamber and the head positioned in the 
nosecone and the body of the mouse was secured to a warmed table pad 
Isoflurane 
vaporizer 
Induction 
chamber Carbon 
filter 
Nose cone 
Operating table 
Tubes controlling flow of 
isoflurane and oxygen 
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(38°C) with tape. Maintenance anaesthesia was kept between 1.5-2.5%; if an 
animal started responding, the mouse was gently restrained in the nosecone 
until fully anesthetized again. Respiration and response to stimulation during 
the procedure were monitored and the anaesthetic adjusted accordingly. On 
completion of the procedure, the vaporiser was turned off and the mouse 
was allowed to breathe O2 until it awoke. The mouse was then placed in a 
recovery area with thermal support until fully recovered. Mice received post-
operative analgesia (buprenorphine 0.25mg/kg s.c.). 
 
3.6 PCR genotyping 
3.6.1 DNA extraction 
Mice were genotyped by amplification of DNA from ear notch digests by the 
polymerase chain reaction (PCR). Ears were marked by cutting of small 
notches in the periphery of the pinna according to a standardized numbering 
protocol.  
 
100µL of NaOH+EDTA was added to the sample and placed on heat block 
(pre-heated to 95°C) for 20 minutes.  After 20 minutes, samples were taken 
off the heat block and 100µL of 40mM Tris-HCl were added.  Samples were 
then vortexed and placed in the fridge to cool down for 30 minutes to 1 hour 
for immediate PCR or stored at 4°C until required. 
 
3.6.2 Conventional polymerase chain reaction  
PCR was performed in 25μL reaction volumes using a thermal cycler (MJ 
Research).  This was performed under a laminar flow hood to prevent any 
contamination, with pipetting via DNAase-free tips. Oligonucleotide primers 
were prepared commercially (Invitrogen), with sequences derived from 
published literature.  Sequences complementary to the human IGFBP-1 
transgene were GCA TCA TGG GCA GCT GGT TTC AC (forward) and CAA 
GGG TAG ACG CAC CAG CAG AG (reverse).  The sequences 
complementary to the alleles encoding InsR null and wildtype functional InsR 
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were TTA AGG GCC AGC TCA TTC CT CC (forward, inside neomycin 
cassette), AGC TCT GCA CTT CCC TGC TC AC (forward, inside 
endogenous receptor allele) and TCT TTG CCT GTG CTC CAC TCT CA 
(reverse, inside endogenous receptor allele).  The PCR products were 
maintained at 4°C after thermal cycling was complete.  
 
Table 1: Reagents quantities (µl) for 25µl reaction volumes and PCR 
amplification profiles as optimised with specific primers 
 IGFBP-1 IRKO 
Buffer 2.5 2.5 
MgCl2 1.5 2 
dNTPS 0.4 0.5 
Primer 1 0.5 0.5 
Primer 2 0.5 0.5 
Primer 3 - 0.5 
Taq polymerase 0.125 0.5 
ddH20 18.475 17 
DNA solution 1 1 
Amplification profile (hold; 3-stage cycle; hold) 95C 5 mins; 
95C 1 min, 
63C 1 min, 
72C 1 min; 
72C 4 mins 
94C 4 mins; 
94C 1 min, 
62C 1 min, 
72C 1 min; 
72C 4 mins 
Cycles x 35 x 31 
Band size (base-pairs) 197 (transgenic) 232 (wildtype)  
255 (Insr null) 
 
PCR product abundance was determined by electrophoresis on a 1.5% 
agarose gel (with ethidium bromide).  Under ultraviolet imaging bands were 
detected and assessed using a software package (Chemilmager 5.5).  PCR 
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products molecular weight was estimated by running a 100 base pair ladder 
on the same gel. 
 
3.6.3 DNA gel-resolution and detection 
Using a 1.2% agarose gel, PCR products were visualised by 
electrophoresis. 1.2% agarose gel was made by denaturing 1.2g agarose 
(Bioline, London) in 120mL TAE buffer (50X solution: 242g TRIS base, 
750mL H20, 57.1mL glacial acetic acid, 100mL 0.5M EDTA pH 8 made up to 
1L with ddH20 (diluted to a 1X solution with ddH20)) in an 800W microwave 
for 1 minute and 30 seconds, using an autoclaved beaker. 5μL ethidium 
bromide (Sigma) was added after cooling to 40°C, and this viscous solution 
was left to cool for 2-3 minutes and then poured into a running tray. A comb 
was placed prior to setting in the running tray, to form indentations into which 
21μL of each PCR reaction solution could subsequently be pipetted. PCR 
product was then separated by electrophoresis by conducting 100V across 
TAE buffer bathing the gel for 60 minutes.  The PCR product was visualized 
in a light cabinet using AlphaEase software (Alpha Innotech Corp, CA) and 
identified by reference to a 100 base-pair ladder. 
 
3.7 Statistical analysis and data presentation 
Graphpad Prism v5 (Graphpad software, San Diego, CA, USA) was used to 
perform statistical and graphical analysis.  Unless stated otherwise, 
continuous data are presented as arithmetic mean and standard error of the 
mean and n is the number of replicates.    2-tailed unpaired t-test was used 
for comparing continuous data for differences in means.  Repeated 
measures one-way ANOVA with post-hoc Newman-Keuls was used for 
analysis for experiments with multiple treatments.  p<0.05 was accepted as 
statistically significant.    
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4 The effects of IGFBP-1 on 
endothelial regeneration 
following vascular injury in 
relation to Insulin resistance 
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4.1 Introduction 
Arterial wall injury following angioplasty, stent insertion and coronary artery 
bypass surgery leads to loss of endothelial cells either through direct trauma, 
apoptosis or necrosis and triggers a number of responses such as smooth 
muscle proliferation and migration (resulting in neointimal hyperplasia)99 and 
recruitment of leucocytes and platelets (resulting in inflammation and 
thrombosis)  Adverse arterial remodelling resulting from endothelial cell loss 
contributes to atherosclerosis103, bypass graft failure104, restenosis105 and 
stent thrombosis106.   
 
Endothelial repair following injury occurs through a series of interactions 
between native EC (migration and proliferation of EC to sites of damage) 
and circulating bone-marrow derived angiogenic progenitor cells 
(APCs)113,114 which are recruited to the diseased vessel.  Studies conducted 
in the 1970s observed the dominant role of EC mitosis and migration in 
endothelial regeneration after vascular damage110–112,115,116.  Recent data 
have shown that APCs promote endothelial regeneration after vascular 
injury166,175, have an athero-protective effect174 and prevent neointima 
formation172.  Numerous human and animal studies have shown diabetes 
and IR to be associated with reduced number and function of APCs with 
delayed endothelial regeneration following arterial injury175,206,265,266.  
 
Interest in a potential role of IGFBP-1 in vascular physiology was prompted 
by previous work in our laboratory, with the generation of a transgenic 
mouse which over-expresses human IGFBP-1.  In this model increased 
circulating IGFBP-1 concentrations were associated with increased basal 
vascular NO production and lower blood pressure232. IGFBP-1 directly 
upregulated NO generation in ECs independently of IGF-1, via a signalling 
pathway comprising PI-3 kinase activation and eNOS phosphorylation267. 
Because endothelial repair is critically dependant on NO bioavailability, one 
may postulate that  IGFBP-1 may have a positive role in endothelial repair 
by increasing NO production.   
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To assess the effects of IGFBP-1 on endothelial regeneration in an insulin 
sensitive and insulin resistant setting, a well-established model of arterial 
injury was performed.  Several models of arterial injury have been described 
including extra-luminal approaches such as simple arterial ligature268, 
perivascular electric current269 and peri-arterial cuff placement270.  A more 
clinically relevant experimental model is endothelial denudation of the carotid 
artery in mice.  However, this experimental model is technically challenging 
and can cause significant complications to the animal271.  In this chapter, a 
well-validated model of femoral arterial injury was used successfully in our 
laboratory206.  This model is clinically relevant and results in complete 
endothelial denudation along with neointimal hyperplasia.  Other advantages 
of this technique include a short operative time, low morbidity and mortality 
rates in comparison to the carotid artery injury technique, and the feasibility 
of performing bilateral studies272. 
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4.2 Aims 
The aims of the investigations described in this chapter were as follows: 
1. To acquire skills in order to establish a reproducible murine model of 
femoral arterial wire-injury which results in complete endothelial 
denudation. 
2. To assess if over-expression of human IGFBP-1 increases endothelial 
regeneration after vascular injury in insulin sensitive (WT) and in 
insulin resistant (IRKO) murine models in vivo.   
3. To assess the regenerative capacity of human IGFBP-1 on murine 
thoracic aorta samples using an aortic ring angiogenesis assay ex 
vivo. 
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4.3 Methods 
4.3.1 Breeding colonies and genotype 
A breeding colony of IRKO*IGFBP-1 mice was established (as described in 
section 3.3.2) and the genotype of male offspring was determined by 
polymerase chain reaction of ear-notch tissue digests (as described in 
section 3.6.2).  Male IGFBP-1, IRKO, IRKO*IGFBP-1 mice aged 12-16 
weeks were compared with age- and sex-matched wild-type littermate 
controls. 
 
4.3.2 Arterial injury technique 
Two comparisons were performed in the arterial injury experiments, the first 
investigating the effects of human IGFBP-1 over-expression in metabolically 
healthy mice (i.e. WT vs IGFBP-1) and secondly, investigating the effects of 
human IGFBP-1 over-expression in insulin-resistant mice (i.e. IRKO vs 
IRKO*IGFBP-1).  The above murine models were subjected to femoral artery 
endothelial denuding wire-injury between 12-16 weeks of age. 
   
Surgery was performed using a dissecting microscope (Zeiss OPMI 1-FC, 
Germany).  Mice were anaesthetised (isoflurane 2-3%) before being 
positioned supine and secured to a table pad (warmed to 38°C) with tape (as 
described in section 3.5).  Mice were fixed in position with upper paws fixed 
on the nosecone and lower extremities abducted and extended.  Hair was 
removed from the lower abdomen and groins with hair removal cream.  The 
lower abdomen and groins were cleaned with providone-iodine solution 
(0.75%). 
 
An incision was made in the mid-thigh and extending towards the midline.  
After blunt dissection of the subcutaneous tissues, the fat pad across the 
vessel (which marks the point of departure of the epigastric artery) was 
identified.  To avoid damage to the epigastric artery the fat pad was handled 
carefully as this artery perfuses the limb when the main artery is ligated.  
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Overlying fascia was removed which revealed the neurovascular bundle.  
The femoral artery was carefully separated from the nerve and vein 
immediately distal to the epigastric branch.  An 8/0 suture was loosely tied 
around the femoral artery at this point and a clamp placed across the 
neurovascular bundle in the proximal operative field at the level of the 
inguinal ligament.  To prevent vasospasm, a drop of 1% lignocaine was 
pipetted onto the artery.  An arteriotomy was performed using iris scissors 
(World Precision Instruments) and then advancing a 0.36mm angioplasty 
guide wire with tapered tip (Hi-torque Cross-it 200XT, Abbott-Vascular, 
Illinois, USA) into the femoral artery using an operating microscope.  The 
angioplasty wire was advanced 3cm (clamp being removed at this point).  3 
passages in total were performed per mouse which resulted in complete 
arterial denudation (confirmed using Evans blue staining as described 
below).  The angioplasty wire was removed completely and suture tightened 
quickly.  The vessel was tied off and skin closed with continuous sutures.  
The contralateral artery underwent an identical operation without passage of 
the wire, a ‘sham’ procedure.   
 
The mouse was then placed in an incubator with thermal support until fully 
recovered. Mice received post-operative analgesia (buprenorphine 
0.25mg/kg s.c.) and were monitored for signs of distress.  All surgical 
operations were performed by Dr. Nadira Yuldasheva. 
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Figure 4-1 Femoral artery denudation.   
The angioplasty guide wire is advanced 3cm into the femoral artery.  (With 
permission from Kahn MB PhD Thesis, University of Leeds). 
 
4.3.3 Endothelial Regeneration 
After 5 days the mice were anaesthetised (this time point was selected 
based on previous data from our laboratory)206.  50 L 5% Evans blue dye 
was injected into the inferior vena cava.  After 10 minutes, the mice were 
perfusion fixed with formaldehyde before the femoral arteries were 
harvested.  Evans blue dye is an azo dye which has a very high affinity for 
albumin.  The dye binds only to exposed inter-cellular matrix when 
endothelial cells are denuded because albumin cannot cross the endothelial 
monolayer.  Therefore, absence of endothelium appears blue when 
damaged and this marks the denuded area of the femoral artery. Perfusion 
fixation was carried out via a 23G needle placed into the left ventricle under 
physiological pressure with 4% paraformaldehyde (pH 7.2).  
Paraformaldehyde was infused until the efflux (from a small incision made in 
the right atrium) ran less blue or the muscles began to fasciculate.  Vessels 
were excised of injured and non-injured femoral arteries up to level of the 
aortic bifurcation and then stored in 4% paraformaldehyde. 
 
Under a dissecting microscope (Olympus Dissecting Stereo Microscope 
5761), the arteries were then cleaned from the overlying fascia and opened 
up longitudinally and images obtained using a digital camera (QiCam 
Olympus digital camera).  The stained and unstained areas in blue were 
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measured microscopically in the injured area 5mm from the proximal suture 
and the percentage areas were calculated using ImagePro Plus 6.2 software 
(Media Cybernetics, Bethesda, USA).  This was done automatically by the 
program once the region of interest was outlined and any blue areas 
identified (Figure 4.2). Endothelial regeneration was quantified separately by 
two investigators blinded to genotype.  
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Figure 4-2 Calculation of endothelial regeneration using ImagePro Plus 
6.2 software.   
The green border represents the region of interest.  The red borders 
represents patches of blue indicating denuded endothelium.  Compare the 2 
vessels and note the patches of blue present on the injured vessel indicating 
denuded endothelium however the non-injured vessel is completely clear 
indicating an intact endothelial monolayer.  
 
 
Injured vessel 
Non-injured vessel 
Area of endothelial regeneration 
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4.3.4 Aortic ring angiogenesis assay 
An aortic ring angiogenesis assay was performed to assess the contribution 
of native mature endothelial cells and surrounding non-endothelial cells to 
angiogenesis in the absence of circulating progenitor cells.  Immediately 
after euthanasia of WT mice, the chest cavity was opened and overlying 
organs excised.  Using fine Vannas scissors (World Precision Instruments, 
Sarasota), descending thoracic aortae were carefully excised, flushed with 
ice-cold PBS until blood free.  The thoracic aorta was then placed in cold 
Krebs-Henselheit solution.  Using a dissecting microscope, surrounding 
fibroadipose tissue was dissected free and the aorta sectioned into 1-mm 
rings.   24 well culture plates were then coated with 200 µL per well of 
growth factor reduced Matrigel (BD Bioscience) and allowed to polymerize 
for 30 minutes at 37°C.  After 30 minutes, rings were then placed on growth 
factor reduced Matrigel and incubated with control vehicle or IGFBP-1 
(500ng/mL) in 10% FBS Endothelial Cell Growth Medium), which was 
replaced on alternate days.  Quantitative analysis of endothelial sprouting 
was performed using images using an Olympus CKX-41 microscope from 
day 7, sprouting analysis could occur up to 14 days from initial plating, 
however it has been known that peak sprouting occurs at day 6 and by day 9 
sprouts become variable273.  The greatest distance from the aortic-ring body 
to the end of the vascular sprouts was measured at 3 distinct points per ring 
and in 3 different rings per mouse as described previously274. 
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4.4 Results 
4.4.1 Endothelial regeneration following vascular injury 
4.4.1.1 Wildtype v. IGFBP-1 transgenic mice 
In order to investigate the effects of IGFBP-1 over-expression on endothelial 
repair in insulin sensitive animals, transgenic and WT mice underwent 
femoral artery denuding wire injury.  Evans blue staining of whole-mounted 
femoral arteries demonstrated no significant difference in endothelial 
regeneration between WT and IGFBP-1 mice. (Re-endothelialised area 
61.65+/-3.87% vs. 56.16+/-3.08% at day 5 following injury, N=7, p=0.29) 
(Figure 4.4A). 
 
4.4.1.2 IRKO v IRKO*IGFBP-1 
In order to investigate the effects of IGFBP-1 over-expression on endothelial 
repair in insulin resistant animals, IRKO and IRKO*IGFBP-1 mice underwent 
femoral artery denuding wire injury.  In keeping with our previous 
experience, endothelial regeneration was significantly impaired in IRKO mice 
compared to WT mice (re-endothelialised area 47.38+/-2.56% vs. 61.19+/-
3.43% at day 5 following injury, p=0.03) (Figure 4.4B).  Evans blue staining 
of whole-mounted femoral arteries demonstrated significantly enhanced 
endothelial regeneration in IRKO*IGFBP-1 mice compared to IRKO. (re-
endothelialised area  54.42+/-1.81% vs. 47.38+/-2.56% at day 5 following 
injury, p=0.03) (Figure 4.4B). 
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              WT        IRKO          IRKO*IGFBP-1 
Figure 4-3 Endothelial regeneration following wire-injury of the femoral 
artery.  
Representative in situ Evans blue staining in vessels 5 days post vascular 
injury (blue staining indicates denuded endothelium) in WT, IRKO and 
IRKO*IGFBP-1 mice (magnification 20x). 
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Figure 4-4 Endothelial regeneration from femoral artery denuding 
injury.   
(A) WT v. IGFBP-1 over-expression, ns=non-significant, unpaired t-test (two-
tailed), n=7. (B) WT (n=5) v. IRKO (n=7) v. IRKO*IGFBP-1 (n=10), **p<0.01, 
*p<0.05, one-way ANOVA with Newman-Keuls post hoc test. 
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4.4.2 Aortic ring angiogenesis assay 
In order to investigate whether IGFBP-1 affects angiogenesis in the absence 
of circulating endothelial progenitor cells, an aortic ring angiogenesis assay 
was performed. This in-vitro assay is considered to come closest to 
simulating in-vivo angiogenesis, because it includes the surrounding non-
endothelial cells and also the endothelial cells have not been preselected by 
ex-vivo expansion274.  The results found no significant difference in the 
length of aortic micro-vessel sprouting between aortic explants from WT 
mice that were exposed to control or IGFBP-1 (500ng/mL).  In conclusion, 
IGFBP-1 did not modulate the angiogenic potential of native mature 
endothelial cells in the vasculature of WT mice (Figure 4.5). 
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Figure 4-5 Aortic ring angiogenesis assay.  
A (WT) & B (IGFBP-1): Representative image demonstrating sprouting 
microvessels from an aortic ring cultured in Matrigel (magnification 40x).  
C: Quantification of microvessels sprouting from aortic rings from WT mice 
treated either with control or IGFBP-1 (500ng/ml), ns=non-significant, paired 
t-test, n=4 per group. 
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4.5 Discussion 
Defective endothelial repair mechanisms in the setting of IR are important 
factors in the delayed and impaired endothelial regeneration following 
vascular injury206, which leads to bypass graft failure104 following surgery and 
restenosis105 and stent thrombosis106 following angioplasty in the clinical 
setting.  IGFBP-1 overexpression has been shown to rescue endothelial 
function and reduce CV risk factors in murine models of both obese and 
non-obese IR.  Over-expression of human IGFBP-1 in atherosclerosis-prone 
mice protects against the development of atherosclerotic plaques, raising the 
possibility that IGFBP-1 could constitute a novel treatment in the prevention 
of cardiovascular disease267. 
 
The present chapter provides new insights into the effect of over-expression 
of human IGFBP-1 on endothelial regeneration in an insulin-sensitive 
(healthy) and insulin resistant setting.  Following endothelium denuding 
arterial injury, over-expression of human IGFBP-1 had no effect on 
endothelial regeneration in insulin-sensitive mice.  In contrast, over-
expression of human IGFBP-1 restored endothelial regeneration to WT 
levels in the insulin resistant setting (Figure 4.4B).  These data represent the 
first time IGFBP-1 has been investigated in its role in endothelial 
regeneration and clearly support an in vivo modulatory role for IGFBP-1 in 
endothelial repair in IR.  The favourable effects of IGFBP-1 may be specific 
to endothelial repair rather than angiogenesis, as no difference in angiogenic 
sprouting was observed following acute ex vivo exposure of aortic segments 
to IGFBP-1.  
 
Surprisingly, no difference was observed between WT mice and mice over-
expressing IGFBP-1 in endothelial regeneration after denuding injury.  A 
possible explanation for this is that in ‘healthy’ animals the endothelial 
reparative measures may already be sufficient and there may be no capacity 
for IGFBP-1 to improve endothelial regeneration further.  In support of this 
argument, a study looking at over-expression of IGF-1 in healthy mice found 
that IGF-1 did not enhance revascularisation and regeneration of skeletal 
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muscle grafts275.  However, in insulin resistant IRKO mice, expression of 
human IGFBP-1 clearly improved endothelial regeneration.  It is not possible 
to comment on whether the favourable effects of IGFBP-1 are truly specific 
for insulin resistance, as it is possible that IGFBP-1 could enhance repair in 
other settings in which endothelial regeneration is suboptimal.  Similarly, 
whether the favourable effects are recapitulated in other models of IR was 
not investigated.  IR is characterised by multiple biochemical and signalling 
abnormalities, which impact on endothelial regeneration and could 
potentially be reversed by IGFBP-1.  Of these, the cellular effects of IGFBP-
1 in a biochemical milieu characterised by increased production of pro-
inflammatory cytokines will be explored further in vitro in Chapter 6. 
 
Limitations of these data should be taken into account.  During the vascular 
injury experiments, endothelial regeneration was recorded at one time-point 
only (5 days). Therefore possible effects of IGFBP-1 on endothelial repair 
beyond 5 days cannot be excluded.  Provisional experiments were 
performed looking at 7 and 14 days, however due to time and resource 
restraints, these were discontinued.  Only one method of assessing 
endothelial regeneration was used through Evan’s blue staining.  Other 
methods that could have been used include scanning electron microscopy, 
or assessing endothelial function by assessing the production of NO.  
However, Evans blue staining is a well-validated model of regeneration but 
not function276.   
 
This project’s main focus is to investigate endothelial regeneration rather 
than angiogenesis, (defined as the formation of new blood vessels from 
existing vascular networks).  Even though both processes have similarities 
involving endothelial cell migration and proliferation, angiogenesis and 
endothelial regeneration are distinct processes and may be differentially 
regulated.  Therefore, the fact that no effect was observed with acute ex vivo 
IGFBP-1 treatment in the aortic ring angiogenesis assay does not 
necessarily detract from a favourable role for IGFBP-1 in vascular 
regeneration.  The aortic ring angiogenesis assay has many advantages 
over other ex vivo angiogenesis assays such as proliferation or migration 
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assays as the assay is seen to stimulate in vivo conditions as surrounding 
non-endothelial cells (pericytes and smooth muscle cells) are present, which 
are involved in the key steps of angiogenesis.  Additionally, ECs are 
quiescent and have not been repeatedly passaged277.  Limitations include 
the fact that that this model does not represent the microvascular 
environment, as angiogenesis occurs typically in microvessels and not major 
arteries such as the aorta which was used in the assay.  Also variation can 
occur within one experiment due to inadequate dissection of surrounding 
adventitia, and this in turn can influence microvessel growth.  The presence 
of endothelial cells in the angiogenic sprouts was not confirmed with an 
immunofluorescence staining marker such as BS1 lectin273.  One could have 
used tissue from IRKO mice rather than WT mice and therefore assessed 
the effects of IGFBP-1 on IRKO endothelial cells; in addition one also could 
have performed a concentration dependent experiment using IGFBP-1.   
 
In summary, overexpression of IGFBP-1 enhanced endothelial regeneration 
following arterial denuding injury in vivo.  These effects were restricted to the 
insulin resistant setting and were not observed in metabolically healthy, 
insulin-sensitive mice.  The findings suggest a favourable, pro-regenerative 
effect of IGFBP-1 on endothelial repair, which may be specific to insulin 
resistance.  Endothelial regeneration at sites of damage is attributed to two 
broad paradigms; native endothelial cells migrating and proliferating towards 
sites of injury181 and angiogenic progenitor cells migrating to sites of injury 
and either releasing pro-angiogenic molecules which stimulate EC 
proliferation or differentiating into mature ECs that integrate into damaged 
vessels166,172,174,278.  The effects of IGFBP-1 on these parameters are 
investigated in Chapters 5 and 6. 
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5 The effects of IGFBP-1 on 
Angiogenic Progenitor Cell 
abundance and function 
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5.1 Introduction 
APCs are thought to exert their function by two main methods: release of 
pro-angiogenic molecules which stimulate proliferation of ECs or other APCs 
or differentiation into mature endothelial cells that integrate into the damaged 
vessels.  For these processes to occur, APCs must first “home” to sites of 
endothelial damage and adhere to damaged/activated ECs or to the 
extracellular matrix, therefore contributing to the endothelial repair 
process167.  Animal studies have shown that APCs contribute to endothelial 
regeneration following endothelium-denuding injury172, bypass grafting173 
and hyperlipidaemia174.  Also, APC infusion reduces the development of 
endothelial dysfunction163 and neointima166.  Taken together, the evidence 
suggests a role for APCs in maintaining endothelial homeostasis and 
preventing atherosclerosis and restenosis. 
 
Human studies have shown that lower numbers of circulating APCs are 
present in diabetic subjects compared to healthy subjects.  In diabetes, 
APCs exhibit functional defects which lead to impaired endothelial 
regenerative capacity203,206,265,279,280.  Although hyperglycaemia may impair 
APC function in diabetes, several abnormalities associated with IR, such as 
reduced NO bioavailability, increased ROS production and down-regulation 
of PI3-kinase/AKt signalling pathways, have the potential to disrupt APC 
numbers and function281.  Previous research carried out in our laboratory 
clearly showed impaired endothelial regeneration in IRKO mice, indicating 
that IR per se is sufficient to jeopardise endothelial repair206. The defective 
repair resulting from IR was attributed to a combination of impaired NO-
dependent APC mobilisation, reduced APC abundance, and dysfunctional 
APCs in this study206. 
 
IGFBP-1 increases NO production through eNOS stimulation via the PI-3 
kinase pathway in ECs267.  As NO bioavailability plays a critical role in APC 
mobilisation and function, we hypothesised that IGFBP-1 over-expression 
would lead to an increase in APC abundance and function in IRKO mice.  
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Investigating the effects of IGFBP-1 on APC abundance and function forms 
the focus of this chapter.  
 
93 
 
5.2 Aims 
The aims of the investigations described in this chapter were as follows: 
 
1. To investigate, using flow cytometric enumeration of circulating APCs, 
whether IGFBP-1 overexpression rescues APC abundance in IRKO 
mice. 
2.  To investigate, through in vitro culture and expansion of APCs 
derived from peripheral blood monocytes and storage depots, whether 
IGFBP-1 overexpression rescues APC abundance and dysfunction in 
IRKO mice. 
 
94 
 
5.3 Methods 
5.3.1 Breeding colonies and genotype 
A breeding colony of IRKO*IGFBP-1 mice was established by mating male 
IGFBP-1 mice with IRKO females (as described in section 3.3.4). Female 
offspring were culled at weaning. The genotype of male offspring was 
determined by polymerase chain reaction of ear-notch tissue digests (as 
described in section 3.6.2). Animals were housed in a conventional animal 
facility with a 12-hour light/dark cycle and received standard laboratory 
chow. Male IRKO*IGFBP-1 mice aged 12-16 weeks were compared with 
age- and sex-matched wild-type, IRKO and IGFBP-1 littermate controls. 
 
5.3.2 Flow cytometry (FACS) 
100µL of peripheral blood was taken from the saphenous vein of each non-
fasted mouse aged between 12-16 weeks (as described in section 3.4.2) 
and collected into capillary blood collection tubes containing 150µL Heparin 
(CP Pharmaceuticals Ltd, Wrexham UK).  This was immediately added to 
3mL of red blood cell lysis solution ‘PharmLyse’ (BD Biosciences) (diluted 
1:10 with sterile water) and incubated for 10 minutes at room temperature. 
The samples were then centrifuged for 10 minutes at 300g and the 
mononuclear cells were resuspended in 1mL of FACS buffer (stock: 500mL 
PBS; 2.5mL FCS; 0.25g BSA), divided into 2 microcentrifuge tubes per 
sample and centrifuged once again. After pouring off the supernatant and 
equilibrating to 100µL with FACS buffer, the samples were incubated with 
10µL FcR blocker (BD Biosciences) for 10 minutes at 40C to prevent non-
specific antibody binding. Appropriate volumes of the following antibodies, or 
their respective isotype controls, were then added for 10 minutes at 40C (in 
darkness): FITC-anti mouse Sca-1 (BD Biosciences); PE-anti mouse Flk-1 
(BD Biosciences). EPCs were enumerated using flow cytometry (Becton 
Dickinson BD-LSRFortessa) to quantify dual stained Sca-1/Flk-1 cells in 
accordance with other studies282.  Isotype control specimens were used to 
define the threshold for antigen presence and to correct for non-specific 
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fluorescence. The cytometer was set to acquire 100,000 events within the 
lymphocyte gate, defined by typical light scatter properties.  
 
5.3.3 APC isolation and culture 
Cell culture experiments were conducted using aseptic techniques. For cell 
number quantification before cell culture, isolated mononuclear cells from 
peripheral blood, spleen or bone marrow were mixed with an equal volume 
of trypan blue.  This cell suspension was then loaded onto a 
haemocytometer and viable cells (i.e. did not stain with trypan blue) were 
counted.  A fixed number of peripheral blood- (1 million), bone marrow- (1 
million) and spleen- (8 million) derived MNCs were seeded into 6-well plates 
(spleen-derived MNCs) and 24-well plates (blood- and bone marrow derived-
MNCs).  Investigations were restricted to ‘early outgrowth’ APCs due to 
difficulties in culturing late outgrowth endothelial colony cells from the blood 
of mice with insulin resistance191. 
 
5.3.3.1 Peripheral blood 
To prevent blood clotting, 50µL of Heparin was aspirated into a 1mL insulin 
syringe (BD Micro-fine, BD Medical).  From this syringe, 1mL of blood was 
aspirated from the inferior vena cava under terminal anaesthesia (as 
described in section 3.4.2) and immediately mixed with 3mL sterile PBS 
(stored at 4°C).  This mixed solution was then expelled into a 50mL falcon 
tube via a 70µm cell strainer (BD Falcon) to separate out any cell clumping 
or clots and kept at 4°C.  Blood samples were carefully layered on top of 
5mL of Histopaque-1083 (Sigma) into 15mL centrifuge tubes.  Density 
gradient centrifugation at 400g for 30 minutes then took place as per 
manufacturer’s instructions.  After density gradient centrifugation, blood 
mononuclear cells were aspirated from the buffy layer and re-suspended in 
PBS before a re-centrifugation washing step at 400g for 10 minutes.  After 
removal of supernatant, the cells were re-suspended in 2mL of lysis buffer 
(1:10) and 8 mL of PBS.  A further re-centrifugation washing step at 400g for 
10 minutes took place. Following purification, mononuclear cells were re-
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suspended in EGM-2 medium supplemented with EGM-2 Bullet kit (Lonza) 
in addition to 20% FCS. Mononuclear cells were seeded on fibronectin 
coated 24-well plates at a seeding density of 1x106 cells/well (suspended in 
0.5mL medium). 
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5.3.3.2 Spleen 
Spleens obtained from mice via a left lateral incision under terminal 
anaesthesia were immediately placed into 5mL of PBS in a 15mL centrifuge 
tube and placed on ice.  Spleen samples were mechanically minced through 
a 70μm cell strainer (BD Falcon) into a sterile petri dish containing 3mL PBS 
using a syringe plunger.   The suspension was then expelled into a 50mL 
centrifuge tube through the cell strainer.  The petri dish was then washed 
with 2mL of PBS.  The wash was then aspirated and added to the 50mL 
centrifuge tube via the cell strainer (total of 5mL Spleen + PBS) to ensure 
any cellular debris was removed. 
 
Spleen samples were carefully layered on top of 5mL of Histopaque-1083 
(Sigma) into 15mL centrifuge tubes and underwent the same centrifugation, 
aspiration and washing step as in the peripheral blood samples as 
mentioned in the previous section.  The spleen samples did not undergo a 
lysis buffer step and had 2 further washing steps with PBS and mononuclear 
cells were re-suspended in EGM-2 medium supplemented with EGM-2 Bullet 
kit (Lonza) in addition to 20% FCS.  Mononuclear cells were seeded on 
fibronectin coated 24-well plates at a seeding density of 8x106 cells/well 
(suspended in 2 mL medium). 
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5.3.3.3 Bone marrow 
Tibias and femurs were obtained from mice under terminal anaesthesia.  To 
obtain the bone marrow, the tibias and femurs were flushed 3x with 3mL 
PBS using a 26G needle, and placed into a 15mL centrifuge tube and placed 
on ice.  The bone marrow suspension was mechanically minced through a 
70µm cell strainer (BD Falcon) into a petri dish using a syringe plunger.  The 
suspension was then expelled into a 50mL centrifuge tube through the cell 
strainer.  The petri dish was then washed with 2mL of PBS.  The wash was 
then aspirated and added to the 50mL centrifuge tube via the cell strainer to 
ensure any cellular debris was removed.  Marrow samples were carefully 
layered on top of 5mL of Histopaque-1083 (Sigma) into 15mL centrifuge 
tubes.  Density gradient centrifugation, aspiration from the buffy layer and 
washing steps as for Spleen samples took place for the bone marrow 
samples and re-suspended in the same medium used.  Mononuclear cells 
were seeded on fibronectin coated 24-well plates at a seeding density of 
1x106 cells/well (suspended in 0.5 mL medium). 
 
5.3.4 APC characterisation 
Following incubation for 4 days at 37°C in 5% CO2, non-adherent cells were 
discarded by gentle washing with PBS and fresh medium was added to the 
well containing the adherent cells.  At day 7, the phenotype of APCs was 
confirmed during an enumeration assay in which APCs were defined as 
adherent cells co-staining for 1,1’-dioctadecy-3,3,3’,3’-
tetramethyllindocarbocyanine-labelled acetylated low-density lipoprotein (DiI-
Ac-LDL) (Life technologies, Paisley, UK) and lectin from Ulex europaeus 
FITC conjugate (Sigma-Aldrich, Gillingham, UK).  APCs from peripheral 
blood, bone marrow and spleen were incubated with DiI-Ac-LDL (Molecular 
Probes) diluted to 10µg/mL in supplemented EGM-2, at 37°C for 3 hours 
prior to fixation in 4% paraformaldehyde for 10 minutes. Cells were next 
washed with PBS twice and incubated with lectin from Ulex europaeus FITC 
conjugate (Sigma), diluted to 10µg/mL in PBS, for a further hour. Cells were 
finally washed thoroughly (3 times with PBS), prior to collecting multiple high 
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power (100x) phase contrast images, along with corresponding red (DiI) and 
green (FITC) fluorescent images using an Olympus CKX-41 fluorescence 
microscope. Cells appearing yellow on overlaid fluorescence images (using 
imageJ) were defined as EPCs in view of their co-staining for DiI-Ac-LDL 
and lectin, as previously reported283. Cell counts were expressed as APCs 
per high power field (Figure 5.1). 
 
 
Figure 5-1 Representative image of APCs following cell culture from 
spleen.  
(100x magnification). 
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5.3.5 In vitro APC functional assays 
To assess functional capacity of APCs, spleen-derived APCs were cultured 
as previously described in section 5.3.3.2 and harvested from the plate using 
enzymatic digestion.  Firstly, cells were washed with warm PBS (37°C) twice 
to ensure removal of latent trypsinases present within FCS.   Pre-warmed 
trypsin/EDTA solution was added at a volume of 40µL/cm2.  Following 
incubation at 37°C for 2 minutes culture plates were forcefully agitated to 
assist cellular detachment, then EGM-2 culture medium containing FCS was 
added to deactivate trypsin. The resultant cell suspension was then 
centrifuged at 400g for 10 minutes, washed with PBS and re-centrifuged. 
The cell pellet was resuspended in culture medium according to the 
functional assay being performed. For the adhesion assay APCs were used 
at day 7. 
 
5.3.5.1 APC Adhesion 
For evaluation of APC adhesion, 50000 spleen-derived APCs were re-
suspended in EGM-2 medium, plated onto fibronectin 24-well plates and 
incubated for 1 hour at 37°C. After washing 3 times with PBS, attached cells 
were counted after collecting 5 high power (100x) phase contrast images 
using an Olympus CKX-41 fluorescence microscope. Adhesion was then 
evaluated as the mean number of attached cells per High Power Field 
(100x).
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5.4 Results 
5.4.1 Quantification of circulating APCs using flow cytometry 
Cell identification by flow cytometry in terms of lymphocyte, monocyte and 
granulocyte populations were defined on the basis of forward and side 
scatter. This was also used to exclude necrotic cells and debris.  
Investigation of cell structure and function was done through fluorescent 
labelling.  APCs were defined as cells that dual stained for phycoerythrin 
labelled Flk-1 and fluorescein labelled Sca-1.  Significantly reduced numbers 
of Sca-1/Flk-1 positive APCs were observed in the IRKO mice compared to 
WT littermate controls (Figure 5.2).  Over-expression of human IGFBP-1 in 
IRKO mice did not alter the number of APCs (Figure 5.2).  
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Figure 5-2 Enumeration of APCs in blood using flow cytometry.  
Numbers of Sca-1/Flk-1-positive cells in WT, IRKO, IGFBP-1 over-
expressing mice and IRKO mice with IGFBP-1 over-expression. (one-way 
ANOVA with Newman-Keuls post hoc test, *P<0.05, n=6 per group). 
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5.4.2 In vitro APC culture – phenotypic analysis 
DiI-ac-LDL/lectin positive early-outgrowth APCs were quantified in cells 
expanded from peripheral blood-, spleen- and bone-marrow-derived 
mononuclear cells.  On day 7, cultivated cells were incubated with DiI-ac-
LDL and lectin. Cells staining positive for both lectin and DiI-ac-LDL were 
judged to be APCs and quantified in 10 randomly selected HPFs (100x) 
(Figure 5.3).  Significantly fewer APCs were cultured from peripheral blood of 
IRKO mice compared to WT controls. There was no difference in APC yield 
from blood of IRKO and IRKO*IGFBP-1 mice (Figure 5.4A). There were no 
significant differences in the numbers of spleen or bone marrow derived-
APCs cultured from all four groups of mice (Figure 5.4B and 5.4C). 
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Figure 5-3 Enumeration of APCs derived from blood, spleen and bone 
marrow by cell culture.   
Fluorescence microscopy revealing the spindle shaped APCs (Phase 
contrast image), lectin bound (green), DiI-ac-LDL uptake (red) and dual 
stained APCs (yellow), (100x magnification).   
 
Phase contrast Lectin bound 
DiI-Ac-LDL Dual stained 
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Figure 5-4 Enumeration of APCs derived from cell culture.   
Blood (A), spleen (B), and bone marrow (C) by cell culture after 7 days in 
WT, IGFBP-1 over-expressing mice, IRKO and IRKO mice with IGFBP-1 
over-expression. Numbers of peripheral blood (n=5-6), spleen (n=6) and 
bone marrow (n=6-9) derived cultured APCs (one-way ANOVA with 
Newman-Keuls post hoc test *P<0.05, n=6 mice per group).   Data are 
presented as mean and SEM. 
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5.4.3 APC function: Adhesion capacity 
To determine whether IGFBP-1 affects the adhesion capacity of APCs, an 
APC adhesion assay was performed.  After 7 days of culture, 50000 spleen-
derived early APCs from WT, IGFBP-1, IRKO and IRKO*IGFBP-1 mice were 
re-suspended in EGM-2 medium and plated onto 24-well plates coated with 
fibronectin (an important extracellular matrix component involved in the initial 
steps of angiogenesis).  Over-expression of human IGFBP-1 did not 
modulate adhesive capacity to fibronectin in insulin-sensitive or insulin-
resistant mice (Figure 5.5). 
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Figure 5-5 APC functional assay.   
APCs were spleen-derived and cultured for 7 days.  (A) Representative 
image of APCs (10x magnification). (B). Adhesion capacity of spleen-derived 
APCs cultured from WT, IGFBP-1, IRKO and IRKO*IGFBP-1 mice 
expressed as number of cells adhering to fibronectin-coated plates (n=5-6 
mice per group).  Data are presented as mean and SEM.  One way ANOVA 
with Newman-Keuls post-hoc test. 
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5.5 Discussion 
The principal findings of this chapter may be summarised as follows: IRKO 
mice had fewer circulating APCs compared to WT littermate controls in 
keeping with a detrimental effect of IR on endothelial repair.  Surprisingly, 
similar circulating APC abundance was seen in WT and IGFBP-1 mice, and 
in IRKO and IRKO*IGFBP-1 mice, indicating that the enhanced endothelial 
regeneration observed in Chapter 4 is not explained by altered abundance of 
APCs.  Finally, no difference was seen between WT, IRKO, IGFBP-1, 
IRKO*IGFBP-1 mice in APC adhesive capacity, suggesting that IGFBP-1 
does not modulate APC reparative functions. 
 
An era of APC-focussed research was born when Asahara’s landmark 
study180 identified and isolated APCs from peripheral blood.  Other findings 
included CD34+ mononuclear blood cells acquiring endothelial-like qualities, 
and homing into angiogenic sites when intravenously transfused into animals 
with hind-limb ischaemia180.  However there is no clear consensus in the 
scientific community over the identification and biological properties of APCs.  
Two broad methods have been used to identify and characterise APCs, 
namely flow cytometry assays and cell culture assays.  With respect to flow 
cytometry, there is no perfect marker to identify and quantify circulating 
APCs, hence making it difficult to compare APC quantification in different 
studies181.  APCs in mice are commonly classified as co-expressing the stem 
cell marker Sca-1 and the endothelial marker KDR172, and these were the 
markers used for flow cytometry studies in this thesis.  However other 
markers, such as c-kit+ have been used by some groups284.  
 
This chapter shows evidence (although non-significant) of reduced APC 
numbers in the peripheral blood of IRKO mice – a finding which is in line with 
published data from our group206.  However there was no difference in the 
number of spleen or bone-marrow derived APCs, suggesting an APC 
mobilisation defect secondary to impaired NO bioavailability206.  Surprisingly, 
IGFBP-1 over-expression did not affect APC numbers in the insulin-sensitive 
or insulin resistant settings nor did it affect APC function as assessed 
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through adhesion.  Overall, this suggests that over-expression of IGFBP-1 
did not rescue the mobilisation defect seen in peripheral blood APCs 
observed in IRKO mice.   
 
IGFBP-1 is known to increase NO production267 in ECs and NO is believed 
to play an important role in EPC mobilisation.  Therefore, contrary to the 
observations reported in this chapter, one would assume over-expression of 
IGFBP-1 would reverse the APC mobilisation defect seen in IRKO mice.  
Kahn et al206 observed that eNOS expression was not detected in bone 
marrow of IRKO but was present in WT mice.  Because IGFBP-1 enhances 
NO bioavailability by phosphorylating eNOS, it is likely that IGFBP-1 
overexpression was unable to enhance bone marrow NO bioavailability in 
IRKO mice in the absence of detectable eNOS.  To investigate this 
possibility, one could assess eNOS expression in the bone marrow in 
IRKO*IGFBP-1 mice.  Other important factors facilitating APC mobilisation 
and homing to sites of injury include stromal cell-derived factor-1-alpha 
(SDF-1α).  In fact, reduced SDF-1α expression is observed in diabetic 
wounds compared to non-diabetic wounds and exogenous administration of 
SDF-1α increased APC numbers and improved wound repair285.  Whether 
IGFBP-1 influences expression of SDF-1α is worthy of investigation. 
 
Results presented in chapter 4 indicate that over-expression of IGFBP-1 
rescued endothelial repair in the insulin resistant setting in vivo.  From the 
results presented in this chapter, one can speculate that the effects of 
IGFBP-1 on vascular endothelial repair are not mediated by alterations in 
APCs but may be occurring at the level of native endothelial cells, perhaps 
through enhancing cell migration and proliferation.  It is interesting to note 
that the trend of endothelial regeneration research may be shifting away 
from APCs back towards the traditional paradigm of native endothelial cell 
migration and proliferation.  Recent research has suggested that endothelial 
regeneration following vascular injury did not involve circulating APCs and 
was mediated solely by EC migration from adjacent healthy endothelium286.  
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Limitations of the data presented in this chapter should be acknowledged.  
There is inconsistency over the identification and characterisation of APCs in 
the published literature with limitations to the two common methods used for 
isolation and enumeration of APCs. Flow cytometry cell counting is based 
upon immunolabelling cells with antibodies directed against intracellular or 
surface antigens182.  There is no universally accepted antigenic phenotype to 
identify APCs, because surface marker expression overlaps with other cell 
lineages.  In addition, the rarity of circulating APCs in peripheral blood 
restricts detection to a limited number of surface antigens, which renders it a 
difficult task to identify a pure cell population.  Despite these limitations, flow 
cytometry is considered the gold standard to obtain quantitative data on 
APCs182,281. 
 
APCs were also identified as DiI-Ac-LDL and lectin positive cells in culture 
expanded mononuclear cells.  These ‘early outgrowth’ APCs are not 
identical to flow cytometrically defined APCs.  However, using these two 
techniques enables us to glean different biological information, even if they 
have shown consistent variation in many studies182, In-vitro culture of APCs 
requires cell expansion from their natural environment and is recognised to 
change the phenotype of cells.  Therefore, the results obtained in vitro may 
not necessarily reflect closely endothelial repair mechanisms occurring in 
vivo.  Caution is therefore required when interpreting the functional assay 
described in this chapter into APC function at the cellular level287.   
 
Perhaps more importantly, during culture of APCs, there was no cell 
exposure to IGFBP-1 in vitro.  Cultured primary cells often retain a ‘metabolic 
memory’ of the environment to which they were exposed in vivo. However, 
experiments investigating the effects of acute and prolonged exposure of 
APCs to IGFBP-1 in vitro would be required to fully exclude a modulatory 
effect of IGFBP-1 on APC-mediated repair.  
 
The investigations described involved cell culture of ‘early outgrowth’ APCs, 
these cells form within 3 days and have an elongated and spindle shape and 
die within 4 weeks.  It is suggested that ‘early outgrowth’ APCs display 
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features of myeloid cells which secrete angiogenic cytokines, rather than 
integrating into neoendothelium to stimulate endothelial regeneration and do 
not differentiate to form mature endothelial cells288.  It is possible that 
IGFBP-1 in an insulin resistant setting can affect ‘late outgrowth’ APCs which 
possess typical endothelial cell morphology, form a confluent cobblestone 
layer and have a higher proliferative potential182,289, this would require further 
study.   
 
In summary, the data presented in this chapter suggest that the enhanced 
endothelial regeneration in IRKO mice over-expressing human IGFBP-1 is 
not explained by modulation of APCs by IGFBP-1.  Another possible 
explanation for increased endothelial regeneration is a local effect of IGFBP-
1 on endothelial cell function. This will be examined in the next chapter. 
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6 The effects of IGFBP-1 on 
endothelial cell adhesion, 
migration and proliferation 
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6.1 Introduction 
Multiple studies of arterial injury have shown the central mechanism in 
endothelial regeneration is through local endothelial cell migration and 
proliferation from adjacent non-injured endothelium110,116–118.  Another 
paradigm suggests APCs contribute to repair and could be exploited 
therapeutically to enhance endothelial regeneration166,175–179.  However, 
despite the large number of reports implicating APCs in endothelial repair 
there is no clear evidence that APCs actually develop into ECs during re-
endothelialisation.  Tsuzuki et al failed to demonstrate any bone-marrow 
derived ECs in re-endothelialised areas following vascular injury in 
animals290.  A recent study by Hagensen et al286 tested whether circulating 
APCs contributed to endothelial repair and found that, contrary to current 
theories, migration of arterial ECs from adjacent intact endothelium was the 
only source of cells involved in endothelial regeneration after endovascular 
injury in mice.  Results presented in Chapter 5 of this thesis indicate that 
over-expression of IGFBP-1 does not modulate the abundance of APCs or 
their function.  Therefore this chapter investigated potential effects of IGFBP-
1 on native endothelial cell function – in particular cell adhesion, migration 
and proliferation. 
 
Adhesion, migration and proliferation are the key attributes of ECs required 
to mediate endothelial repair.  IGFBP-1 has been shown to promote 
migration in various cell types225,242 but has not until now been studied in 
ECs.  As described in this chapter, an ex-vivo model of EC adhesion was 
developed, using denuded human saphenous vein to assess the ability of 
IGFBP-1 to modulate the number of human ECs adhering to the saphenous 
vein matrix.  Two different methods of analysing EC migration were 
employed; linear wound assay and modified Boyden Chamber.  Finally, the 
role of IGFBP-1 on EC proliferation was investigated.  In healthy blood 
vessels, the basal rate of EC proliferation is low as mature ECs are 
terminally differentiated, however certain regions in the endothelium display 
a higher rate of EC proliferation, for example, regions where there is 
disturbed blood flow111.  In addition, cardiovascular risk factors and age lead 
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to increased EC proliferation112.  Following arterial injury, the denuded 
vessel is exposed to many circulating factors which can impede EC 
proliferation and therefore regeneration, hence it is vital to investigate agents 
to promote EC proliferation.   
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6.2 Aims 
The aims of the investigation described in this chapter were as follows: 
 
To assess the effects of IGFBP-1 on native human endothelial cell adhesion, 
migration and proliferation. 
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6.3 Methods 
6.3.1 Adhesion Assay 
The potential for IGFBP-1 to modulate EC adhesion was investigated in 
adhesion assays performed with HCAECs.  EC suspensions (100,000 
cells/mL) were seeded onto sterile cover slips which were placed on the 
surface of a culture well plate a well, 6 in total of a 12 well culture plate were 
used.  Vehicle-treated wells contained 1% FCS and treatment wells 
contained 500ng/mL of IGFBP-1 in 1% FCS.  One vehicle-treated well and 
one corresponding IGFBP-1 well were fixed after 2 hours, 4 hours and 6 
hours of incubation at 37C in 4% paraformaldehyde and stained with 
Haematoxylin & Eosin for 1 minute.  Finally, the cover slips were mounted 
onto microscope slides using glycerol gelatin and 10 random fields 
containing the adherent cells were counted at 400x magnification.   
 
6.3.2 Ex-vivo endothelial regeneration 
To assess the effects of IGFBP-1 on EC adhesion and regeneration in 
human vessels ex-vivo, I set-up and optimised an experiment in which 
endothelial cell adhesion to the lumen of a human saphenous vein matrix 
was quantified. This was to try and mimic an environment akin to that found 
in vivo.  Pilot studies looked at the feasibility of ECs adhering on the 
saphenous vein assessed through confocal imaging.  One of the first 
problems encountered was that staining of ECs with CellTracker CM-Dil 
(Lot:983910, Invitrogen, Oregon, USA) was not effectively staining cells.  
The manufacturer’s protocol advised 1 hour of incubation with CellTracker, 
however this was advised for non-endothelial cells.  I then proceeded to 
incubate the EC with CellTracker overnight, which proved to be successful.   
 
Excess lengths of EC denuded human saphenous vein segments were 
kindly provided by Mr. David O’Regan (Consultant Cardiac Surgeon at 
Leeds General Infirmary) from patients who were undergoing coronary artery 
bypass graft surgery.  Segments of human saphenous vein were placed and 
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each corner of the segment pinned on to an organ culture plate, followed by 
250µL (50,000 cells) of EC suspension (20% FCS ECGM) being placed onto 
the segment.  Following incubation at 37C/5% CO2 for indicated times, the 
organ dish (Figure 6.1) was washed 3 times with PBS and full (20% FCS) 
ECGM was added to cover the whole dish and segment.  The saphenous 
vein segments were imaged on a coverslip plate using confocal microscopy 
(Zeiss LSM S10 META Upright Confocal).  Once the technique was 
optimised, the time course of EC adhesion was evaluated to determine the 
most appropriate time point at which to investigate a potential effect of 
IGFBP-1.  5 minutes of EC exposure to the vein matrix was felt to be ideal to 
detect a difference using IGFBP-1.   
 
 
Figure 6-1  Sample of human saphenous vein pinned to an organ 
culture plate. 
 
HCAECs stained with CellTracker CM-Dil (Lot:983910, Invitrogen, Oregon, 
USA) were incubated at 37C/5% CO2 for 1 hour at a fixed density (250,000 
cells/mL) in full (20%) ECGM suspension with either vehicle-treated or 
IGFBP-1 (500ng/mL).  50,000 cells from each treatment group were seeded 
onto a denuded segment of human saphenous vein, incubated at 37C/5% 
CO2 for 5 minutes and the cell suspension was gently washed with PBS, 
Hoecht stain (to identify cell nuclei) were added to the saphenous vein 
segment and finally re-suspended in full (20%) ECGM. Images were 
obtained by confocal microscopy (as mentioned) of the vein segments, 
assessing the number of cells adhering to the saphenous vein matrix per 
high powered field (100x magnification). 
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6.3.3 Linear wound healing assay 
Before plating ECs, the underside of the plates were marked with linear 
reference points using a blade not more than 1mm apart (Figure 6.2). This 
was used as a reference point for the linear wounds and imaging.  ECs were 
plated at 100,000 cells per well (12-well plate) in full ECGM.  Once 
confluent, they were serum depleted (1% FCS) overnight and the following 
morning the cell layer was “scratched” using a sterile 10mL Gilson pipette 
tip. The tip was used to scrape off the ECs in a straight line.  The cells were 
then washed with PBS, placed into appropriate media with treatment for 
“time zero” images and incubated at 37C/5% CO2 with images taken at 24 
hours and 48 hours.  Observations were quantified by counting the number 
of cells that had migrated more than 200 microns past the wounded edge at 
the end of 48 hours.  4 fields per well were imaged and analysed291. 
 
 
 
 
Figure 6-2 Example of underside of culture well marked with reference 
points for linear wound assay. 
 
Preliminary studies were conducted to ascertain the optimum concentration 
of FCS to use in subsequent experiments investigating the effects of IGFBP-
1 on migration.  After selecting 5% and 10% serum growth media 
concentrations as the baseline growth media concentration, comparisons 
were made with vehicle-treated versus IGFBP-1 (500ng/mL) and finally 
comparisons were made with co-incubation with TNF-α (Peprotech 
Incorporated, Rocky Hill, New Jersey, USA) (10ng/mL).   
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Figure 6-3 Representative image of linear wound assay.   
(A) a linear wound is made initially, then a 0 hour time point image is 
acquired. (B) Endothelial cells are seen migrating past the wound edge after 
48 hours.  
Endothelial cells 
Wound edge 
Migrating 
endothelial 
cells 
Reference point for 
image acquisition 
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6.3.4 Boyden Chamber 
The modified Boyden chamber assay consists of two chambers, an upper 
and a lower chamber that are separated by a porous membrane (pore size 8 
m).  ECs were seeded in the upper chamber and a chemotactic agent was 
added to the lower chamber.  The cells sense and migrate along the 
chemotactic gradient.  After six hours, cells that have crossed the membrane 
are stained and counted. 
 
Confluent 25cm3 tissue culture flasks of EC were serum deprived in 1% FCS 
for 12 hours.  750L of chemoattractants was added to each of the lower 
chambers and all migration assays were set up in triplicate.  The 
chemoattractants used were serum-containing growth media in different 
concentrations, IGFBP-1 (500ng/mL), and Vascular Endothelial Growth 
Factor (VEGF) (50ng/mL).  Cells were prepared at 200,000 cells/mL in 1% 
FCS and 500L of cell solution were added to each of the upper Boyden 
chambers.  The cells were left to migrate for 6 hours in an incubator at 
37C/5% CO2 then fixed overnight at -20°Celsius in 70% ethanol.   
 
Each Boyden chamber was washed with tap water and using a cotton bud 
non-migrated cells were removed from the upper surface of the membrane.  
The chambers were Haematoxylin & Eosin stained for 30 seconds per stain 
and the membrane of the Boyden chambers was then cut out using a small 
surgical blade and mounted using glycerol gelatin on a microscope slide.  10 
high-powered microscope fields were randomly selected and the migrated 
cell nuclei were counted at 400x magnification. Migration was quantified as 
the average number of cells per high-powered field for each condition.   
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Figure 6-4 Modified Boyden Chamber.   
Modified Boyden chamber assay used to study EC migration. ECs are 
loaded into the upper chamber and actively migrate towards a chemotactic 
stimulus through the porous membrane.   
 
6.3.5 Cell Proliferation Assay 
HUVECs and HCAECs were seeded at 20,000 cells/well on a 24-well plate 
and left to attach to the fibronectin coated surface for 24 hours.  Cells were 
then serum deprived overnight (16 hours) using 1% FCS to quiesce the 
cells.  The following morning (designated day 0), medium was removed from 
the wells, cells were washed with PBS and were then treated accordingly in 
triplicates.  Day 0 counts of cells were also performed using a 
haemocytometer.  Following treatment, cells were incubated at 37ºC and 5% 
CO2 and treatments were replaced every 2 days.  On day 5, cells were 
washed with PBS then 200µL of trypsin added, once cells were detached 
800 µL of full ECGM were added to each well.  The cell suspensions were 
then centrifuged at 600g for 6 minutes in 1.5mL microcentrifuge tubes.  The 
supernatant was then aspirated off and the pellet was re-suspended in 50µL 
of full ECGM.  50µL trypan blue were added and mixed to the suspension, 
ready to be counted. 
 
Initially, different FCS concentrations were compared to assess their effects 
on cell proliferation and in order to find an optimal concentration whereby a 
potential benefit of IGFBP-1 could be observed.  After selecting 2.5% serum 
Chemoattractant 
Upper chamber 
EC suspension 
Porous membrane 
Lower chamber 
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growth media concentration, proliferation was quantified in response to 
IGFBP-1 (500ng/mL).  Insulin (100ng/mL) was used as a positive control.   
 
Finally, the ability of IGFBP-1 to rescue TNF-α (10ng/mL)-induced inhibition 
of cell proliferation was investigated in (20% FCS) ECGM.  20% FCS was 
chosen as lower concentrations of FCS would not have been conducive to 
cell survival in the presence of TNF-α.  Initial studies found 10ng/mL of TNF-
α led to marked inhibition of cell proliferation where no effects of co-
incubation of IGFBP-1 could be observed.  A dose response assay was 
subsequently performed comparing the inhibitory effects of 0.01ng/mL, 
0.1ng/mL, 1ng/mL and 10ng/mL TNF-α on cell proliferation.  From this set of 
studies 0.1ng/mL of TNF-α was selected to investigate the effects of IGFBP-
1 on cell proliferation. 
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6.4 Results 
6.4.1 Adhesion on to a plastic surface 
HCAECs were incubated with IGFBP-1 and the time course of adhesion of 
ECs onto a plastic sterile cover slip was investigated.  IGFBP-1 did not alter 
adhesive capacity over the time course studied (Figure 6.5). 
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Figure 6-5 Time course Adhesion Assay – Control v. IGFBP-1 in 
HCAECs.   
No significant difference (paired t-test) was seen between control and 
IGFBP-1 (500ng/ml) at 2, 4 and 6 hours (n=3). 
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6.4.2 Ex-vivo endothelial regeneration 
6.4.2.1 Pilot studies 
Pilot studies were performed to assess the feasibility of the experiment in 
terms of labelling endothelial cells and ascertaining whether cells would 
adhere to the saphenous vein matrix.  Representative images of exposed 
smooth muscle cells on the surface of endothelium-denuded human 
saphenous vein (Figure 6.6A) and of endothelial cells labelled with 
CellTracker adhering onto the saphenous vein matrix (Figure 6.6B) are 
provided.  
 
6.4.2.2 Time course experiments 
Initial experiments investigated the effect of exposing the saphenous vein 
matrix to HCAECs for 2 hours, then washing away the unattached cells in 
the cell suspension and re-suspending the vein sample in full ECGM. The 
vessel was imaged at the following time-points: 0 hours, 24 hours, 48 hours 
and 72 hours.  At 24 hours there was a peak in the number of cells adhering 
and spreading towards each other but after this time point the EC tended to 
detach (Figure 6.7A).   
 
Subsequent studies investigated shorter time points of exposure and peak 
cell exposure was found to occur at 30 minutes. Reproducible and sub-
maximal cell adhesion was observed after 5 minutes of exposure, which was 
therefore selected to examine any potential effects of IGFBP-1 on cell 
adhesion (Figure 6.7B). 
 
6.4.2.3 IGFBP-1 enhances EC adhesion ex vivo 
CellTracker-labelled HCAECs were pre-treated for 1 hour with IGFBP-1 
(500ng/mL) at 37°C in 5% CO2.  These cells were then placed onto denuded 
saphenous vein for 5 minutes after which the cell suspension was washed 
away and the vein was immediately imaged.  There was a significant 
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increase in adhesion to saphenous vein of HCAECs co-incubated with 
IGFBP-1 in comparison to untreated cells (Figure 6.8C). 
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A            B   
 
 
Figure 6-6 Representative images (200x magnification) of human 
saphenous vein under confocal microscopy  
(A) Nuclei of smooth muscle cells of endothelium-denuded human 
saphenous vein (B) CellTracker-labelled endothelial cells adhering onto the 
human saphenous vein matrix. 
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(A) Time course of HCAEC retention to human saphenous vein 
following 2 hour exposure  
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(B) Acute exposure of HCAEC attachment to human saphenous vein 
over a time course of 5-30 minutes 
 
 
 
 
 
 
 
 
Figure 6-7 Time course of re-endothelialisation of human saphenous 
vein matrix by HCAECs.  
(A) Time course imaging experiment where denuded saphenous vein 
segments were imaged serially after 2 hours of incubation with endothelial 
cell suspension. Images were taken immediately, then at 24, 48 and 72 
hours after incubation with HCAECs. Data represent mean numbers of 
adherent CellTracker +ve cells per high power field  (n=5-6). (B) Re-
endothelialisation of saphenous vein segments following short term 
incubation with HCAECs. Images were acquired immediately after incubation 
of denuded saphenous vein with HCAECs for 5, 10, 15, 20 or 30 minutes. 
Data represent mean numbers of adherent CellTracker +ve cells per high 
power field, n=5-10. 
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Figure 6-8 Effects of IGFBP-1 on adhesion of HCAECs to human 
saphenous vein.   
Endothelium-denuded segments of human saphenous vein were imaged 
after incubation with CellTracker-labelled HCAECs for 5 minutes.  
Representative confocal microscopy images (100x magnification) of human 
saphenous vein following incubation with  vehicle treated HCAECs (A) or 
IGFBP-1 (500ng/ml) treated HCAECs (B). Mean data are presented in (C) 
***p<0.001, paired t-test; n=5. 
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6.4.3 Linear Wound Assay 
6.4.3.1 Concentration dependent effect of foetal calf serum 
Initial experiments were performed to identify the optimal concentration of 
FCS to use for studies of cell migration.  In both HCAECs and HUVECs, a 
significant concentration-dependent increase in cell migration was observed 
at increasing FCS concentrations at 24 hours and 48 hours (Figure 6.9).   
 
6.4.3.2 IGFBP-1 does not modulate EC migration  
From the above experiments, 5% and 10% concentrations of ECGM were 
selected for use in subsequent experiments to investigate whether IGFBP-1 
has a pro-migratory effect on EC. We considered that higher concentrations 
of serum growth media may mask any IGFBP-1 response. Incubation of 
HUVEC or HCAEC with IGFBP-1 did not modulate migration in the linear 
wound assay.  (Figure 6.10)   
 
6.4.3.3 In a pro-inflammatory setting IGFBP-1 reverses impaired 
EC migration  
Having observed no effect of IGFBP-1 on migration of ‘healthy’ ECs, we 
speculated that any modulatory effect of IGFBP-1 of EC migration may be 
restricted to an insulin resistant setting.  This would parallel the 
augmentation of endothelial regeneration by IGFBP-1 in vivo, described in 
Chapter 4, which was only observed in insulin resistant mice.  In order to 
simulate insulin resistance in vitro, we incubated ECs with TNF-α, a pro-
inflammatory cytokine which is upregulated in insulin resistant states.  In 
HUVECs, incubation with TNF- significantly inhibited cell migration (Figure 
6.11A).  The addition of IGFBP-1 to TNF-α rescued cell migration to vehicle-
treated levels (Figure 6.11A).  In HCAECs, a trend to impaired migration was 
observed in cells incubated with TNF-α (Figure 6.11B).  Co-incubation of 
TNF-α-treated HCAECs with IGFBP-1 significantly enhanced migration 
(Figure 6.11B).  It is interesting to note that overall fewer HCAECs migrated 
compared to HUVECs. 
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(B) HUVECs 
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Figure 6-9 Concentration dependent effect of Foetal calf serum (FCS) 
on cell migration (linear wound assay).  
(A) Concentration dependent effect of FCS on cell migration in HCAECs. 
**P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA with Newman-Keuls 
post hoc test. Comparisons are made with 1% ECGM. n=4. (B) 
Concentration dependent effect of FCS on cell migration in HUVECs. 
**P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA with Newman-Keuls 
post hoc test.  Comparisons are made with 1% ECGM, n=3. 
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(B)  HCAECs 
5 5 5 5
0
5 0
1 0 0
1 5 0
2 0 0
2 4  h o u rs
4 8  h o u rs
p = 0 .6 5
p = 0 .8 5
T re a tm e n t
N
o
. 
o
f 
m
ig
r
a
te
d
 c
e
ll
s
 p
e
r
 m
m
 o
f 
w
o
u
n
d
 w
id
th
F C S  C o n c e n t r a t io n
  -             +               -              +            IG F B P - 1
 
1 0 1 0 1 0 1 0
0
5 0
1 0 0
1 5 0
2 0 0
2 4  h o u rs
4 8  h o u rsp = 0 .8 6
p = 0 .1 6
T re a tm e n t
N
o
. 
o
f 
m
ig
r
a
te
d
 c
e
ll
s
 p
e
r
 m
m
 o
f 
w
o
u
n
d
 w
id
th
  -             +               -              +            IG F B P - 1
F C S  C o n c e n t r a t io n
 
 
 
Figure 6-10 Effect of IGFBP-1 on EC migration in a linear wound assay  
(A) Effect of incubation with IGFBP-1 (500ng/ml) on cell migration in 
HUVECs at 48 hours, paired t-test, n=3. (B)  Effect of incubation with IGFBP-
1 on cell migration in HCAECs at 48 hours, paired t-test, n=3. 
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(B)  HCAECs 
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Figure 6-11 Effects of IGFBP-1 on migration of TNF-α-treated ECs in a  
linear wound assay.   
(A) Effect of TNF-α (10ng/ml) and IGFBP-1 (500ng/ml) on migration of 
HUVECs at 48 hours, **p<0.01, *p<0.05; one-way ANOVA with Newman-
Keuls post hoc test (n=9). (B) Effect of TNF-α (10ng/ml) and IGFBP-1 
(500ng/ml) on migration of HCAECs at 48 hours *p<0.05; one-way ANOVA 
with Newman-Keuls post hoc test) (n=6). 
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6.4.4 Boyden chamber Assay 
6.4.4.1 Effects of IGFBP-1 on EC chemotaxis    
 
Having shown that IGFBP-1 modulated migration in a scratch wound assay, 
here whether IGFBP-1 acted as a chemotactic stimulus in a Boyden 
chamber assay was investigated.  When IGFBP-1 (500ng/mL) was present 
in the lower chamber, a trend towards increased migration was seen in 
HCAECs (P=0.07) but not in HUVECs (Figure 6.12A and B). 
 
6.4.4.2 Effects of VEGF and IGFBP-1 on chemotaxis 
Next, we investigated whether incubation with IGFBP-1 modulated the 
chemotactic response of ECs to other agents.  VEGF is a potent chemo-
attractant for endothelial cells and plays an essential role in angiogenesis.  
When VEGF (50ng/mL) was in the lower chamber, a significant increase in 
migration was observed (Figure 6.12C).  When VEGF and IGFBP-1 were 
placed in the lower chamber, no additional effect on migration was observed 
(Figure 6.12C). 
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Figure 6-12 Effects of IGFBP-1 and VEGF on cell migration in HCAECs 
& HUVECs (Boyden Chamber).   
(A) Effects of IGFBP-1 (500ng/ml) on cell migration in HCAECs P value 
=0.07 paired t-test, n=5, (B)  Effects of IGFBP-1 (500ng/ml) on cell migration 
in HUVECs, P=0.99, paired t-test, n=3, (C) Effects of IGFBP-1 (500ng/ml) 
and VEGF (50ng/ml) on cell migration in HCAECs, **P<0.01, One way 
ANOVA with Newman-Keuls post hoc test, n=6.  
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6.4.5 Cell Proliferation Assay 
6.4.5.1 Concentration dependent effect of foetal calf serum 
Initial experiments were performed to define a sub-maximal EC proliferative 
response so either an increase or decrease could be detected when IGFBP-
1 was applied in subsequent experiments.  In HUVECs, an increase was 
observed in cell proliferation at increasing FCS concentrations at day 2 and 
day 5 (Figure 6.13).  2.5% FCS concentration was selected for subsequent 
experiments with insulin and IGFBP-1,  
 
6.4.5.2 Effects of IGFBP-1 on EC proliferation 
A strong trend was seen toward IGFBP-1 promoting proliferation of both 
HUVECs (P=0.076) and HCAECs (P=0.01).  (Figure 6.14 and 6.15A) 
 
6.4.5.3 In a pro-inflammatory setting IGFBP-1 reverses impaired 
EC proliferation  
As in the linear wound assay, TNF-α incubation was again used to assess 
whether the modulatory effect of IGFBP-1 on cell proliferation was 
exaggerated in a pro-inflammatory setting.  In HCAECs incubated in full 
(20%) ECGM, TNF- (10ng/mL) significantly inhibited cell proliferation but 
appeared to induce apoptosis (n=3).  The addition of IGFBP-1 to TNF-α at 
this concentration (10ng/mL) did not rescue cell proliferation (Figure 6.13A). 
A concentration-response experiment was then performed to select the 
optimum concentration of TNF-α at which to examine modulatory effects of 
IGFBP-1 (n=3) (Figure 6.15B).  A sub-maximal anti-proliferative 
concentration of TNF-α (0.1ng/mL) was selected. At this lower concentration 
of TNF-α, IGFBP-1 significantly improved cell proliferation on par with 
vehicle-treated levels (n=6) (Figure 6.15C). 
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Figure 6-13 Concentration dependent effect of Foetal calf serum (FCS) 
on cell proliferation.   
(A) Concentration dependent effect (5% vs 10% FCS) on cell proliferation in 
HUVECs, n=4 (B) Concentration dependent effect (2.5% vs 5% vs 10%) on 
cell proliferation on HUVECs, n=2. 
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Figure 6-14 Effect of IGFBP-1 on cell proliferation in HUVECs.   
Effect of IGFBP-1 (500ng/ml) on cell proliferation in HUVECs in (2.5% FCS) 
ECGM, insulin was used as a positive control. *p<0.05, one-way ANOVA 
with Newmans-Keul post hoc test, n=4.   
  
 138 
(A) Effect of TNF-α (10ng/mL) on cell proliferation with and without 
IGFBP-1 in HCAECs 
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(B) Concentration-dependent effect of TNF-α on cell proliferation in 
HCAECs 
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(C) Effects of TNF-α (0.1ng/mL) on cell proliferation with and without 
IGFBP-1 in HCAECs 
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Figure 6-15 Effects of IGFBP-1 and TNF-α on cell proliferation in 
HCAECs.   
(A) Initial experiment demonstrating the effect of TNF-α and IGFBP-1 
(500ng/ml) on cell proliferation, n=3. (B) Concentration dependent effect of 
TNF-α on cell proliferation. Cells were incubated with decreasing 
concentrations of TNF-α, n=3 (except TNF-α = 0.01ng/ml, n=2). (C) Effect of 
TNF-α and IGFBP-1 (500ng/ml) on cell proliferation, ****p<0.0001, ***p 
<0.001, **p <0.01, *p <0.05. One-way ANOVA with Newmans-Keul post hoc 
test, n=6. 
 139 
6.5 Discussion 
The experiments conducted in this chapter provide a number of new insights 
in to the modulatory effects of IGFBP-1 on the properties of EC pertinent to 
endothelial regeneration.  First, IGFBP-1 was shown to enhance 
regeneration of human saphenous vein segments by augmenting the 
adhesion of HCAECs to the denuded vein.  Second, IGFBP-1 was shown to 
rescue the impairment of endothelial cell migration induced by a pro-
inflammatory stimulus.  Finally, IGFBP-1 was found to rescue the impairment 
of endothelial cell proliferation induced by a pro-inflammatory setting.  
 
Effective endothelial regeneration of injured vessels is dependent on ECs 
adhering to the extra-cellular matrix.  In this chapter, it was shown that pre-
treatment of cells with IGFBP-1 significantly enhanced adhesion onto a 
native human saphenous vein matrix.  The denuded vessel matrix consists of 
vascular smooth muscle cells and the extra-cellular matrix to which the ECs 
bind.  The saphenous vein model is of particular interest as this correlates 
with the clinical setting.  It mimics the changes  which happen following 
coronary artery bypass graft surgery in humans, in which ECs in the vein are 
damaged and then repopulated by neighbouring endothelial cells.  
Identification of a pro-reparative effect of IGFBP-1 in this model supplements 
the data derived in mice in chapter 3 and suggests the potential for 
translation in to clinical studies.  However, further studies using the 
saphenous vein model could first be considered.  For example, the rate of re-
endothelialisation by human ‘late-outgrowth’ APCs pre-treated with IGFBP-1 
could be investigated with this model, as Xu et al successfully showed that 
de-cellularised human internal mammary artery samples could be 
transplanted into a murine model and are repopulated after 2-4 weeks by 
cells expressing endothelial cell markers suggestive of angiogenic progenitor 
cells292.  
 
In the saphenous vein model, ECs adhere to denuded vascular matrix. 
Although this is biologically relevant, adhesion to specific matrix components 
(e.g. fibronectin and collagen) could also be investigated individually.  
 140 
Adhesion of ECs to extra-cellular matrices is dependent on the action of cell 
surface integrins.  Integrins are heterodimeric transmembrane adhesion 
receptors comprising α and β subunits, which play an important role not only 
in adhesion but also in migration139.  Experiments investigating the effect of 
IGFBP-1 on cell surface expression of integrins are presented in the next 
chapter.  
 
The in vitro studies assessed endothelial cell migration using a linear wound 
assay and modified Boyden Chamber assay.  HUVECs were used initially as 
these are most widely studied ECs, are readily available and are relatively 
simple to culture.  However HUVECs are of foetal origin and are venous 
cells, factors which may limit the translation of experiments conducted in 
HUVECs to arterial regeneration in adult humans.  It is recognised that adult 
ECs have a different phenotype to HUVECs due to exposure to hormones 
and cytokines293.  In later experiments, HCAECs were employed as they are 
adult cells which are derived from coronary arteries.  HCAECs potentially 
provide a more relevant insight into endothelial cell reparative functions as 
endothelial dysfunction and atherosclerosis mainly affect arteries.  It may be 
considered good practice, as here, to replicate experiments in ECs derived 
from more than one primary source, as ECs do differ widely in morphology 
and function294.  From the results presented, it is interesting to note that in 
the linear wound assay the HCAECs migrated at a slower rate compared to 
HUVECs, possible because HCAECs are mature cells and have less 
regenerative capacity.    
 
The experiments conducted in this chapter found that IGFBP-1 does not 
modulate EC migration in healthy cells.  In the modified Boyden Chamber 
assay, IGFBP-1 did not promote EC migration. However, this finding should 
be interpreted with caution as this assay investigates migration in response 
to a chemotactic stimulus.  One perhaps would not expect there to be a 
chemotactic effect of IGFBP-1 as in vivo there is unlikely to be a natural 
concentration gradient of IGFBP-1 in injured vessels.  However, neither did 
IGFBP-1 modulate EC migration to the known chemotactic stimulus VEGF. 
Pre-incubation of IGFBP-1 was also investigated prior to seeding and was 
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not found to modulate the migratory response of ECs in the Boyden 
Chamber assay. 
   
The linear ‘scratch’ wound assay is arguably a more appropriate assay as to 
a degree the assay mimics cell migration in vivo.  Here, ECs migrate to areas 
of denuded endothelium to close the wound.  In the linear wound assay, 
there was no significant effect of IGFBP-1 on migration of  ‘healthy’ cells, 
perhaps because there was no ‘damaging’ stimulus similar to interpretation 
of the in vivo studies comparing femoral arterial regeneration in WT and 
IGFBP-1 mice described in Chapter 4.  Another possibility could be that 
IGFBP-1 binds to IGFs in the growth medium.  IGF-1 on its own has been 
shown to enhance endothelial cell migration295.  In this case, inhibition of IGF 
bioavailability by IGFBP-1 could  potentially counteract any IGF-independent 
effects of IGFBP-1 on cell migration.  To investigate this possibility further, 
synergy studies with and without IGF-1 and IGFBP-1 would need to be 
conducted.  Synergy studies using des-IGF-1296 would be particularly 
informative.  Des-IGF-1 is an IGF-1 variant, which has a very low affinity for 
binding proteins.  
 
A potential limitation from the in vitro studies are the growth factors being 
present in the Endothelial Cell Growth Media, especially whether IGF-1 or 
IGFBP-1 are already present and whether the effects of IGFBP-1 being 
applied are inhibited or enhanced.  It was not known by the manufacturers 
whether IGF-1 or IGFBP-1 were present in the growth media.  One could 
have performed ELISA studies assessing IGFBP-1 and IGF-1 levels of the 
growth media used or could have added IGF-1 receptor antibodies to ensure 
that adding IGFBP-1 would have not bound to IGF-1 and therefore inhibit the 
actions of IGFBP-1. 
 
Having observed no modulatory effect of IGFBP-1 on migration of ‘healthy’ or 
‘insulin-sensitive’ EC, the linear wound assay was repeated following  
incubation of ECs with TNF-α to compromise EC function and to induce a 
pro-inflammatory stimulus characteristic of IR.  As discussed in chapter 1, 
pro-inflammatory cytokines such as TNF-α, Interleukin-1,-6,-8, are 
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upregulated in IR and have been implicated in vascular pathology297–299. In 
this chapter, TNF-α was shown to inhibit cell migration significantly in 
HUVECs with a trend to inhibition of migration observed in HCAEC.  In both 
types of primary cells, incubation with IGFBP-1 was found to rescue cell 
migration to control levels.  These findings suggest that IGFBP-1 exerts a 
modulatory effect on EC migration which appears to be specific for a pro-
inflammatory state characteristic of IR.  
 
Certain limitations from the studies reported in this chapter must be 
acknowledged. TNF-α concentrations were not measured in IRKO mice in 
Chapter 4.  Such information would be useful to better correlate the in vitro 
data generated in this chapter with the in vivo data in Chapter 4.  However, it 
has been shown that raised TNF-α levels are present in other insulin-
resistant mice300.   
 
We selected incubation with TNF-α as this cytokine is increased in 
individuals with IR, correlates with endothelial dysfunction and cardiovascular 
events and is known to impair insulin signalling in EC86,301.  However, other 
methods of inducing in vitro insulin resistance in ECs could have been 
considered.  For example, ECs could be pre-treated with insulin receptor 
blocking antibodies or incubated with palmitate, a free fatty acid which is 
increased in insulin resistant states in vivo.  Other options include culturing 
cells in high insulin or high glucose concentrations.  Although time pressures 
precluded these experiments being conducted in this thesis, ideally the in 
vitro experiments should be repeated to confirm these effects in other 
models of IR. 
 
The linear wound assay is an inexpensive method and easy to perform, 
however there is a limitation presented by the manual nature of the wound 
formed.  Other methods of cell migration are available – for example the 
stamping assay, in which an EC monolayer is punched to form a 
reproducible and consistent pattern of injury.  Also, an optical method is 
available in which a laser induces photomechanical effects on the cell 
layer302.  This is computer controlled and has the advantages of consistency 
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reproducibility, automatic analysis of wound healing and the ability to create 
differing wound shapes302. 
 
The in vitro studies also assessed the effects of IGFBP-1 on cell proliferation 
in ECs. There was a trend towards enhanced cell proliferation when ECs 
were incubated with IGFBP-1.  Having observed restoration of the inhibitory 
effect of TNF-α on EC migration with the addition of IGFBP-1, the same 
conditions were applied in the cell proliferation assay. TNF-α has also been 
observed to inhibit cell proliferation in vitro in studies303.  Using the same 
concentration of TNF-α as in the linear wound assay (10ng/mL) provoked 
toxicity in ECs, probably due to cells requiring continued exposure for 5 days 
in proliferation assays rather than 48 hours in the linear wound assay.  It is 
likely that any potential benefits of IGFBP-1 on proliferation were masked at 
this concentration of TNF-α.  It was therefore necessary to perform a TNF-α 
concentration-response experiment to select a concentration at which the 
anti-proliferative effects of TNF-α were sub-maximal and apoptosis could be 
avoided.  From this set of studies, a TNF-α concentration of 0.1ng/mL was 
chosen.  The cell proliferation assay was then repeated to demonstrate that 
impaired proliferation induced by TNF-α, was significantly enhanced by co-
incubation with IGFBP-1.  Other proliferation assays are available, such as a 
DNA synthesis cell proliferation assay where 5-bromo-2'-deoxyuridine (BrdU) 
is applied to cells and the BrdU becomes incorporated into newly formed 
DNA. However, the direct cell counts performed here are superior to DNA 
synthesis assays because an assumption is made with the DNA assays that 
cells have divided.  In addition, effects of TNF-α may not have been apparent 
at the shorter time points typically used with the DNA assay.   
 
In summary, the data presented in this chapter demonstrate multiple effects 
of IGFBP-1 on functional properties of ECs contingent with effective 
endothelial repair, albeit apparently specific for a pro-inflammatory setting. 
The potential mechanisms underpinning the effects of IGFBP-1 on 
endothelial responses such as migration and adhesion will be investigated in 
the next chapter.  
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7 Mechanistic pathways and 
effects of IGFBP-1 on 
endothelial repair 
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7.1 Introduction 
So far in this project IGFBP-1 has been demonstrated to enhance endothelial 
regeneration in an insulin resistant setting in vivo, enhance endothelial cell 
migration, proliferation in a pro-inflammatory environment in vitro and 
augment EC adhesion ex vivo.  The effects of IGFBP-1 on endothelial 
regeneration are likely to be mediated by modulation of endothelial cells 
rather than angiogenic progenitor cells.  It is therefore important to determine 
the underlying mechanistic basis by which IGFBP-1 improves endothelial 
repair processes such as adhesion, migration and proliferation.   
 
Cell migration is a coordinated process that involves rapid changes in actin 
filament dynamics, together with the formation and disassembly of cell 
adhesion sites141.  External stimuli that affect cell migration are transduced 
into intracellular biochemical signals through the interaction of 
transmembrane integrins which bind to the extra-cellular matrix (ECM).  
Integrin activation allows the functional connection between focal adhesions 
and actin cytoskeleton that is needed for cell migration304. 
 
Remodelling of actin, the major cytoskeletal component, is seen as the 
central factor involved in EC migration.  Actin is composed of 43-kDa 
monomeric subunits (G-actin) that polymerize into filaments (F-actin).   The 
actin cytoskeleton constantly remodels into filopodia, lamellipodia and stress 
fibres, which are essential for cell migration.  The Rho family GTPases 
RhoA, Rac and Cdc42 are major regulators of the actin cytoskeleton and cell 
migration140 and are the most studied members157.  These members are 
molecular switches cycling between an inactive guanosine diphosphate 
(GDP)-bound and an active guanosine triphosphate (GTP)-bound state to 
activate the GTPase158,  RhoA induces the formation of actin stress fibres 
and focal adhesions and stimulates cell contraction through downstream 
effectors ROCK and mDia.  Rho-kinase (ROCK) is an effector of GTPase 
RhoA159, whilst Rac and Cdc42 regulate the polymerisation of actin to form 
peripheral lamellipodial and filopodial protrusions158. 
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Integrins are a family of cell adhesion molecules, which interact with the 
ECM or with adhesion molecules on other cells135.  In all, 24 integrins have 
been identified and each is a heterodimer of an α and a β subunit135.  
Integrins exhibit both inside-out/outside-in (bidirectional) signalling, i.e. 
signals within the cell cause integrins to change which leads to integrin 
activation and therefore an increased affinity for extracellular ligands.  In the 
opposite direction, integrins binding to their ligands can initiate change to 
their cytoplasmic domains and activate multiple signalling pathways136.  An 
ECM protein such as fibronectin can engage several integrins, the most 
commonly expressed fibronectin-binding integrins are αVβ3 and α5β1, both 
bind to the RGD sequence within fibronectin134. 
 
Focal adhesion kinase (FAK) was identified in 1992 in normal cells as a 
highly tyrosine-phosphorylated protein that localised to integrin-enriched cell 
adhesion sites known as focal adhesions141.  Focal adhesions are formed at 
ECM-integrin junctions and bring together cytoskeletal and signalling 
proteins during the processes of cell migration and adhesion.  Early studies 
showed that FAK could be activated by growth factors and phosphorylation 
of FAK is a rapid event associated with focal adhesion formation143.  FAK 
regulates cell migration through a number of pathways but in particular 
through affecting the Rho subfamily of small GTPases and the 
assembly/disassembly of actin cytoskeleton148.  It has also been shown that  
FAK-deficient cells spread slower on ECM, exhibit an increased number of 
prominent focal adhesions and migrate poorly in response to haptotactic and 
chemotactic signals144–147.     
 
Data presented in this thesis show that IGFBP-1 enhances EC adhesion, 
and promotes EC migration and proliferation in a pro-inflammatory setting. 
IGFBP-1 has previously been shown to promote cell migration in non-
vascular cells independently of IGFs via the Arg-Gly-Asp (RGD) motif 
present in its C-domain305.  This RGD motif is an integrin recognition 
sequence and can bind to integrins such as α5β1 on the cell surface leading 
to integrin-mediated signalling.  Therefore a potential mechanism for the 
findings reported in this thesis is that IGFBP-1 mediates its effects on 
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endothelial cells via integrin signalling which in turn phosphorylates FAK.  In 
this chapter, the role of IGFBP-1 in modulating integrin expression, FAK 
phosphorylation, RhoA activity and cytoskeletal rearrangement will be 
examined.  
 
 148 
7.2 Aims 
The aims of this chapter are to explore potential candidates by which IGFBP-
1 enhances adhesion, migration and proliferation. 
  
The following will be investigated in detail: 
1. The effects of IGFBP-1 on FAK phosphorylation and RhoA activity  
2. The role of IGFBP-1 on the actin cytoskeleton in ECs and additionally 
on integrin expression on the EC surface 
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7.3 Methods 
7.3.1 Western blot analysis of endothelial cells assessing FAK 
phosphorylation 
Western blot analysis, undertaken by Mrs Jessica Smith who had previously 
optimised the experimental conditions in our laboratory, was used to quantify 
FAK phosphorylation in HUVECs.  After 4 hours of serum-starvation, 
endothelial cells were treated with IGFBP-1 for 15 minutes. VEGF (10 
minutes) served as a positive control. Vehicle treated cells were used as a 
negative control. Protein was extracted in lysis buffer and quantified using 
the protein Bicinchoninic Acid (BCA) assay (Sigma-Aldrich, Gillingham, UK). 
Then, 30µg of protein were separated by electrophoresis through 4–12% 
SDS-PAGE gels (Invitrogen Life Technologies, Carlsbad, CA) and 
transferred onto polyvinylidene fluoride membranes.  Membranes were 
probed with primary antibodies (FAK antibody 1:1000 (#3285, Cell Signalling 
technology, USA and phosphoFAK antibody 1:1000 (#8556S, Cell Signalling 
technology, USA), and 1:3000 actin antibodies (BD Bioscience), as 
previously described211.  The steps are described in detail as follows: 
 
7.3.1.1 Total protein quantification 
Equal protein concentration was estimated using the Bicinchoninic Acid 
assay (Pierce, Rockford, USA).  Initially 12.5µL of each lysate sample were 
diluted 12-fold in distilled water in a centrifuge tube.  25 µL of this solution 
were then loaded onto a 96-well plate in duplicate.  Standards were obtained 
by serial dilution of 2mg/mL BSA (Sigma-Aldrich, Gillingham, UK) (0, 25,125, 
250, 500, 750, 1000, 1500 and 2000µg/mL) and loaded in duplicate.  200µL 
of 50:1 BCA:4% copper (ii) sulphate were then pipetted into each well.  The 
amount of copper reduced is proportional to the amount of protein present in 
the solution, reduced copper is chelated by BCA to form a purple coloured 
complex.  After covering the plate with sealing foil, the plate was incubated at 
370C for 30 minutes.  After this time period, absorption spectra were 
measured by colorimetric assay at 562nm.  Protein content was calculated 
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by reference to the standard curve, with correction for the initial 5-fold 
dilution.  Co-efficient of variation between duplicates was only accepted at 
<10%, and R2 value of 0.99 for standards. 
 
7.3.1.2 Protein gel-resolution transfer 
Lysate sample volume containing 30µg of protein was calculated as above 
and boiled for 5 minutes after mixing with appropriate volumes of 4X loading 
buffer and 10X reducing agent (NuPage, Invitrogen, CA).  Reduced samples 
were chilled on ice, vortexed and then pulse-centrifuged, and finally loaded 
onto 4-12% SDS-PAGE gels (Invitrogen).  One well for reference was loaded 
with a protein standard ladder.  Samples were resolved through 
electrophoresis at 160V for 60 minutes using a gel running system 
(Invitrogen) bathed in running buffer (NuPAGE, Invitrogen). Next, the gel with 
resolved protein was extracted from the gel-case and placed over a PVDF 
membrane (Millipore, MA) soaked in methanol (15 seconds), distilled water 
(2 minutes) and transfer buffer (2 minutes; see appendix). The gel / 
membrane were then sandwiched between 3mm-thick filter papers with 
sufficient pressure to ensure firm contact, and placed in a transfer-cassette 
orientated to ensure correct direction of transfer. The cassette was bathed in 
chilled transfer buffer conducting 90V for 90 minutes. 
 
7.3.1.3 Western immunoprobe 
Membranes were re-activated by immersing in methanol for 15 seconds and 
then placing in water for 2 minutes and then TBS/Tween-20 (5 minutes; see 
appendix).  The membrane was then blocked for non-specific proteins by 
washing in 10mL of 5% non-fat milk / TBS / Tween-20 solution for 1 hour, 
using a container on a roller at room temperature. Blocked membranes were 
then transferred to a new container with 5mL 5% milk / TBS / Tween-20 
solution containing the primary antibody of interest (1:1000 FAK antibody, 
1:1000 phospho-FAK antibody and 1:5000 actin antibodies). After being 
probed overnight at 40C by washing on a roller, the membrane was washed 
in TBS / Tween solution on a rocking device for 3 cycles of 10 minutes each, 
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with fresh solution at each cycle. Next, the membrane was probed by a 
secondary rabbit anti-mouse antibody conjugated to HRP (1:5000) (Dako) in 
fresh 5mL 5% milk / TBS / Tween solution for 1 hour at room temperature. 
TBS / Tween washes were performed and repeated three times to remove 
excess antibody. The membrane was then superficially covered with 
chemiluminescent substrate solution (Millipore) for 5 minutes in darkness, 
after which excess solution was allowed to run off and the membrane 
sandwiched between 2 translucent acetate films. Fluorescence was then 
detected by exposure of the sandwiched membrane to a Kodak Image 
Station 2000R. The blot densities were analysed with Image J (version 1.47) 
software (NIH, USA). Band densities were quantified and background signal 
subtracted. Proteins of interest (FAK and phospho-FAK) were normalised to 
same-sample actin density as a control.  
 
7.3.2 RhoA Activity Assay 
The RhoA activity assay was performed using a Rho G-LISA kit 
(Cytoskeleton Inc., Denver, Colorado, USA) which contains a Rho-GTP-
binding protein linked to the wells of a 96-well plate.   
 
Initially, HCAECs were seeded at 100,000 cells/well into a 6 well fibronectin-
coated plates.  Once they achieved 80% confluence cells were serum 
starved overnight and then treated with IGFBP-1 for different time points (0 
minutes, 10 minutes, 20 minutes and 40 minutes).  After treatment, the 
medium was aspirated and washed thrice with ice-cold PBS being especially 
careful to remove all residual PBS.  Cells were then lysed with 120 µL of ice-
cold lysis buffer (1:100 of Protease inhibitor:lysis buffer), harvested and 
transferred into microcentrifuge tubes on ice.  The samples were centrifuged 
at 10,000g, 4 °C for 2 minutes.  20µL of lysate were taken off and stored at 4 
°C for protein quantification and the remainder used for the RhoA activity 
assay by the RhoA ELISA (Cytoskeleton, Inc., Denver, Colorado, USA).   
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7.3.2.1 Total protein quantification 
It is important to measure the total protein concentrations of the cell lysates 
to ensure standardisation of results.  Using a 96-well plate, 10µL of lysis 
buffer were added into the top 2 wells, and then 10µl of each sample place in 
duplicates.  300 µL of Precision RedTM Advanced Protein Assay Reagent 
were added into each well and left to incubate for 1 minute at room 
temperature.  After this time period, absorbance was then measured at 
595nm. 
 
7.3.2.2 Running G-LISA Assay 
The next step was to set up a standard curve, this consisted of a blank 
sample (60µL lysis buffer and 60µL Binding buffer = lysis buffer solution), 
sample 0.25 (15µL of a pre-made mix {24 µL Rho Control Protein + 96µL 
lysis buffer} + 45 µL lysis buffer solution), sample 0.5 (30 µL pre-made mix + 
30 µL lysis buffer solution) and sample 1 (60 µL of pre-made mix).  Next, 60 
µL of Binding buffer were added to each sample.  Using the assay strips, the 
powder in the wells was dissolved with 100µL of milliQ water, whilst the plate 
with the strips was kept on ice.   
 
Using the treated cell lysate samples, 60 µL were placed into a fresh 
microcentrifuge tube and then 60 µL of binding buffer were added to each 
sample.  With the 96-well plate, water was completely removed by a series of 
vigorous pats onto a paper towel.  This is an important step as complete 
removal of solution from the wells is required between steps of the G-LISA 
as this avoids high background readings in the buffer only wells. 50 µL of 
each sample in duplicate were added including the standard curve samples 
onto each well and the plate placed on a cold orbital microplate reader 
(200rpm) at 4°C for 30 minutes.   
 
After 30 minutes, the solution was removed and washed twice with 200 µL of 
wash buffer with vigorous removal after each wash.  200 µL of Antigen 
Presenting Buffer were pipetted into each well and incubated at room 
temperature for exactly 2 minutes, followed by vigorous removal and washed 
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thrice with 200 µL of wash buffer.  50 µL of diluted anti-RhoA primary 
antibody (1/250 ratio, 2 µL of anti-RhoA primary antibody to every 500 µL 
Antibody Dilution buffer) were added to each well and the plate was placed 
on the orbital microplate shaker (200rpm at room temperature) for 45 
minutes.   
 
Following this, the solution was removed vigorously, washed thrice with 200 
µL of Wash Buffer and 50 µL of diluted secondary antibody (1/62.5 ratio, 8 
µL of secondary HRP labelled antibody to every 500 µL Antibody Dilution 
buffer) were added to each well and the plate was placed on an orbital 
microplate shaker (200rpm at room temperature) for 45 minutes. Following 
this, the secondary antibody solution was removed vigorously and the wells 
washed thrice with 200µL of Wash Buffer.  50µL of HRP detection reagent 
were added to each well and incubated at 37°C for 15 minutes.  Then 50µL 
of HRP Stop buffer were added to each well.  The signal was immediately 
read by measuring the absorbance at 490nm using a microplate 
spectrophotometer. 
 
7.3.3 Visualisation of cytoskeletal re-arrangement 
HCAECs were seeded at 3000 cells/well into 1% gelatin-coated chamber 
slides in full (20% FCS) ECGM for 48 hours.  After gentle washing with PBS, 
cells were treated in 10% FCS ECGM with IGFBP-1 (500ng/mL) or TNF-α 
(10ng/mL).  After treatment for 24 hours, HCAECs were washed with PBS 
twice before ﬁxation in 4% paraformaldehyde for 10 minutes and washed 
with PBS twice again.  The cells were permeabilised and blocked in PBS 
containing 10% goat serum and 0.05% Triton X-100 (this allows the 
rhodamine phalloidin to enter the cells but prevents non-specific binding). 
After washing twice with PBS, fixed cells were treated with a ﬂuorescent 
marker to stain the F-actin cytoskeleton (rhodamine phalloidin, 1:40) in PBS 
for 20 minutes in the dark. After 20 minutes the solution was removed and 
the slide was then mounted on to a cover slip using ProLong Gold.  The slide 
was then left overnight in the dark and incubated at room temperature to 
allow the ProLong Gold to set and therefore be able to obtain images.  
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Stained cells were visualised using 20× objective on a LSM510 Axiovert 
200M high throughput ﬂuorescence microscope the following day.  
Interpretation was assessed subjectively through observing cytoskeletal 
arrangement. 
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7.3.4 Integrin-mediated cell adhesion assay 
Effects of IGFBP-1 on cell surface expression of subunit or heterodimer 
integrins were quantified using an integrin-mediated cell adhesion array kit 
(ECM532, Millipore, Billerica, Massachusetts, USA). In the assay, mouse 
monoclonal antibodies directed against specific human subunit (α1, α2, α3, α4, 
α5, αV, β1, β2, β3, β4, β6) or heterodimer (αVβ3, αVβ5 and α5β1) integrins were 
immobilised to the surface of the wells using goat anti-mouse antibody.  
Negative wells were coated with the goat anti-mouse antibody only.  
HCAECs were grown to confluence in 75cm3 flasks and harvested using 
Gibco® Cell Dissociation Buffer.  HCAECs were co-incubated with or without 
IGFBP-1 for 1 hour before 100,000 cells were added to the integrin antibody-
coated and control wells and incubated for 2 hours at 37°C.  Unbound cells 
were then washed off and the adherent cells stained. The optical density of 
nuclear stain extracts was measured at 540nm (OD540nm) on a MRX TC 2 
microplate reader (DYNEX Technologies, U.K.). 
 
Prior to starting the assay, the strips from the kit were rehydrated with 200 µL 
of PBS per well for 10 minutes at room temperature.  The PBS was removed 
from the strip by turning over the plate and gently tapping out the PBS.  
HCAECs were harvested using Gibco® Cell Dissociation Buffer and rinsed 
twice with Gibco® Cell Dissociation Buffer.  After re-suspension, cells were 
re-suspended in Assay Buffer and aliquoted into 1,000,000 cells/mL and 
were treated and incubated with vehicle or IGFBP-1 (500ng/mL) for 1 hour.  
After 1 hour, the cell suspension was gently mixed and 100 μL applied to 
each well of the mouse anti-α or anti-β integrin capture and control wells in 
duplicate.  The plate was then incubated for 2 hours at 37°C in a CO2 
incubator, followed by gentle aspiration and washed 3 times with 200 µL of 
Assay Buffer.  100 µL of cell stain solution were added to each well and 
allowed to incubate for 5 minutes at room temperature, followed by gentle 
aspiration and washed 5 times with deionized water, aspirated, allowed to 
dry and 100 μL of Extraction Buffer added to each well.  The plate was 
incubated on an orbital shaker at room temperature until the cell-bound stain 
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was completely solubilised, which approximately took 5-10 minutes.  The 
absorbance was determined at 540-570 nm on a microplate reader.  
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7.4 Results 
7.4.1 The role of IGFBP-1 in focal adhesion kinase phosphorylation  
Because phosphorylation of FAK is critically implicated in integrin signalling 
and EC migration, western blotting was employed to assess whether acute 
exposure to IGFBP-1 induces FAK phosphorylation.  There was a strong 
trend towards IGFBP-1 induced FAK phosphorylation in HUVECs (Figure 
7.1) suggesting that integrin-FAK signalling may contribute to the functional 
effects on EC migration observed in Chapter 6. 
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Figure 7-1 Evaluation of FAK phosphorylation in HUVECs.  
IGFBP-1 (100ng/ml and 500ng/ml) concentration-dependently 
stimulated FAK phosphorylation in HUVECs, VEGF was used as a 
positive control. (A) representative Western Blot showing FAK 
phosphorylation in HUVECs in tyrosine 397 residue.  Beta actin is 
presented as a loading control. (B) mean data of FAK phosphorylation 
(values normalised to beta actin), *p<0.05; one-way ANOVA with 
Newman-Keuls post hoc test; n=3. 
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7.4.2 IGFBP-1 activates RhoA 
RhoA is a small GTP-binding protein which regulates actin cytoskeleton in 
the formation of stress fibres and plays a role in cellular motility.   HCAECs 
were serum-starved overnight and exposed to IGFBP-1 for different time 
intervals.  A significant rapid yet transient activation of RhoA in HCAECs 
(n=5) following exposure to IGFBP-1 (Figure 7.2) was observed, which 
returned to baseline levels within 40 minutes.  RhoA was activated within 10 
minutes of exposure to IGFBP-1 and was maintained at 20 minutes.   
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Figure 7-2 RhoA activation of HCAECs in response to IGFBP-1.   
HCAECs were exposed to IGFBP-1 (500ng/ml) at different time points and 
RhoA activity was measured at the times indicated  (0 = serum starved cells 
with no IGFBP-1 treatment).  **p<0.01 vs unstimulated cells; one-way 
ANOVA with Newman-Keuls post hoc test, n=5. 
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7.4.3 Rhodamine Phalloidin staining of endothelial cells 
Having shown that IGFBP-1 improves EC migration, proliferation and 
adhesion, cytoskeletal remodelling in response to IGFBP-1 was investigated 
next.  The clear effect on cell migration suggests a potential role for IGFBP-1 
in modulating cyto-skeletal rearrangement.  To investigate this, ECs were 
stained with rhodamine phalloidin to visualise the F-actin cytoskeleton.  Pilot 
studies were performed investigating the correct density of cells to seed 
initially as if the wells were too confluent it may not prove possible to 
visualise individual cells completely.  5000 cells/well were used initially, this 
led to a confluent well and therefore difficulty in visualising individual cells. 
Cell density was then reduced to 3000 cells/well.  Initial studies investigated 
whether TNF-α disrupted the actin cytoskeleton of HCAECs after 24 hours of 
incubation.  TNF-α (10ng/mL, 24 hours) was qualitatively noted to induce 
substantial disruption of the cytoskeleton (Figure 7.3B and 7.3C).   
 
IGFBP-1 had no discernable effect on the cytoskeleton of quiescent cells 
(Figure 7.4B).  However, IGFBP-1 (500ng/mL, 24 hours) appeared to almost 
completely ameliorate the cytoskeletal disruption induced by TNF-α (Figure 
7.4D).   
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Figure 7-3 Rhodamine Phalloidin staining of HCAECs with TNF-α.   
Representative images (200x magnification) showing the actin cytoskeleton 
of control HCAECs (A) and those exposed to TNF-α (10ng/ml) for 24 hours 
(B).  Possible TNF-α induced cytoskeletal disruption after 24 hours, n=3. 
 
F-actin filaments 
Filament disruption 
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Figure 7-4 Rhodamine Phalloidin staining of HCAECs with TNF-α and 
IGFBP-1.   
Representative images (200x magnification) showing the actin cytoskeleton 
of (A) control HCAECs and those exposed to (B) IGFBP-1 (500ng/ml) (C) 
TNF-α and (D) TNF-α + IGFBP-1 (500ng/ml) for 24 hours.  IGFBP-1 
(500ng/ml) alone seemed to have no effect on cytoskeletal rearrangement.  
TNF-α appears to have caused disruption of the cytoskeleton which then 
appeared to be partially restored with co-incubation of IGFBP-1 (500ng/ml), 
n=4. 
Filament disruption 
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7.4.4 IGFBP-1 increases cell-surface expression of α5β1 and αVβ3 
integrins 
In the previous chapter, IGFBP-1 was shown to increase endothelial cell 
adhesion.  This raises the possibility that IGFBP-1 may increase cell-surface 
availability of integrins capable of binding extra-cellular matrix.  Here, 
incubation of HCAEC with IGFBP-1 (500ng/mL) for 1 hour significantly 
increased cell-surface expression of α5β1, α2, αV (Figure 7.5A) and αVβ3 
integrins (Figure 7.5B) (n=6). 
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Figure 7-5 Effects of IGFBP-1 on cell surface integrin expression in 
HCAECs.   
HCAECs were incubated with IGFBP-1 (500ng/mL) for 1 hour before 
quantifying cell-surface expression of a panel of integrins (A) Effects of 
IGFBP-1 on cell surface α integrin expression in HCAECs (B) Effects of 
IGFBP-1 on cell surface β integrin expression in HCAECs, *p<0.05 and 
**p<0.01; Paired t-test; n=6.  
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7.5 Discussion 
This chapter extends the functional insights reported in the preceding 
chapters by providing a number of key mechanistic insights into the 
influence of IGFBP-1 on key signalling nodes and cytoskeletal changes in 
ECs.  First, IGFBP-1 was shown to potentially phosphorylate the signalling 
node FAK which plays a critical role in cell proliferation and migration.  
Second, IGFBP-1 was found to activate RhoA which mediates cytoskeletal 
rearrangements necessary for EC motility.  Third, IGFBP-1 was seen to 
potentially restore partial disruption of actin remodelling induced by the pro-
inflammatory cytokine TNF-α.  Finally, IGFBP-1 was noted to increase cell 
surface expression of integrins recognised to mediate adhesion to 
extracellular matrices. 
 
Since the 1960s and 1970s it has been long thought that endothelial 
regeneration in response to arterial injury is a local process involving cell 
migration and proliferation of EC adjacent to the site of injury.  In the present 
chapter the mechanisms by which IGFBP-1 exerts its effects on EC 
adhesion, migration and proliferation were elucidated.  IGFBP-1 was found 
to modulate multiple processes involved in EC responses, including actin 
cytoskeletal remodelling and the upregulation of cell surface integrins.   
 
The findings of this chapter lead to a proposed mechanism by which IGFBP-
1 promotes functional responses in ECs (Figure 7.6). First, the RGD-domain 
of IGFBP-1 binds to integrins such as α5β1 and αVβ3 on the cell surface of 
ECs. This in turn induces FAK phosphorylation, which leads to assembly 
and disassembly of focal adhesions permitting increased cell adhesion and 
proliferation.  A separate pathway is transduced by FAK phosphorylation, 
where the Rho-Family GTPases are activated and interact with downstream 
targets.  In particular, RhoA is activated, targeting ROCK, which in turn 
activates actin:myosin filament assembly, ultimately leading to increased cell 
contraction and migration.   
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This is the first demonstration of these effects of IGFBP-1 in ECs and is 
supportive of a modulatory role of IGFBP-1 in vascular regeneration.  The 
findings are consistent with previously reported data on IGFBP-1 actions in 
non-vascular cells, reflecting the recognised roles of IGFBP-1 in other organ 
systems – for example the central nervous system and reproductive system. 
IGFBP-1 migration in oligodendrocytes by activating integrin-mediated intra-
cellular signalling306.  IGFBP-1 interaction with α5β1 integrin has been shown 
to be responsible for enhancing migration in Chinese hamster ovary cells305, 
smooth muscle cells307 and extra-villous trophoblast cells308.  These actions 
of IGFBP-1 proved to be independent of IGF-1.  It has also been 
demonstrated that members of the RHO GTPase family, such as RHO 
kinase, RHOC and RAC1, are essential for IGFBP-1 induced migration in 
extravillous trophoblasts309.  In schwannoma cells, enhanced adhesion and 
proliferation were shown to be elicited by IGFBP-1-induced FAK 
phosphorylation310. 
   
The increased cell surface expression of certain integrins in cells incubated 
with IGFBP-1 is intriguing, as it is assumed that interaction of IGFBP-1 itself 
with α5β1 integrin is the mechanism by which IGFBP-1 can signal 
independently of IGF-1.  The short duration of IGFBP-1 incubation used in 
these experiments is unlikely to be sufficient for integrins to be 
transcriptionally and translationally upregulated.  Instead, it is likely that 
IGFBP-1 incubation promotes recycling of integrins from intra-cellular stores 
and increase their availability for binding extra-cellular matrices at the cell 
surface311,312.  Elucidation of the mechanism by which IGFBP-1 facilitates 
integrin expression requires further study. 
 
Although the finding of FAK phosphorylation in ECs is likely, in keeping with 
other studies, to have been mediated through interaction of IGFBP-1 with 
integrins, it must be acknowledged that IGFBP-1-integrin interactions were 
not specifically investigated in this thesis.  One could demonstrate that 
enhancement of cell migration/proliferation/adhesion by IGFBP-1 is integrin-
mediated by pre-incubating ECs with anti-α5β1 or αVβ3 integrin-blocking 
antibodies and repeating the endothelial cell functional assays with IGFBP-1.  
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Another potential limitation is that the effects of IGFBP-1 on cytoskeletal 
rearrangement were seen only after TNF-α incubation, whereas the RhoA 
activity assay was performed in quiescent ECs unstimulated by TNF-α.  The 
benefit of investigating IGFBP-1 in isolation, allowed us to elucidate the role 
of IGFBP-1 without confounding factors such as TNF-α.  Nevertheless, the 
data confirming that IGFBP-1 activates RhoA are supportive of these 
mechanisms being implicated in the modulatory effects of IGFBP-1 on cell 
migration.  
 
In summary, the studies reported in this chapter have uncovered important 
mechanisms by which IGFBP-1 stimulates cell proliferation, adhesion and 
migration.  Understanding the mechanistic basis of the actions of IGFBP-1 in 
ECs is an essential step for IGFBP-1 to be considered as a potential 
therapeutic to enhance endothelial repair in an insulin resistant setting.   
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Figure 7-6 Proposed mechanistic pathway by which IGFBP-1 
modulates adhesion, migration and proliferation in ECs.   
This schematic summarises the proposed signalling pathways by which 
IGFBP-1 increases proliferation, cell-matrix adhesion and migration through 
interaction of its RGD domain and α5β1/αVβ3 integrins on endothelial cells.  
IGFBP-1 binds to integrins on the cell membrane, which activates focal 
adhesion kinase (FAK) by promoting its phosphorylation.  The effects of FAK 
on formation of focal adhesions leads to enhanced cell adhesion, increased 
cell migration and cell proliferation.  FAK activates the Rho GTPase family 
(RhoA, Rac, Cdc42) which regulates cytoskeletal arrangement (actin 
organisation) and thus cell migration. 
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8 General Discussion 
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8.1 Summary of key findings 
The investigations into the vascular role of IGFBP-1 and in particular 
endothelial regeneration described in this thesis were prompted by a 
considerable body of epidemiological data inversely associating IGFBP-1 
with IR and CVD.  Our laboratory has shown previously that IGFBP-1 directly 
upregulates NO generation in ECs, independently of IGF-1, via PI-3 kinase 
activation and eNOS activation.  Also, in an insulin resistant murine model, 
overexpression of human IGFBP-1 rescued endothelial function and 
endothelial insulin sensitivity267. 
 
During the course of this research project, in vivo studies were first carried 
out investigating the effects of over-expression of human IGFBP-1 on 
endothelial regeneration following arterial injury in insulin sensitive mice and 
in a murine model of IR.  IGFBP-1 was found to enhance endothelial 
regeneration, although this effect was specific for the insulin resistant 
setting.   
 
Secondly, in vitro studies examined the effect of IGFBP-1 on the functional 
properties of APCs and human ECs implicated in endothelial repair.  
Impaired APC abundance and mobilisation, as a consequence of reduced 
NO bioavailability, are known to be responsible for the delayed endothelial 
regeneration resulting from IR in IRKO mice206,  IGFBP-1 has been shown to 
enhance NO bioavailability and therefore might have been expected to 
improve APC abundance and function in IR mice.  However, surprisingly flow 
cytometry and cell culture analyses did not show an improvement in APC 
abundance in IRKO mice when IGFBP-1 was over-expressed. Furthermore, 
no improvement in APC function was elicited by IGFBP-1 over-expression.  
EC functional studies investigated the effects of IGFBP-1 on EC adhesion, 
migration and proliferation.  IGFBP-1 enhanced endothelial cell adhesion on 
a human saphenous vein matrix, although no direct effect of IGFBP-1 was 
observed on migration or proliferation in ‘metabolically healthy’ ECs.  
However, in ECs exposed to the pro-inflammatory cytokine TNF-α 
 171 
(mimicking IR), co-incubation of IGFBP-1 significantly improved migration 
and proliferation. 
 
Finally, studies probed the effects of IGFBP-1 on intracellular signalling 
pathways and cytoskeletal rearrangements necessary for endothelial repair.  
Mechanistically, IGFBP-1 was shown to increase expression of α5β1 and 
αVβ3 integrins on the surface of ECs, phosphorylate FAK, activate RhoA and 
improve cytoskeletal arrangement in a compromised setting.  A proposed 
mechanism is that IGFBP-1 through its RGD domain binds to α5β1 and αVβ3 
integrins on the EC surface, activating ‘outside-in’ integrin signalling, and 
phosphorylating FAK.  FAK phosphorylation leads to increased EC 
adhesion, migration and proliferation.  In addition to this direct effect, the 
Rho GTPase family is activated which regulates cytoskeletal arrangement 
and therefore cell migration.  
 
Endothelial regeneration is vital in a clinical setting, e.g. post-angioplasty 
and stent insertion to prevent neointima formation and thrombosis and to 
restore vascular homeostasis expediently125,313.  Through this project, 
IGFBP-1 has been identified as an endogenous protein which enhances 
endothelial regeneration in an insulin resistant setting and exhibited multiple 
favourable effects on EC function in vitro.  These results have been 
demonstrated for the first time and show that not only is IGFBP-1 a 
biomarker of CVD, but plays an important role in endothelial repair especially 
in a diseased setting. 
 
8.2 Differential effects of IGFBP-1 on endothelial cells and 
angiogenic progenitor cells 
There has been a considerable shift in focus of vascular biology research 
over the last twenty years. Asahara’s180 landmark study identifying 
angiogenic progenitor cells stimulated intense interest in investigating APCs 
and their involvement in endogenous regenerative mechanisms and 
maintenance of endothelial integrity.  However, more recent reports draw 
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into question the contribution of APCs to endothelial regeneration286,290 and 
the tide may now be turning back towards recognition that native ECs hold 
the key towards endothelial repair. 
   
Data presented in this thesis show that over-expression of IGFBP-1 has no 
effect on the abundance of APCs or their function.   In contrast, the results 
from this thesis suggest that IGFBP-1 mediates its effects in vivo through 
modulating the reparative function of endothelial cells rather than through 
APCs which is consistent with Hagensen’s findings286.   
 
8.3 Selective effects of IGFBP-1 on endothelial regeneration 
in the insulin resistant setting 
Another intriguing finding was that in a ‘healthy’ or a normal metabolic 
setting, whether in vivo or in vitro¸ IGFBP-1 had no effect on endothelial 
regeneration or EC function.  However, in an insulin resistant setting, IGFBP-
1 enhanced endothelial regeneration, and in a pro-inflammatory setting, 
migration and proliferation were enhanced.  The observation of a more 
pronounced effect of IGFBP-1 in IR is not unexpected, given the 
epidemiological links between IR, CVD and low circulating concentrations of 
IGFBP-1254,256,259,314,315.  Low IGFBP-1 concentrations in individuals with IR 
may be permissive for the development of CVD.  Based on the findings of 
this thesis, one could argue that increasing IGFBP-1 concentrations could 
have a prominent effect in these individuals. 
  
Finding that favourable effects of a protein under investigation are specific 
for IR is not exclusive to IGFBP-1.  A study in the literature, for example, 
investigated the effects of interferon tau (an anti-inflammatory agent) on IR 
in an obesity-induced mouse model, reversal of IR (decreased 
hyperglycaemia and decreased blood insulin levels) was observed with 
lower levels of pro-inflammatory cytokines such as TNF-α, however no effect 
of interferon tau was found in insulin sensitive mice316.    
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TNF-α was chosen in this thesis to induce a pro-inflammatory state in vitro 
characteristic of the altered biochemical milieu in individuals with IR.  TNF-α 
is known to induce impaired insulin signalling in ECs86,301 however, this was 
not confirmed in experiments reported here.  TNF-α is also known to induce 
endothelial dysfunction through other mechanisms including increased ROS 
formation317 and to have a direct effect on the p38 MAP kinase pathway301.  
Further studies could look into whether IGFBP-1 has a direct effect on ROS 
production through inhibition of the p38 MAP kinase pathway.  
 
8.4 Future studies 
8.4.1 Therapeutic strategy 
The in vivo studies reported in Chapter 4 demonstrate a favourable effect of 
IGFBP-1 on endothelial regeneration following arterial injury in insulin 
resistant mice. Although these data were corroborated by the experiments 
conducted in primary ECs and reported in chapters 6-7, potential limitations 
of data generated from gene-modified mice should be acknowledged. 
IGFBP-1 was expressed using conventional transgenic techniques under the 
control of its native promoter.  Whilst this permits regulation of IGFBP-1 in 
response to physiological cues, animals will have been exposed to 
increased IGFBP-1 concentrations throughout their development.  It cannot, 
therefore, necessarily be inferred that the enhanced endothelial regeneration 
observed would be translated to a favourable effect if IGFBP-1 
concentrations were to be increased acutely at the time of injury.  This is an 
important question if IGFBP-1 is to be exploited as a therapeutic target.  To 
address this issue, a gene-modified mouse in which IGFBP-1 is expressed 
conditionally would be preferable.  A number of approaches are available to 
regulate transgene expression in a temporal fashion in mice – e.g. 
tamoxifen-inducible cre-lox technology318; or tetracycline-inducible 
systems319.  Alternatively, IGFBP-1 could be expressed transiently in mice 
using adenoviral transduction. 
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A perhaps more attractive approach from the translational/therapeutic 
perspective would be to investigate short term administration of IGFBP-1 to 
mice following arterial injury. This would necessitate parenteral 
administration and the short half-life of IGFBP-1 in the circulation may 
present challenges in achieving consistently elevated plasma 
concentrations.  Reassuringly, however, other investigators have 
successfully employed parenteral administration of IGFBP-1 with favourable 
effects in other organ systems320,321.   
 
8.4.2 Integrin signalling as a therapeutic target 
The findings reported in chapter 7 suggest that the functional effects of 
IGFBP-1 in EC may be mediated through outside-in integrin signalling. 
Further studies are now required to confirm that interaction of the RGD 
domain of IGFBP-1 with integrins on the EC surface is required for IGFBP-1 
effects.  This could be achieved by repeating the signalling studies using 
antibodies to block integrin binding or following knock-down of integrin sub-
units in ECs.  Additionally, a recombinant IGFBP-1 protein in which the RGD 
motif has been mutated has recently been generated in our laboratory. 
Unfortunately this only became available after the experimental work 
reported here had been completed.  This would be ideal to determine 
whether an intact RGD domain is required to mediate the functional effects 
of IGFBP-1 on ECs. 
 
Pending the findings of these further studies, α5β1 mediated signalling may 
be confirmed as a potential target to increase endothelial regeneration.  
However, there will then be the question of whether the entire IGFBP-1 
protein is required to mediate modulatory effects on ECs, or whether these 
could be reproduced by shorter peptides able to activate integrin signalling. 
Small hexapeptides such as Gly-Arg-Gly-Asp-Thr-Pro which activate 
integrins are already available and could be used to investigate their effects 
on cell migration and proliferation in vitro, and on endothelial regeneration in 
vivo. 
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8.4.3 IGF-independent effects of IGFBP-1 
Although it is likely that the effects of IGFBP-1 on EC signalling and 
functional properties reported in this thesis were IGF-independent, a 
contribution to the findings through modulation of IGF bioavailability by 
IGFBP-1 cannot be fully excluded.  IGF-1 was not added in any of the in-
vitro experiments, however IGF-1 will have been present in vivo and small 
amounts of IGF-1 are produced by cultured cells.  Synergistic studies could 
be performed with IGF-1, des-IGF-1 and IGFBP-1 to evaluate the relative 
contributions of IGF-1 and IGFBP-1 to EC responses in vitro.  A perhaps 
more attractive approach is to repeat the in vitro experiments with a 
recombinant form of IGFBP-1 in which the IGF-binding domain of the protein 
has been mutated.  This has recently become available in our laboratory but 
not whilst this project was being undertaken. 
   
Determining whether the favourable effects of IGFBP-1 are independent of 
IGF-1 binding is also highly relevant to exploiting IGFBP-1 as a potential 
therapeutic target.  If IGF-1 interaction is not required, a mutated IGFBP-1 
protein able to interact with cell surface integrins but unable to alter IGF-1 
bioavailability may offer the attraction of favourable vascular effects without 
off-target effects. 
 
8.4.4 APC studies 
Although the results of chapter 5 suggest that a modulatory effect of IGFBP-
1 on APCs is unlikely, this possibility has not been fully discounted.  Further 
studies could investigate whether addition of IGFBP-1 to cells directly 
modulates the phenotype or expansion of early outgrowth APCs in vitro. 
Future studies could also look at whether IGFBP-1 modulates the properties 
of human ‘late outgrowth’ APCs.  Such experiments may be productive, as 
the phenotype of late outgrowth APCs is close to that of native ECs.   
 
Finally the findings of this project require human translation, the rationale for 
phase one human trials of IGFBP-1 are strengthened by the findings of this 
project, especially as IGFBP-1 is an endogenously expressed protein. 
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8.4.5 Mechanistic studies 
Chapter 7 provided evidence of some of the molecular mechanisms by 
which IGFBP-1 modulates EC responses.  For example, IGFBP-1 was 
shown to activate RhoA in EC.  It would be interesting to further investigate 
this link by repeating functional endothelial cell assays such as cell migration 
by using the Rho kinase inhibitor Y-27632.  Further western blot analyses 
could be conducted investigating downstream Rho-kinase signalling, probing 
ROCK1 and ROCK2 using available primary antibodies.  Finally, 
investigating RhoA activity in an insulin resistant setting in animal and 
cellular models would help deepen our understanding of the apparent 
specificity of the functional responses to IGFBP-1 to insulin resistant or pro-
inflammatory environments. 
 
8.5 Conclusions 
The experiments reported in this thesis have yielded intriguing and novel 
results which could play a key role in the development of potential new 
therapies to augment vascular repair.  IGFBP-1 has been shown in this 
project to enhance endothelial regeneration in an insulin resistant setting.  
These reparative effects are mediated through multi-factorial influences of 
IGFBP-1 on EC function associated with enhanced FAK-RhoA signalling and 
cytoskeletal modulation.  IGFBP-1 was thus shown to be a vasculo-
protective agent and relative IGFBP-1 deficiency has already been 
implicated in the increased CV risk in individuals with low plasma IGFBP-1.  
Further investigations are now required to corroborate understanding of the  
mechanistic basis for IGFBP-1 effects, before considering therapeutic 
studies looking at the translational effects of IGFBP-1.  IGFBP-1 or EC FAK 
signalling could be targeted therapeutically to enhance repair in insulin 
resistance.
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Appendix 
 
Endothelial Cell (20% FCS) Growth Medium (for cell culture): 
 
380 mL Basal Medium M199 (Sigma) 
100 mL FCS 20%  
10 mL 1M HEPES  
5 mL Antibiotic Anti-mycotic solution (Penicillin 10,000 units/mL, 
Streptomycin 10,000 µg/mL, Fungizone 25 µg/mL) 
2.5 mL ECGS (3 mg/mL) 
1 mL Sodium Pyruvate (55 mg/mL) 
2.5 mL Heparin (1,000 units/mL)  
 
Serum Free Media: 
500 mL M199 
10 mL 1M HEPES  
5 mL Antibiotic Anti-mycotic solution (Penicillin 10,000 units/mL, 
Streptomycin 10,000 µg/mL, Fungizone 25 µg/mL) 
2.5 mL ECGS (3 mg/mL) 
1 mL Sodium Pyruvate (55 mg/mL)  
2.5 mL Heparin (1,000 units/mL) 
 
 
Endothelial Cell Basal Medium-2 plus Clonetics EGM-2 Bulletkit CC-3162 
(for APC culture): Commerical kit, medium was made according to 
manufacturer’s instructions 
500 mL Endothelial Cell Basal Medium-2 
50 mL FCS 20% 
Hydrocortisone 0.2mL 
hFGF-B 2mL 
VEGF 0.5mL 
R3-IGF-1 0.5mL 
Ascorbic acid 0.5mL 
hEGF 0.5mL 
GA-1000 0.5mL 
Heparin 0.5mL 
 
Transfer Buffer (Western Blot) 
70.5g Glycine (Sigma) 
15g Tris-Base (Sigma) 
1000mL methanol 
Then made up to 5L with ddH20 
 
10x TBS/Tween 
12.1g Tris-base (Sigma) 
87.65g NaCl (vWR) 
Made up to 1L with ddH20, pH to 7.4 
20µL Tween added to 1L of 1 x TBS 
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